

Curriculum Vitae and Bibliography

John C Lieske, MD

Personal Information

Place of Birth: Havre de Grace, MD
Citizenship: United States of America
Work Address: Mayo Clinic Rochester
200 First St SW
Rochester, MN 55905-0001
507-284-2064
Email Address: lieske.john@mayo.edu



Present Academic Rank and Position

Consultant (Joint Appointment) - Division of Clinical Core Laboratory Services, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 04/30/2003 - Present
Consultant (Joint Appointment) - Division of Clinical Biochemistry & Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 04/30/2003 - Present
Consultant - Division of Nephrology & Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 2004 - Present
Professor of Medicine - Mayo Clinic College of Medicine and Science 08/01/2006 - Present
Full Faculty Privileges in Biomedical Engineering & Physiology - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science 02/07/2007 - Present
Consultant (Joint Appointment) - Department of Physiology & Biomedical Engineering, Mayo Clinic, Rochester, Minnesota 07/12/2007 - Present
Medical Director Renal Function Laboratory - Department of Laboratory Medicine and Pathology, Mayo Clinic, Unknown 2008 - Present

Education

Northwestern University - BS, Biomedical Engineering 1982
University of Chicago - MD 1986
Emory University - Resident, Internal Medicine 1986 - 1989
Emory University - Internship, Internal Medicine 1986 - 1989
University of Chicago - Fellow, Clinical Nephrology 1989 - 1990
University of Chicago - Fellow, Research Nephrology 1990 - 1993

Certification

Board Certifications

American Board of Internal Medicine (ABIM)

Internal Medicine	1989 - Present
Nephrology	1992 - 2022

Other Certifications

Mayo Clinic Quality Academy

Mayo Clinic Quality Fellow: Bronze Level Certification	2011
--	------

Licensure

Minnesota	42527 (Medical)
-----------	-----------------

Honors and Awards

Dean's List, 12 quarters - Northwestern University	01/1978 - 12/1982
Three time letter winner (Swimming) - Northwestern University	01/1978 - 12/1982
Tau Beta Pi, Honor Engineering Society - Northwestern University	05/1981
Graduated with Highest Distinction - Northwestern University	06/1982
Alpha Omega Alpha, Honor Medical Society - University of Chicago	12/1985
National Research Service Award - National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health	07/1991 - 06/1993
Trainee Award - Midwest Section of the American Federation for Clinical Research and Central Society for Clinical Research	11/1991
Clinical Investigator Award - National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health	01/1994 - 12/1998
Robert M. Kark Award for Meritorious Research - Chicago Society of Internal Medicine	06/1994
Fellow - American College of Physicians	01/2002
Fellow - American Society of Nephrology	01/2005

Previous Professional Positions and Major Appointments

Instructor In Medicine - Section of Nephrology, University of Chicago, Chicago, Illinois	1993 - 1995
Assistant Professor Of Medicine - Section of Nephrology, University of Chicago, Chicago, Illinois	1995 - 2000
Research Chair - Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	2000 - 2009

Senior Associate Consultant - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota	05/01/2000 - 04/29/2003
Senior Associate Consultant - Division of Nephrology & Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	05/01/2000 - 04/29/2003
Associate Professor of Medicine - Mayo Clinic College of Medicine and Science	07/01/2000 - 07/31/2006
Consultant - Division of Nephrology & Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	04/30/2003 - 2004

Professional Memberships and Societies

Professional Memberships and Services

American Board of Internal Medicine	
Subspecialty of Nephrology	
Exam Committee Member	09/01/2015 - Present
Subspecialty Board Member	10/01/2020 - Present
American College of Physicians	
Member	01/1988 - Present
Fellow	01/2003
American Society of Nephrology	
Member	1990 - Present
Invited Speaker	10/2000
Invited Speaker	10/2004
Fellow	01/2005
Invited Speaker	10/2006
Invited Speaker	10/2007
Invited Speaker	11/2012
Invited Speaker	11/2014
Abstract Review Committee	
Member	10/2002
Member	10/2004
Member	10/2005
Member	10/2012
American Urological Association	
Member	01/2002 - Present
International Society of Nephrology	
Member	01/1995 - Present
National Kidney Disease Educational Program (NKDEP)	
Laboratory Working Group	
Member	2008 - Present
National Kidney Foundation	

Member	01/2001 - Present
Northwestern University	
Biomedical Engineering Advisory Board	
Member	01/2005 - 12/2010
McCormick School of Engineering Advisory Board	
Member	01/2003 - 12/2005
Oxalosis and Hyperoxaluria Foundation	
Member	01/1999 - Present
Scientific Advisory Board	
Chair	02/2016 - Present
Research on Calculus Kinetics (ROCK) Society	
Member	2001 - Present
President	2012 - 2013

Study Sections

National Institutes of Health	
Study Section Reviewer	2000 - Present
Study Section Reviewer	07/2002
Study Section Reviewer	07/2009
Standing Member	10/2013 - 10/04/2017
Study Section Reviewer	06/2014

Journal Responsibilities

Journal Other Responsibilities

American Journal of Kidney Diseases	
Ad Hoc Reviewer	2005 - Present
American Journal of Nephrology	
Ad Hoc Reviewer	2005 - Present
American Journal of Physiology	
Ad Hoc Reviewer	1996 - Present
Cardiovascular Diseases	
Ad Hoc Reviewer	2009 - Present
Clinical Chemistry	
Ad Hoc Reviewer	2008 - Present
Clinical Journal of the American Society of Nephrology	
Ad Hoc Reviewer	2009 - Present
Editorial Reviewer	2010 - 07/01/2018
Hormone and Metabolic Research	
Ad Hoc Reviewer	2009 - Present
Journal of the American Society of Nephrology	
Ad Hoc Reviewer	1997 - Present

Kidney International	
Ad Hoc Reviewer	01/1995 - Present
Editorial Reviewer	2012 - Present
Nephrology Dialysis Transplantation	
Ad Hoc Reviewer	2007 - Present
Nutrition and Metabolism	
Ad Hoc Reviewer	2009 - Present
Pediatric Nephrology	
Ad Hoc Reviewer	2008 - Present
The Journal of Urology	
Ad Hoc Reviewer	2001 - Present
Urological Research	
Ad Hoc Reviewer	01/2001 - Present

Education Interests and Accomplishments

Curriculum and Course Development

Pathology Residents/ Clinical Chemistry Fellowship Lecture Series	2006 - Present
Develop lecture series in renal physiology/pathophysiology and laboratory testing.	
Mayo Graduate School of Medicine	
Rochester, Minnesota	

Teaching

Nephrology Grand Rounds	
Renal Biopsy conference	
Nephrology Journal Club	
Medical Grand Rounds	
Chronic Kidney Disease, Acute renal failure; urinalysis; nephrolithiasis	
Core Lectures	
Clinical Chemistry Post-doctoral Fellows and Pathology Residents	
Stone Disease	01/2000 - Present
Division Of Nephrology Core Lecture Series	
Rochester, Minnesota	
Stone Disease	2001 - 2005
Department of Laboratory Medicine and Pathology, Clinical Biochemistry and Immunology and CCLS Core Curriculum	
Rochester, Minnesota	
Basic Science Update for the Practicing Nephrologist	04/2001
Mayo Graduate School of Medicine CME Course	
Scottsdale, Arizona	

Stone Disease Mayo Graduate School of Medicine Physicians Assistants Lecture Series Rochester, Minnesota	07/2001 - 07/2002
A practical guide to nephrolithiasis Mayo Graduate School of Medicine CME course Minneapolis, Minnesota	10/2005
Renal Physiology/pathophysiology and laboratory testing Lecture series to Pathology residents and Clinical Chemistry fellows Mayo Graduate School of Medicine Rochester, Minnesota	2006 - Present
Assessment of Renal Function Mayo Medical Ventures CME course St Cloud, Minnesota	04/2006
Dietary Management of Renal Stones 17th Annual Advances and Controversies in Clinical Nutrition Mayo Graduate School of Medicine CME course Savannah, Georgia	04/13/2007
Laboratory Assessment of Renal Function and Renal Disease Professional Acknowledgment for Continuing Education Aberdeen, South Dakota	05/03/2007
Lab tests/ radiographic imaging for Primary Hyperoxaluria Oxalosis Hyperoxaluria Foundation Patient and Family Day Rochester, Minnesota	04/2008
Laboratory assessment of renal function and renal disease Union Memorial Hospital Baltimore, Maryland	05/2008
Nephrology Update CME Course American Physician Institute Comprehensive Review of Internal Medicine	06/19/2009 - Present
Biomarkers of Acute Renal Failure Mayo Medical Laboratories Hot Topic Web Presentation Mayo Medical Laboratories	07/2009
Kidney Stones - Update in Diagnosis and Management Mayo Medical Laboratories Hot Topic Web Presentation Mayo Medical Laboratories	12/2009
Update in Nephrolithiasis Mayo Medical Laboratories Hot Topic Web Presentation Mayo Medical Laboratories	02/2015
Assessment of Renal Function (GFR) Lecture Clinical Pathology Core Seminar Series Rochester, MN	04/07/2015 - Present

Lab Assessment of Chronic Kidney Disease (beyond GFR) Lecture Clinical Pathology Core Seminar Series Rochester, MN	04/14/2015 - Present
Use of Urinalysis in the Diagnosis of Kidney Disease Lecture Mayo Medical Laboratories Hot Topic Rochester, MN	04/15/2015 - Present
Urinary Stone Disease Lecture Clinical Pathology Core Seminar Series Rochester, MN	04/22/2015 - Present
Complex metabolic conditions CME Course AUA Annual Meeting Rochester, Minnesota	05/18/2015 - Present
Dietary and Medical Management of Stone Disease Lecture Mayo Clinic Urology CME course Rochester, MN	08/14/2015 - Present
Dietary and Medical Management of Stone Disease Lecture Update in Nephrology and Transplantation Minneapolis, MN, Minnesota	09/18/2015 - Present
Metabolic Evaluation of Nephrolithiasis CME Course AUA Annual Meeting Rochester, Minnesota	05/16/2016 - Present
Medical and Surgical Management of Urinary Stone Disease CME Course American Society of Nephrology Chicago, Illinois	11/16/2016 - Present
Assessment of Kidney Function Lecture Clinical Pathology Core Seminar Series Rochester, MN	04/05/2017 - Present
Laboratory Assessment of Chronic Kidney Disease Lecture Clinical Pathology Core Seminar Series Rochester, MN	04/26/2017 - Present
Urinary Stone Disease Lecture Clinical Pathology Core Seminar Series Rochester, MN	05/10/2017 - Present

Dietary and Medical Management of Stone Disease Lecture Update in Nephrology and Transplantation Amelia Island, Florida	02/23/2018 - Present
Medical Management of Urinary Stone Disease CME Course American Urological Association San Francisco, California	05/19/2018 - Present
Medical and Surgical Management of Urinary Stone Disease CME Course American Society of Nephrology Chicago, Illinois	10/24/2018 - Present
Assessment of Kidney Function Lecture Clinical Pathology Core Seminar Series Rochester, MN	04/17/2019 - Present
Chronic Kidney Disease Lecture Clinical Pathology Core Seminar Series Rochester, MN	04/24/2019 - Present
Urinary Stone Disease Lecture Clinical Pathology Core Seminar Series Rochester, MN	05/01/2019 - Present
Medical Management of Urinary Stone Disease CME Course American Urological Association Chicago, Illinois	05/03/2019 - Present
Hypokalemia and Renal Tubular Acidosis Lecture Mayo Nephrology Fellowship Core Lecture Series Rochester, Minnesota	06/06/2019 - Present
Laboratory Workup of Urinary Stone Disease Lecture Mayo Clinic Laboratory Sales Workforce Training Rochester, Minnesota	10/02/2019 - Present
Cystatin C and eGFR; Renal Biopsy related testing; Membranous Nephropathy Testing Lecture Mayo Clinic Laboratory Sales Workforce Training Rochester, Minnesota	10/16/2019 - Present
Use of Cystatin C and Other Methods to Assess GFR CME Lecture	02/03/2020 - Present

American Society of Clinical Pathology Webinar Rochester, Minnesota	
Renal Stone Disease CME Course Mayo Clinic 2019 Endocrine Update Kohala Coast, Kona, Hawaii	02/13/2020 - Present
Beauty and the Beast CME Course Mayo Clinic Nephrology Update Course Phoenix, Arizona	02/28/2020 - Present
Laboratory Workup of Urinary Stone Disease Lecture Mayo Clinic Laboratory Sales Workforce Training Rochester, Minnesota	03/03/2020 - Present
Cystatin C and eGFR; Renal Biopsy related testing; Membranous Nephropathy Testing Lecture Mayo Clinic Laboratory Sales Workforce Training Rochester, Minnesota	03/03/2020 - Present
Laboratory Workup of Urinary Stone Disease Lecture Mayo Clinic Laboratory Sales Workforce Training Rochester, Minnesota	03/04/2020 - Present
Surgical and Medical Management of Stone Guidelines Update: A Case Based Approach CME Course AUA Annual Meeting Rochester, Minnesota	05/26/2020 - Present

Mentorship

Koka, Rima (Undergraduate Student) Description: Undergraduate, University of Chicago. Senior Thesis: Adhesion of uric acid crystals to the surface of renal epithelial cells Current Status: Outcome:	01/1997 - 01/1999
Kim, Soo (Undergraduate Student) Description: Current Status: Outcome:	01/1999 - 01/2000
Zago PhD, Anna (Postdoctoral Fellow) Description: Current Status: Outcome:	01/1999 - 01/2000

Kumar PhD, Vivek (Postdoctoral Fellow) Description: Current Status: Associate Director Automated Chemistry, Beaumont Hospitals, Gross Pointe, MI Outcome:	01/2000 - 07/2007
Monico MD, Carla (Assistant Professor) Description: Current Status: Assistant Professor, University of Mississippi Outcome:	06/2000 - 01/2007
Pena de La Vega, Lourdes (Postdoctoral Fellow) Description: Current Status: Outcome:	07/2002 - 07/2004
Yu Ph.D., Shihui (Postdoctoral Fellow) Description: Current Status: Outcome:	08/2002 - 07/2004
Nelson, Wayne (Medical Student) Description: Current Status: Outcome:	01/2004 - 01/2005
Ho MD, Linh (Postdoctoral Fellow) Description: Current Status: Outcome:	06/2004 - 07/2005
Wu MD, Jimmy (Internal Medicine Resident) Description: Current Status: Outcome:	01/2005 - 01/2006
Smith, Travis (Medical Student) Description: Current Status: Outcome:	01/2005 - 06/2006
Schwartz, Maria (Mayo Ph.D. Student) Description: Thesis: Human-derived nanoparticles and arterial disease Current Status: Lecturer, Saint Johns University, MN Outcome:	01/2005 - 01/2009
Sinha MD, Mukesh (Internal Medicine Resident) Description: Current Status: Private Practice Nephrology Outcome:	01/2005 - 06/2009
Le MD, Carter (Postdoctoral Fellow) Description:	06/2005 - 06/2006

Current Status:**Outcome:**

Rule, Andrew (Faculty)

01/2006 - Present

Description:**Current Status:** Professor of Medicine, Mayo Clinic College of Medicine**Outcome:**

Greer MD, Erin (Internal Medicine Resident)

01/2006 - 12/2006

Description:**Current Status:****Outcome:**

Liang MD, Kelly (Nephrology Fellow)

07/2006 - 06/2008

Description:**Current Status:** Associate Professor of Medicine University of Pittsburgh**Outcome:**

Saucier MD, Nathan (Nephrology Fellow)

07/2007 - 06/2009

Description:**Current Status:****Outcome:**

Shiekh PhD, Farooq (Postdoctoral Fellow)

09/2007 - 09/2009

Description:**Current Status:** Instructor, Avalon University School of Medicine, Curacao, Netherland**Outcome:**

Kashani, Kianoush (Faculty)

01/2009 - Present

Description: Clinical Certificate and Masters Mentor**Current Status:** Professor of Medicine**Outcome:**

Murata, Kazuroni (Clinical Chemistry Fellow)

01/2009 - 01/2010

Description: Acting Medical Director Renal Laboratory**Current Status:** Medical Director Clinical Chemistry, Sloan Kettering Cancer Institute, New York, NY**Outcome:**

Schinstock, Carrie (Nephrology Fellow)

01/2009 - 01/2011

Description:**Current Status:** Associate Professor of Medicine**Outcome:** Consultant, Mayo Clinic Division of Nephrology and Hypertension

Semret, Merfake (Nephrology Fellow)

01/2009 - 01/2011

Description:**Current Status:****Outcome:**

Tsapenko, Mykola (Nephrology Fellow)

01/2009 - 01/2011

Description:**Current Status:****Outcome:**

Franco Palacios, Carlos (Nephrology Fellow)	01/2009 - 01/2012
Description:	
Current Status: Practicing Nephrologist	
Outcome:	
Linnes, Michael (Postdoctoral Fellow)	01/2009 - 01/2012
Description:	
Current Status: Graduate Communications/Research Coordinator, Purdue University College of Engineering	
Outcome:	
Nwoko, Rosemary (Nephrology Fellow)	07/2009 - 01/2012
Description:	
Current Status:	
Outcome:	
Amer MD, Hatem (Faculty)	01/2010 - Present
Description:	
Current Status: Associate Professor of Medicine	
Outcome:	
Herrmann, Sandra (Fellow)	01/2011 - 01/2013
Description: Research Mentor	
Current Status: Associate Professor of Medicine, Mayo Clinic Division of Nephrology and Hypertension	
Outcome:	
Keddis, Mira (Fellow)	01/2011 - 01/2013
Description: Clinical Certificate in Research Mentor	
Current Status: Associate Professor of Medicine, Mayo Clinic Arizona Division of Nephrology and Hypertension	
Outcome:	
Wang MD, Xiangling (Postdoctoral Trainee)	01/2011 - 06/2016
Description:	
Current Status: Assistant Professor of Medicine, Cleveland Clinic	
Outcome:	
Meeusen PhD, Jeffrey (Clinical Chemistry Fellow)	01/2012 - Present
Description:	
Current Status: Instructor of Laboratory Medicine and Pathology	
Outcome: Senior Associate Consultant, Mayo Clinic Department of Laboratory Medicine and Pathology	
Tang MD, Xiaojing (Postdoctoral Fellow)	01/2012 - 01/2014
Description:	
Current Status: Assistant Professor of Medicine	
Outcome: Staff Nephrologist Shanghai Changzheng Hospital, China	
Zhao MD, PhD, Fang (Postdoctoral Fellow)	01/2012 - 06/2015
Description:	
Current Status: Pathology Resident, Mayo Clinic Rochester	
Outcome:	

Perinpam, Majuran (Visiting Medical Student)	01/2014 - 12/2015
Description:	
Current Status: Medical Student	
Outcome: Completed one year elective with 3 peer reviewed publications	
Chirackal, Robin	09/2015 - 06/2017
Description:	
Current Status: Geriatrics Fellowship	
Outcome: Publication, Internal Medicine Residency	
Brady, Clayton (SURF Student)	05/2016 - 08/2019
Description:	
Current Status: MD PhD Student University of Buffalo	
Outcome: Abstract at ASN, paper	
Jessica, Saw (Medical Students)	06/2016 - Present
Description: Pursuing PhD at University of Illinois before completing MD at Mayo Clinic College of Medicine	
Current Status: PhD student University of Illinois	
Outcome: 2 publications	
Dhondup, Tsering (Nephrology Fellow)	07/2016 - 06/2018
Description:	
Current Status: Private Practice, Seattle, WA	
Outcome: Publication	
Hommos, Mussab (Nephrology Fellow)	07/2016 - 06/2018
Description:	
Current Status: Assistant Professor of Medicine	
Outcome: Publication	
D'Costa, Matthew (Mentee)	01/2017 - Present
Description:	
Current Status:	
Outcome:	
Jayachandran, Muthuvel (Mentee)	01/2017 - Present
Description:	
Current Status:	
Outcome:	
Schrank, Zachary (SURF Student)	05/2017 - 08/2017
Description:	
Current Status: Research Technician University of Washington	
Outcome: Abstract at ASN	
Mohammed PhD, Abdelsalam	07/2017 - 07/2018
Description: PhD Thesis committee	
Current Status: Postdoctoral Fellow, University of Barcelona	
Outcome: PhD	
Sutthimethakorn, Suchitra (Ph.D. Student)	10/2017 - 10/2018
Description:	

Current Status: Postdoctoral Fellow Outcome: PhD Thesis, publication	
Sanjay, Kumar (Postdoctoral Research Fellow)	03/2018 - Present
Description: Current Status: Postdoctoral Fellow Outcome: PhD Thesis, publication	
Wilson, Elena (SURF Student)	05/2018 - 08/2019
Description: Current Status: Research Trainee NIH Outcome: Abstract at ASN	
Lin, Zhijian (Research Trainee)	06/2018 - 06/2019
Description: Current Status: Associate Professor Outcome: 1 publication	
Shah, Ronak (Research Trainee)	06/2018 - 06/2019
Description: Current Status: Internal Medicine Resident, Cleveland Clinic Outcome: 2 publications, Internal Medicine Residency	
Singh, Prince (Mentee)	01/2019 - Present
Description: Current Status: Outcome:	
Geoffrey, Chen (SURF Student)	05/2019 - 09/2019
Description: Current Status: Undergraduate Student University of Maryland Baltimore County Outcome: SURF abstract	
Victor MD, Lopez Baez (Research Trainee)	06/2019 - 09/2020
Description: Current Status: Practicing Nephrologist Outcome: 1 publications	
Zhang MBBS, Jiqing (Research Trainee)	06/2019 - 09/2020
Description: Current Status: Associate Professor Outcome: 2 publications	
Debjan MD, Pegah	03/2020 - Present
Description: Current Status: Postdoctoral Fellow Outcome:	
Arroyo, Jennifer (Fellow)	04/2020 - Present
Description: Current Status: Outcome:	

Siebens, Cynthia (Fellow)	04/2020 - Present
Description:	
Current Status:	
Outcome:	
Arnous, Muhammad (Fellow)	05/2021 - Present
Description:	
Current Status:	
Outcome:	
Hosain, Mohammad (Trainee)	07/2021 - 07/2022
Description:	
Current Status:	
Outcome:	
Hill, Austin (Summer Undergraduate Research Fellow)	06/2022 - 08/2022
Description:	
Current Status:	
Outcome:	
Ro, Han (Visiting Research Fellow)	09/2022 - Present
Description:	
Current Status:	
Outcome:	

Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other Activities

Mayo Clinic in Rochester

Department of Internal Medicine	
Division of Nephrology & Hypertension	
Research Chair	04/2004 - 09/2009
Education Committee	
Member	07/2007 - Present
Research Committee	
Member	04/2004 - Present
Chair	04/2004 - 09/2009
Steering and Practice Committee	
Member	04/2004 - 09/2009
Division of Nephrology & Internal Medicine	
Research Chair	01/2000 - 04/2004
Research Advisory Group	
Member	01/2000 - 09/2009
Department of Laboratory Medicine and Pathology	
Division of Clinical Biochemistry & Immunology	
Renal Function Laboratory	
Co-Director	01/2000 - 12/2007
Medical Director	01/2008 - Present

Proteomics Core Lab Oversight Workgroup

Member

2012 - Present

Research Committee

Member

01/2004 - Present

Test Development/New Technologies Subcommittee

Member

2012 - Present

Presentations Extramural**National or International****Invited**

Cell-crystal interactions and urolithiasis

07/1998

Lecture

International Congress on Renal Stone Disease

Fiuggi, Italy

Inhibition of crystal adhesion to renal cells by diverse anions

01/1999

Lecture

Finlayson Colloquium on Urolithiasis

Gainesville, Florida

Adhesion of calcium oxalate crystals to renal cells

03/1999

Lecture

Fifth Workshop on Primary Hyperoxaluria

Zurich, Switzerland

Calcium Oxalate crystal interactions with renal cells

08/1999

Lecture

FASEB Summer Research Conference

Copper Mountain, Colorado

Nephrolithiasis: Key Pathogenetic and Clinical Issues in 2000

10/2000

Lecture

American Society of Nephrology Annual Meeting

Toronto, Ontario, Canada

Oxalosis and Calcium Oxalate Stone Disease

11/2000

Lecture

NIDDK Conference

Columbia, Maryland

Oxalate, calcium oxalate crystals and nephrolithiasis

04/2002

Lecture

Nephrology Gastroenterology Workshop

Bergamo, Italy

Calcium Oxalate Monohydrate Crystal Binding Molecules On The Surface Of

05/2002

Renal Cells

Lecture

Sixth International Conference on Hyperoxaluria

Hannover, Germany

Calcium Oxalate in Biological Systems Lecture FASEB Summer Research Conference Saxtons River, Vermont	08/2002
Nanobacteria and fatty acids Lecture NASA Johnson Space Center Houston, Texas	10/13/2003
Probiotic Therapies for Hyperoxaluria Lecture NIDDK Oxalosis and Hyperoxaluria Conference Annapolis, Maryland	11/2003
The PH and Dent's Registry: role of a database and demonstration Lecture NIDDK Oxalosis and Hyperoxaluria Conference Annapolis, Maryland	11/2003
Renal Cell-Urinary Crystal Interactions in the pathogenesis of Renal Lithiasis Lecture 10th International Symposium on Urolithiasis Hong Kong, China	05/2004
Cell-crystal interactions and urolithiasis Lecture American Society of Nephrology Annual Meeting St Louis, Missouri	10/2004
Diverse responses of renal cells to oxalate Lecture Seventh International Workshop on Primary Hyperoxaluria Rochester, Minnesota	10/2004
Report from the International Registry Lecture Seventh International Workshop on Primary Hyperoxaluria Rochester, Minnesota	10/2004
Detection and propagation of calcified nanostructures within human aneurysms Lecture NASA Cell Science Texas	02/23/2005
Calcium Oxalate in Biological Systems Lecture FASEB Summer Research Conference Tucson, Arizona	07/2005
Detection and propagation of calcified nanostructures within human aneurysms and kidney stones	11/30/2005

Lecture Research Conference Iowa State Ames, Iowa	
Cell Biology of Pathologic Renal Calcification Lecture FASEB symposium San Francisco, California	05/2006
Urinary Crystal Adhesion Inhibitors Lecture Research on Calculous Kinetics Society Session at the American Urological Association Meeting Atlanta, Georgia	05/2006
Role of Nanobacteria in calcific diseases Lecture Fetzer Foundation Symposium Auburn, Alabama	10/2006
Renal complications after Roux en Y Bypass for Obesity Lecture American Society of Nephrology San Diego, California	11/2006
Candidate reference method for urinary albumin Lecture National Kidney Disease Education Program Washington, District of Columbia	03/13/2007
Dietary Management of Renal Stones Lecture 16th Annual Advances & Controversies in Nutrition Savannah, Georgia	04/13/2007
Surgery for Obesity and Stones Lecture European Urolithiasis Symposium Lisbon, Portugal	07/06/2007
Nephrolithiasis: A Bacterial Disease? Evidence Supporting and Against a Role of Nanobacteria in Calcium Stone Formation Lecture American Society of Nephrology San Francisco, California	11/03/2007
Establishing a Registry for a Rare Disease: Practicalities and Pifalls Lecture 2008 Cystinuria Symposium New York, New York	07/26/2008
Oxidative stress and kidney stone disease Lecture	09/2008

Cancer Preventive Material Development Research Center Symposium at
Kyunghee University
Seoul, South Korea

Genetics of Urolithiasis 04/2009

Lecture

Research on Calculous Kinetics Society Session at the American Urological
Association Meeting
Chicago, Illinois

Kidney Stones - Update in Diagnosis and Management 04/2009

Lecture

American College of Physicians Annual Meeting
Philadelphia, Pennsylvania

How do kidney stones start? 12/2011

Lecture

Second International Istanbul Urolithiasis Days
Istanbul, Turkey

What can epidemiology teach us regarding the pathogenesis and
consequences of kidney stones? 12/2011

Lecture

Second International Istanbul Urolithiasis Days
Istanbul, Turkey

Stones from the Inside Out: What every urologist sees but few 01/2012

Nephrologists know about.

Lecture

Hong Kong Society of Nephrology Renal Commissioned Training 2011/2012
Hong Kong, China

Hypertension and Urolithiasis 05/2012

Lecture

12th International Symposium on Urolithiasis
Ouro Preto, Brazil

Primary Hyperoxaluria: not such a rare disease? 05/2012

Lecture

Research on Calculous Kinetics Society Session at the American Urological
Association Meeting
Atlanta, Georgia

Kidney Stones 2012 11/03/2012

Lecture

American Society of Nephrology Annual Meeting
San Diego, California

Plaques, Plugs and Kidney Stones 02/2013

Lecture

Cleveland Clinic Nephrology Urology Joint Grand Rounds
Cleveland, Ohio

The Key Role of the Laboratory to Diagnose & Monitor Kidney Disease Lecture HOLLAND HOSPITAL & HOLLAND PHO PRESENT CLINICAL UPDATE: Nephrology Update Holland, Michigan	02/2013
Bariatric Surgery and Nephrolithiasis Lecture Nephrolithiasis: a systemic disorder Rome, Italy	03/22/2013
Methods to estimate GFR- MDRD, CKD-EPI AND Cystatin C Lecture 5th South Brazilian Congress of Nephrology Gramado, Brazil	04/2013
Pathophysiology of Kidney Stones: New Insights from Papillary Pathology Lecture 5th South Brazilian Congress of Nephrology Gramado, Brazil	04/2013
How to recognize a rare kidney stone Lecture Research on Calculous Kinetics Society Session at the American Urological Association Meeting San Diego, California	05/2013
Nephrolithiasis and CKD Lecture American Urological Association San Diego, California	05/06/2013
Dent Disease Lecture Biennial Meeting Nordic Society of Nephrology Reykjavik, Iceland	08/2013
The microbiome and kidney stone disease Lecture NIH Host Microbiota Interactions Workshop Bethesda, Maryland	09/2014
Calcium Oxalate Stones, Urate and Other Nephrolithiasis Lecture American Society of Nephrology Annual Meeting Philadelphia, Pennsylvania	11/2014
Nephrolithiasis, Nephrocalcinosis, and Related Disorders Lecture American Society of Nephrology Annual Meeting Philadelphia, Pennsylvania	11/2014

Detection of causes in idiopathic stone formers Lecture Consensus conference for the metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations Rome, Italy	03/27/2015
What are the strategies to prevent stone diseases Lecture NIDDK Urinary Stone Diseases Conference Bethesda, Maryland	04/02/2015
The genetics of rare and common kidney stones Invited Lecture Mayo Clinic PUCRS Joint Meeting Porto Alegre, Brazil	06/26/2015
New insights regarding crystalline nephropathy Lecture University of Chicago Nephrology Symposium Chicago, Illinois	11/13/2015
Nephrolithiasis: an update for internists Lecture Internal Medicine Grand Rounds Rochester, MN, Minnesota	12/02/2015
Rare and common causes of kidney stones Lecture Mayo Clinic Florida Internal Medicine Grand Rounds Jacksonville, Florida	01/27/2016
Characterization of inner medullary collecting duct plug formation among idiopathic calcium oxalate stone formers Lecture 13th International Symposium on Urolithiasis Chiba, Japan	07/22/2016
Plasma oxalate can be interpreted in relation to GFR to detect the likelihood of primary hyperoxaluria, enteric hyperoxaluria and common urinary stone disease Lecture 13th International Symposium on Urolithiasis Chiba, Japan	07/22/2016
Renal histopathological features of Dent disease, a rare but important cause of calcium stones to recognize Lecture 13th International Symposium on Urolithiasis Chiba, Japan	07/22/2016
Urinary Biomarkers for renal damage in primary hyperoxaluria Lecture	07/22/2016

13th International Symposium on Urolithiasis Chiba, Japan	
Mayo Clinic O'Brien Urology Research Center Lecture University of Washington PPG Semi-Annual Meeting Seattle, Washington	08/17/2016
Key Pathogenic factors in nephrolithiasis: Not all stones are created equal Lecture Mayo Clinic/ Trondheim Renal Research Group Trondheim, Norway	09/02/2016
Recent Advances in the Pathophysiology and Potential Treatment of Rare Kidney Stone Diseases Lecture American Society of Nephrology Annual Meeting Chicago, Illinois	11/17/2016
Visualization and pathophysiology of renal stone precursor lesions Lecture 2016 Urology Program Directors Conference Pacific Grove, California	12/06/2016
Kidney Health Initiative: Biomarkers for Primary Hyperoxaluria Research Lecture 12th International Primary Hyperoxaluria Workshop Tenerife, Spain	07/12/2017
Liver Transplantation for type 2 Primary Hyperoxaluria Lecture 12th International Primary Hyperoxaluria Workshop Tenerife, Spain	07/12/2017
Rare causes of Kidney Stones Lecture 2nd International Renal Conference Brugge Brugge, Belgium	03/16/2018
KHI Hyperoxaluria Project: Endpoints for Clinical Trials in Hyperoxaluria Lecture American Society of Nephrology Annual Meeting	10/23/2018
Causes and Consequences of Enteric Hyperoxaluria Lecture ROCK Annual Meeting	03/30/2019
Identification of appropriate endpoints for clinical trials in hyperoxaluria Lecture KHI Stakeholders Meeting	06/19/2019
What have we learned from patient registries? Lecture	06/19/2019

2019 OHF International Hyperoxaluria Workshop
Boston, Massachusetts

Obesity, Bariatric Surgery and Kidney Stones 11/07/2019
Lecture
ASN annual meeting
DC, Washington

Oral

Oxalate and the Risk of Kidney Stones and Kidney Failure 02/21/2015
Lecture
ROCK Society Annual Meeting
Fort Lauderdale, Florida

Poster

Nedosiran in Patients with Primary Hyperoxaluria1: Interim Results from an Extension Trial (PHYOX3) 11/2022
American Society of Nephrology Annual Meeting
Orlando, Florida

Performance of a Novel Race-Independent GFR Estimating Equation in Kidney Transplant Recipients Based on NMR-Measured Metabolites 11/2022
American Society of Nephrology Annual Meeting
Orlando, Florida

Race-Independent eGFR Equations in Assessing Renal Function in Patients with Liver Disease 11/2022
American Society of Nephrology Annual Meeting
Orlando, Florida

Late Presentation of Bartter Syndrome Type 2 11/2022
American Society of Nephrology Annual Meeting
Orlando, Florida

Lumasiran for Patients with Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-month Analysis of the Phase 3 ILLUMINATE-C Trial 11/2022
American Society of Nephrology Annual Meeting
Orlando, Florida

Clinical Characterization of a Dent Disease-1 Cohort Including Genotype-Phenotype Correlations 11/2022
American Society of Nephrology Annual Meeting
Orlando, Florida

Genotype-Phenotype Correlation in Cystinuria 11/2022
American Society of Nephrology Annual Meeting
Orlando, Florida

Regional

Invited

Medical Management of Urolithiasis 04/2001
Lecture

Upper Midwest Chapter, Society of Urologic Nurses and Associates Rochester, Minnesota	
Kidney Stones Radio Interview and Question and Answer KROC "Healthline" Rochester, Minnesota	12/2005
Evaluation of Renal Function Lecture ASCLD-SD & Siouxland CLMA 2007 Spring Conference Aberdeen, South Dakota	05/08/2007
Laboratory Assessment of Renal Function and Renal Disease Lecture American Society of Clinical Laboratory Science-ND Annual Spring Meeting Grand Forks, North Dakota	04/2009
Evaluation of Renal Function Lecture ASCLD-SD & Siouxland CLMA 2009 Spring Conference Grand Forks, North Dakota	05/2009
What is CKD and how to prevent it. Lecture Mayo Clinic Outreach Bloomington, Minnesota	06/2010
Methods to rapidly isolate and measure biomarkers in urinary microvesicles Lecture Mayo Clinic Exosome Workshop Rochester, MN	02/12/2015
Improving stone disease treatment by accurate phenotyping and risk stratification Lecture Mayo Clinic PKD Center Grand Rounds Rochester, MN	12/14/2015
What does race have to do with GFR? Lecture Mayo Clinic Nephrology and Hypertension Grand Rounds	08/18/2020
What does race have to do with GFR? Lecture Mayo Clinic CBI/CCLS Grand Rounds	10/08/2020
Oral	
Nanobacteria: What are they? Do they cause disease? Lecture Nephrology and Hypertension Grand Rounds Rochester, Minnesota	07/2002

Use of probiotics to decrease urine oxalate excretion in enteric hyperoxaluria Lecture Nephrology and Hypertension Grand Rounds Rochester, Minnesota	12/2005
Use of probiotics to decrease urine oxalate excretion in enteric hyperoxaluria Lecture Mayo Clinic Division of Nephrology Endocrinology Grand Rounds Rochester, Minnesota	05/02/2006
Trading One Problem for Another: Kidney Stones after Bariatric Surgery Lecture Nephrology and Hypertension Grand Rounds Rochester, Minnesota	10/02/2007
Quantification of urinary proteins for diagnosing and monitoring renal disease Lecture Nephrology and Hypertension Grand Rounds Rochester, Minnesota	10/07/2008
How do kidney stones start anyway? Lecture Nephrology and Hypertension Grand Rounds Rochester, Minnesota	08/25/2009
Methods to estimate and measure GFR Lecture Nephrology and Hypertension Grand Rounds Rochester, Minnesota	01/04/2011
Biomarkers for Early Detection of Acute Kidney Injury Lecture Mayo Critical Care Grand Rounds Rochester, Minnesota	03/02/2011
Stones from the Inside Out: What every urologist sees but few Nephrologists know about Lecture Mayo Clinic Nephrology and Hypertension Grand Rounds	01/10/2012
Mayo Clinic O'Brien Urology Research Center: Defining the Causes and Consequences of Nephrolithiasis Lecture Nephrology and Hypertension Grand Rounds Rochester, Minnesota	01/08/2013
Some New Twists on Assessment of Renal Function in 2014 - What the Renal Lab Can Do For You' Lecture	01/28/2014

Nephrology and Hypertension Grand Rounds
Rochester, Minnesota

Some new twists on assessment of renal function in 2014 02/05/2014

Oxalosis and Hyperoxaluria Conference
Mayo Clinic Department of Laboratory Medicine and Pathology Grand Rounds
Rochester, Minnesota

High incidence of kidney stones after bariatric surgery 05/14/2014

Lecture
Bariatric Workgroup Meeting
Rochester, Minnesota

Implementation of AKI biomarkers at Mayo Clinic: Opportunities and Pitfalls 08/18/2015

Lecture
Nephrology and Hypertension Grand Rounds
Rochester, MN

Unclassified

Race and estimated GFR: Confounding of social and biological variables 04/06/2022

Mayo Clinic DLMP Grand Rounds
Rochester, Minnesota

Metabolic evaluation on kidney stones and monogenetic disorders of 05/06/2022

nephrolithiasis
2nd symposium on Kidney Stones and Mineral Metabolism
Brussels, Belgium

Role of Inflammation in the Pathogenesis of Kidney Stone Disease 05/06/2022

2nd symposium on Kidney Stones and Mineral Metabolism
Brussels, Belgium

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria 05/12/2022

Type 1: 24-Month Analysis of the ILLUMINATE-A Trial
AUA annual meeting
New Orleans, Louisiana

The Surgical and Medical Management of Stones Guidelines: Update and 05/12/2022

Complex Cases
AUA annual meeting
New Orleans, Louisiana

New Therapeutics in Genetic Kidney Stone Disorders 09/15/2022

9th Annual Genetics Education Symposium – Genetics & Genomics:
Applications for the Diagnosis and Management of Kidney Diseases
Cleveland, Ohio

Choosing the Best GFR Measurement Technique in Clinical Practice 11/03/2022

American Society of Nephrology
Orlando, Florida

Genetic and Clinical Factors Associated with Magnesium Levels in the Population American Society of Nephrology Orlando, Florida	11/05/2022
Renal macrophages in the pathogenesis of human urinary stones and Randall's plaque formation in mice CAIRBU NIDDK Urology Centers meeting Bethesda, Maryland	11/30/2022

Visiting Professorship

Visiting Professorships

Alberta Heritage Foundation for Medical Research University of Alberta Edmonton, Alberta, Canada	11/2003
Free University of Berlin Berlin, Germany	07/2005
University of Louisiana Shreveport Shreveport, Louisiana	02/2007
NYU School of Medicine New York, New York	07/2008
Urology Grand Rounds Plaques, Plugs and Kidney Stones Cleveland Clinic Cleveland, Ohio	02/12/2013
Rare causes of a common disease University of Texas Southwestern Dallas, Texas	04/18/2014

Quality Initiatives

Quality Improvement Projects

Use of Cystatin-C, in Hospitalized Patients with Acute Kidney Injury Allows for Earlier Recognition of Recovery and Early Hospital Discharge (Silver Project) Abdurrahman M. Hamadah, M.D. (Project Editor, Team Lead), Kamel gharaibeh, M.D. (Team Lead), Nelson Leung, M.D. (Team Lead), John C. Lieske, M.D. , Ziad Zoghby, M.D., M.B.A..	08/04/2016
Enteric Hyperoxaluria (Silver Project) Theresa I. Schnell, R.N. (Project Editor), Brigid M. Amberg, R.N. (Team Lead), Amanda R. Frodermann, R.N., Hatem Amer, M.D., Erin M. Dahlen, R.N., Carol A. Nash, R.N., gwen M. Davidson, R.N., Theodore L. Mueller, R.N., Melissa K. gay, R.N., John C. Lieske, M.D. , Jennifer L. Wells-Pittman, APRN, CNS, M.S..	05/25/2017
Cystatin C-guided Vancomycin Dosing in Critically Ill Patients: A SILVERuality Improvement Project (Silver Project) Erin F. Barreto, Pharm.D., R.Ph. (Project Editor, Team Lead), Nelson Leung, M.D. (Team Lead), Philip J.	02/24/2017

Kuper, Pharm.D., R.Ph., Andrew D. Rule, M.D., **John C. Lieske, M.D.**,
Kianoush B. Kashani, M.D., M.S., Jason N. Barreto, Pharm.D., Abinash Virk,
M.D..

Research Grants Awarded

Active Grants

Federal

Program Director / Principal Investigator	Kidney Disease Research Training Program. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (T32 DK 07013)	05/2019 - 04/2025
Program Director / Principal Investigator	An individualized medicine approach to urinary stone disease. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R01 DK 133171)	09/2022 - 05/2026
Program Director / Principal Investigator	Admin Core. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (P20 DK 135097)	09/2022 - 06/2026
Program Director / Principal Investigator	Research Project. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (P20 DK 135097)	09/2022 - 06/2026

Federal sub award

Program Director / Principal Investigator	USDRN Prevention of Urinary Stones with Hydration (PUSH) Study (sub to Wash U). Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 110986)	09/2022 - 08/2025
Program Director / Principal Investigator	Long Term Pyridoxine Safety and Efficacy in PH1. Funded by Novo Nordisk	03/2024 - 02/2025
Program Director / Principal Investigator	USDHub: community resource for Urinary Stone Disease research. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK140865)	09/2024 - 05/2029
Co-Investigator	RESEARCH. Funded by Food and Drug Administration. (FD 05938)	09/2023 - 08/2028
Co-Investigator	Leveraging a unique dog model to determine the role of uromodulin in kidney stone disease. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK132046)	09/2024 - 08/2025

Foundation

RE-AIMS 7/7/2025 4:50:12 PM - Latest Update 7/6/2025 11:36:34 PM

Program Director / Principal Investigator	OHF Primary Hyperoxaluria Registry. Funded by Oxalosis and Hyperoxaluria Foundation	04/2020 - 03/2026
Industry		
Program Director / Principal Investigator	Amendment 2: Dicerna 301 IRB#18-011726 SoA 1,2 and 3. Funded by Dicerna Pharmaceuticals, Inc.. (DCR-PHXC-301)	12/2019 - 12/2025
Program Director / Principal Investigator	Amendment 2: Long Term Treatment Arm. Funded by Dicerna Pharmaceuticals, Inc.. (DCR-PHXC-301)	12/2019 - 12/2025
Program Director / Principal Investigator	Cohort A <10kg ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1). Funded by Alnylam Pharmaceuticals. (ALN-GO1-005 GO105)	02/2020 - 02/2025
Program Director / Principal Investigator	Cohort A >10kg ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1). Funded by Alnylam Pharmaceuticals. (ALN-GO1-005 GO105)	02/2020 - 02/2025
Program Director / Principal Investigator	Cohort B <10kg ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1). Funded by Alnylam Pharmaceuticals. (ALN-GO1-005 GO105)	02/2020 - 02/2025
Program Director / Principal Investigator	Cohort B >10kg ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1). Funded by Alnylam Pharmaceuticals. (ALN-GO1-005 GO105)	02/2020 - 02/2025
Program Director / Principal Investigator	Amendment 2: Estimation of the Number of ESKD Events Avoided with Lumasiran Treatment in Patients with PH1. Funded by Alnylam Pharmaceuticals	09/2021 - 02/2024
Program Director / Principal Investigator	AM1:BONAPH1DE, A prospective observational study of patients with primary hyperoxaluria type 1 (PH1). Funded by Alnylam Pharmaceuticals. (ALN-GO1-007)	12/2021 - 12/2026
Program Director / Principal Investigator	Analysis of Relationship Between Urine Oxalate (UOx) and Estimated Glomerular Filtration Rate (eGFR) in Longitudinal Data in Patients with PH1. Funded by Alnylam Pharmaceuticals	05/2022 - 04/2023

Program Director / Principal Investigator	Natural History of Nephrocalcinosis in Patients With PH1 . Funded by Alnylam Pharmaceuticals. (PO 4530015189)	08/2022 - 01/2023
Program Director / Principal Investigator	DCR-PHXC-204 Dicerna 20-009669. Funded by Novo Nordisk. (DCR-PHXC-204)	08/2024 - 02/2030
Program Director / Principal Investigator	Outcomes in PH3 patients who take oral citrate. Funded by Novo Nordisk	09/2024 - 08/2025
Program Director / Principal Investigator	Natural History of Nephrocalcinosis in Patients With PH1: Report review. Funded by Alnylam Pharmaceuticals	03/2025 - 02/2026
Program Director / Principal Investigator	A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Pt with Primary Hyperoxaluria Type 1 (PH1). Funded by Arbor Biotechnologies. (ABO-101-101)	04/2025 - 03/2030
Co-Investigator	21-005579 Dicerna 203: Nedosiran in Pediatric Patients from Birth to 5 Years of Age with PH and Relatively Intact Renal Function. Funded by Dicerna Pharmaceuticals, Inc.. (DCR-PHXC-203)	09/2021 - 04/2022

Completed Grants**Federal**

Principal Investigator	Cells,crystals and renal stones. Funded by National Institutes of Health. (Individual NRSA)	01/1991 - 01/1992
Principal Investigator	Urinary Crystal-Renal Cell Interactions. Funded by National Institute of Diabetes and Digestive Kidney Diseases. (DK 02272)	01/1994 - 12/1998
Principal Investigator	Pathogenesis of crystal adhesion to renal cells. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R01 DK 53399)	05/1999 - 04/2006
Principal Investigator	Oxalate-Induced Renal Scarring and Crystal Retention. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R01 DK 60707)	03/2002 - 12/2004
Principal Investigator	Role of Nanobacteria in Human Calcifying Disease. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R21 DK 62021)	08/2003 - 07/2007
Program Director /	Use of symbiotics to reduce urinary oxalate excretion. Funded by National Center for Complementary and Alternative Medicine. (R21 AT 02534)	09/2005 - 09/2009

Principal Investigator		
Program Director / Principal Investigator	Nephrolithiasis and Chronic Kidney Disease. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R21 DK 77321)	09/2006 - 02/2009
Program Director / Principal Investigator	Genetic determinants of urine lithogenicity. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R01 DK 77950)	03/2008 - 02/2014
Program Director / Principal Investigator	Kidney Disease Research Training Program. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (T32 DK 07013)	05/2008 - 04/2014
Program Director / Principal Investigator	Core A - Administration (Lieske). Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (P50 DK 83007)	09/2008 - 10/2013
Program Director / Principal Investigator	Core C - Urinary Phenotyping Core (Lieske). Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (P50 DK 83007)	09/2008 - 10/2013
Program Director / Principal Investigator	Project 2 - Lieske. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (P50 DK 83007)	09/2008 - 10/2013
Program Director / Principal Investigator	Pilot Project Program. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2009 - 09/2014
Program Director / Principal Investigator	Project 4: Dents Disease. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2009 - 09/2014
Program Director / Principal Investigator	Training Program. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2009 - 09/2014
Program Director / Principal Investigator	Core A: Administrative Core. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 100227)	09/2013 - 12/2018
Program Director /	Core C. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 100227)	09/2013 - 12/2018

Principal Investigator		
Program Director / Principal Investigator	Project 2: Drs. Lieske & Krambeck. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 100227)	09/2013 - 12/2018
Program Director / Principal Investigator	Kidney Disease Research Training Program. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (T32 DK 07013)	05/2014 - 04/2019
Program Director / Principal Investigator	Pilot Projects. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2014 - 03/2020
Program Director / Principal Investigator	Project 4: Dent Disease. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2014 - 03/2020
Program Director / Principal Investigator	Training Program. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2014 - 03/2020
Program Director / Principal Investigator	Facilitating personalized medicine of monogenic stone patients by genetic characterization. Funded by National Center for Advancing Translational Sciences. (R21 TR 03174)	05/2020 - 04/2022
Co-Investigator	Prevention of Renal Damage in Primary Hyperoxaluria. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R01 DK 73354)	09/2005 - 07/2010
Co-Investigator	Hyperoxaluria and Nephrolithiasis After Gastric Bypass Surgery for Obesity. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R21 DK 77669)	07/2007 - 06/2010
Co-Investigator	Nanoparticles and Arterial Disease. Funded by National Heart, Lung, and Blood Institute. (R21 HL 88988)	06/2008 - 05/2011
Co-Investigator	Pilot Projects (Years 3-5) Program. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (P50 DK 83007)	09/2008 - 10/2013
Co-Investigator	Administrative Unit. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2009 - 09/2014
Co-Investigator	The macro- and micro- anatomy and pathology of the aging kidney. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R01 DK 90358)	02/2011 - 03/2016

Co-Program Director / Principal Investigator	Project 3: Dr. Rule. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 100227)	09/2013 - 12/2018
Co-Investigator	Project 1: Primary Hyperoxaluria. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2014 - 03/2020
Co-Program Director / Principal Investigator	Project 2: Cystinuria. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (U54 DK 83908)	09/2014 - 03/2020
Co-Investigator	The Aging Kidney Anatomy Study. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R01 DK 90358)	03/2016 - 01/2022
Co-Investigator	Quantitative, non-invasive characterization of urinary stone composition and fragility using multi-energy CT and machine learning techniques. Funded by National Institute of Biomedical Imaging and Bioengineering. (R01 EB 28591)	06/2019 - 11/2023

Federal sub award

Program Director / Principal Investigator	Validation of LC-MS/MS as a reference measurement procedure for urine albumin. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 60990)	05/2009 - 04/2015
Program Director / Principal Investigator	PI Effort and Biobanking. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 83912)	07/2014 - 09/2019
Program Director / Principal Investigator	Oxalate in Chronic Kidney Disease. Funded by National Institutes of Health	09/2015 - 08/2017
Program Director / Principal Investigator	Oxalate in Chronic Kidney Disease. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 103784)	09/2015 - 12/2017
Program Director / Principal Investigator	First year effort prorated 9 months-cost. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 110988)	09/2018 - 11/2023
Program Director / Principal Investigator	USDRN Prevention of Urinary Stones with Hydration (PUSH) Study. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 110988)	09/2018 - 11/2023

Program Director / Principal Investigator	Chronic Kidney Disease (CKD) Biomarkers Consortium Data Coordinating Center. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 103225)	09/2018 - 07/2020
Program Director / Principal Investigator	Nephrotic Syndrome Rare Diseases Clinical Research Network. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 83912)	09/2019 - 06/2024
Program Director / Principal Investigator	Nephrotic Syndrome Rare Disease Clinical Research Network III. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 83912)	07/2022 - 06/2024
Co-Investigator	Rare Diseases Clinical Research Network - NephCure. Funded by NephCure Foundation. (NCF01)	09/2009 - 09/2012
Co-Investigator	PI Effort and Biobanking. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 83912)	09/2009 - 06/2014
Co-Investigator	Pilot Year 1 Only. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 83912)	09/2009 - 06/2014
Co-Investigator	Pilot Year 1 Only. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 83912)	07/2014 - 09/2019
Co-Investigator	NEPTUNE II. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (DK 83912)	07/2015 - 06/2019

Foundation

Principal Investigator	Calcium Oxalate Crystal Nucleation onto Renal Cells. Funded by Oxalosis & Hyperoxaluria Foundation	05/2000 - 12/2000
Program Director / Principal Investigator	Characterization and pathogenic potential of biologic nanoparticles. Funded by The John E. Fetzer Memorial Trust, Inc.	03/2007 - 05/2009
Program Director / Principal Investigator	OHF FDA White Paper. Funded by Oxalosis & Hyperoxaluria Foundation	02/2017 - 02/2018
Co-Investigator	Proposal to Establish a Clinical Center for Primary Hyperoxaluria. Funded by Oxalosis & Hyperoxaluria Foundation. (OHF 2-02)	07/2002 - 06/2005
Co-Investigator	Proposal to Establish a Clinical Center for Primary Hyperoxaluria. Funded by Oxalosis & Hyperoxaluria Foundation	04/2003 - 03/2005
Co-Investigator	Regulation of Renal Epithelial Cell Surface Calcium Oxalate Binding Molecules. Funded by Oxalosis & Hyperoxaluria Foundation	07/2005 - 06/2007

Consultant	Novel renal biomarkers to improve the safe and effective use high-dose methotrexate for malignancy. Funded by Hematology/Oncology Pharmacy Association (HOPA)	01/2018 - 12/2019
Industry		
Principal Investigator	Therapeutic Effect of Lactic Acid Bacteria in Enteric Hyperoxaluria. Funded by VSL Pharmaceuticals. (VSL#2 1A4393)	01/2002 - 12/2006
Program Director / Principal Investigator	Amendment 1 -Replacement Budget NGAL Services Agreement. Funded by Gilead Palo Alto, Inc	05/2009 - 04/2010
Program Director / Principal Investigator	NGAL Services Agreement. Funded by Gilead Palo Alto, Inc	05/2009 - 04/2010
Program Director / Principal Investigator	A Pilot Study to Evaluate the Safety and Efficacy of Oxazyme (OC4) in Patients with Hyperoxaluria. Funded by OxThera AB	03/2010 - 02/2011
Program Director / Principal Investigator	Use of Tolvaptan to reduce urinary supersturation: a pilot proof of principle study. Funded by Otsuka America Pharmaceutical, Incorporated. (Otsuka Contract # 20131539)	01/2012 - 12/2013
Program Director / Principal Investigator	Urinary biomarkers of ongoing renal damage in primary hyperoxaluria. Funded by OxThera AB	11/2012 - 10/2013
Program Director / Principal Investigator	Retrospective review of outcomes in primary hyperoxaluria in relation to urinary oxalate excretion. Funded by OxThera AB	07/2014 - 12/2014
Program Director / Principal Investigator	Amendment 3: An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at high risk of progression. Funded by Mallinckrodt Medical, Inc.	08/2014 - 01/2019
Program Director / Principal Investigator	A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers with Hyperoxaluria. Funded by Prolong Pharmaceuticals. (0000649-01)	09/2015 - 08/2016
Program Director / Principal Investigator	Replacement Am 3_A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium	09/2015 - 08/2016

	Oxalate Kidney Stone Formers with Hyperoxaluria. Funded by Allena Pharmaceutical. (0000649-01)	
Program Director / Principal Investigator	Validation of Urinary Cystine concentration measurement using colorimetric versus LC-MS/MS methods.. Funded by Retrophin Inc.	09/2015 - 08/2016
Program Director / Principal Investigator	Amendment 1: Markers of renal failure and kidney stone formation in patients with idiopathic and enteric hyperoxaluria-statistical budget (Allena). Funded by Allena Pharmaceutical	02/2016 - 06/2018
Program Director / Principal Investigator	A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN 177 Treatment Over 28 Days in Patients with Secondary Hyperoxaluria and Kidney Stones. Funded by Allena Pharmaceutical. (0000713-02)	03/2016 - 03/2017
Program Director / Principal Investigator	A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN 177 Treatment Over 28 Days in Patients with Secondary Hyperoxaluria and Kidney Stones. Funded by Allena Pharmaceutical. (0000713-02)	03/2016 - 03/2017
Program Director / Principal Investigator	Open Label Group Budget: Alnylam (ALN-GO1-001) / FP00094685. Funded by Alnylam Pharmaceuticals. (ALN-GO1)	08/2017 - 08/2019
Program Director / Principal Investigator	Randomized Group Budget: Alnylam (ALN-GO1-001) / FP00094685. Funded by Alnylam Pharmaceuticals. (ALN-GO1)	08/2017 - 08/2019
Program Director / Principal Investigator	Identification of PH Patients with Potential to Benefit from Enhanced GI Oxalate Excretion. Funded by OxThera AB	12/2017 - 06/2018
Program Director / Principal Investigator	Amendment 2: A phase III double-blind, randomised study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria. Funded by OxThera AB. (OC5-DB-02)	12/2017 - 12/2019
Program Director / Principal Investigator	Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study. Funded by Allena Pharmaceutical. (ALLN-177-301)	06/2018 - 05/2019
Program Director / Principal Investigator	Amendment 1: Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia. Funded by Allena Pharmaceutical. (ALLN-177-206)	07/2018 - 07/2019

Program Director / Principal Investigator	Amendment 1: ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults with Primary Hyperoxaluria Type 1. Funded by Alnylam Pharmaceuticals. (ALN-GO1-003 (GO103))	12/2018 - 12/2023
Program Director / Principal Investigator	Amendment 1: A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria. Funded by Dicerna Pharmaceuticals, Inc.. (DCR-PHXC-201)	05/2019 - 04/2020
Program Director / Principal Investigator	Alnylam-Mayo Clinic Registry Funding 2019. Funded by Alnylam Pharmaceuticals	07/2019 - 12/2019
Program Director / Principal Investigator	Dicerna PH Development Programs Data Study (RKSC PH Registry). Funded by Dicerna Pharmaceuticals, Inc.	09/2019 - 12/2019
Program Director / Principal Investigator	Dicerna Registry Query #1. Funded by Dicerna Pharmaceuticals, Inc.	07/2020 - 06/2021
Program Director / Principal Investigator	A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients with Primary Hyperoxaluria Type 3. Funded by Dicerna Pharmaceuticals, Inc.. (DCR-PHXC-104)	10/2020 - 03/2021
Program Director / Principal Investigator	19-009656 ALLN-177-302 URIROX-2 Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study. Funded by Allena Pharmaceutical. (ALLN-177-302)	12/2020 - 12/2026
Program Director / Principal Investigator	Dicerna OHF-RKSC Ancillary Study PH3 Stone Events. Funded by Dicerna Pharmaceuticals, Inc.	03/2021 - 09/2021
Program Director / Principal Investigator	20-010654 Dicerna 502. Funded by Dicerna Pharmaceuticals, Inc.. (DCR-PHXC-502)	04/2021 - 04/2024
Program Director /	Amendment 2: A Retrospective Study of the Natural History of Patients with Advanced Primary Hyperoxaluria	06/2021 - 02/2022

Principal Investigator	Type 1 (PH1). Funded by Alnylam Pharmaceuticals. (ALN-GO1-NT-001)	
Program Director / Principal Investigator	Dicerna OHF - Assessment of Health-related Quality of Life in Primary Hyperoxaluria. Funded by Dicerna Pharmaceuticals, Inc.	07/2021 - 12/2021
Program Director / Principal Investigator	Predicted Prevalence of Primary Hyperoxaluria. Funded by Dicerna Pharmaceuticals, Inc.	07/2021 - 10/2021
Program Director / Principal Investigator	A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYN8802 in Healthy Volunteers and in Patients with Enteric Hyperoxaluria. Funded by Synlogic Therapeutics. (SYN8802-CP-001)	08/2021 - 03/2022
Program Director / Principal Investigator	MCP: Identification and characterization of Types 1, 2, and 3, Primary Hyperoxaluria Patients. Funded by Nference, Inc.	12/2021 - 02/2022
Program Director / Principal Investigator	Novome: Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients with Enteric Hyperoxaluria. Funded by Novome Biotechnologies, Inc. (NOV-001-CL01 NOV01CL1)	01/2022 - 07/2022
Program Director / Principal Investigator	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels. Funded by Alnylam Pharmaceuticals. (ALN-GO1-008)	05/2022 - 08/2023
Co-Investigator	Effect of Cystone on Calcium and Cystine Nephrolithiasis IRB 2115-05. Funded by The Himalaya Drug Company	08/2005 - 07/2009
Co-Investigator	MMV Agreement - Nanoparticles and Arterial Disease. Funded by Nanobac Labs	10/2006 - 06/2009
Co-Investigator	A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of Oxabact™ to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria. Funded by OxThera AB	12/2007 - 12/2008
Co-Investigator	Open-label (OL) Study evaluating the Long-Term Safety of Oxabact™ in Subjects with Primary Hyperoxaluria who participated in the Double-Blind (DB) Efficacy Study. Funded by OxThera AB	05/2008 - 05/2009

Co-Investigator	A Study to Determine Feasibility of Procedures for 24 Hour Urine Collections and Variability in Urinary Oxalate and Creatinine Excretion Test Results. Funded by OxThera AB. (CLN-027)	07/2009 - 07/2010
Co-Investigator	A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Oxabact to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria. Funded by OxThera AB. (OC3-DB-02)	11/2009 - 11/2010
Co-Investigator	Central Lab-A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Oxabact to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria. Funded by OxThera AB. (OC3-DB-02)	11/2009 - 11/2010
Co-Investigator	A phase 2, open label, multi-centre study to evaluate the efficacy and safety of Oxabact® to reduce plasma oxalate in subjects with primary hyperoxaluria who are on dialysis. Funded by OxThera AB. (Protocol OC5-OL-01)	04/2014 - 03/2017
Co-Investigator	Repl Am 1_Exploratory studies of urine biomarkers in nephrotic syndrome.. Funded by Bristol-Myers Squibb Research and Development	12/2015 - 07/2017
Co-Investigator	PHYOS: An observational study of patients with Primary Hyperoxaluria type1. Funded by Dicerna Pharmaceuticals, Inc.. (DCR-PH1-501)	01/2016 - 06/2017
Co-Investigator	INTERNAL Amendment 3: Natural History of PH Patients Undergoing Dialysis (OxThera). Funded by OxThera AB	12/2017 - 06/2019
Co-Program Director / Principal Investigator	Amendment 1: RKSCPH Registry Study: Define Natural History of PH1 Relative to Baseline Urinary Oxalate Excretion. Funded by Alnylam Pharmaceuticals	12/2018 - 12/2020
Co-Investigator	Amendment 2: Exploratory studies of urine biomarkers in nephrotic syndrome.. Funded by Bristol-Myers Squibb Research and Development	01/2019 - 12/2019

Mayo Clinic

Principal Investigator	Role of Nanobacteria in Human Calcifying Disease. Funded by Other Mayo	01/2002 - 12/2003
Principal Investigator	Genetic and Environmental Risks for Nephrolithiasis. Funded by Mayo Foundation	08/2005 - 07/2007
Principal Investigator	Clinical utility of two herbal extracts for prevention of nephrolithiasis. Funded by Mayo Foundation	08/2005 - 07/2008
Principal Investigator	Using LC-MSe to identify and quantify peptide fragments of albumin in urine as an early marker of renal disease.. Funded by Mayo Rochester	08/2008 - 08/2009

Principal Investigator	Using LC-MSe to identify and quantify peptide fragments of albumin in urine as an early marker of renal disease.. Funded by Mayo Rochester	08/2008 - 08/2009
Co-Investigator	Microbial Biofilms and Breast Implant Failure. Funded by CR Programs	11/2007 - 10/2009
Co-Investigator	Measurement of Serum FGF23 Levels in Patients with Kidney Stones and in Control Human Subjects. Funded by SGP - Small Grants Program <\$10K	08/2013 - 07/2015
Co-Investigator	Identifying risk factors for acute kidney injury in hospitalized patients. Funded by SGP - Small Grants Program <\$10K	10/2015 - 10/2017
Co-Investigator	NMR Profiling of Urine and Plasma in Rare Kidney Stone Patients. Funded by CCaTS-CBD Pilot Awards for Team Science	01/2019 - 12/2019

Inventions, Commercialization and Offering

A. Patent	Patent Number	Country	Date Filed	Date Issued
Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells Toback; F. Gary (Chicago, IL); Lieske; John C. (Evanston, IL)	5618917	US	02/1995	04/1997
Treatment of Nephrolithiasis and Urolithiasis Using 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) John C. Lieske M.D., Sung-Hoon Kim Ph.D.	8754052	USA	07/2011	06/2014

Bibliography

Peer-reviewed Articles

1. Hammerman C, Strates E, Zaia W, **Lieske J**. Theophylline and the patent ductus arteriosus. J Perinatology. 1984; 4:21-3.
2. **Lieske JC**, MM Walsh-Reitz, FG Toback. Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. Am J Physiol 262 (. 1992; Renal Fluid Electrol: F622-30.
3. **Lieske JC**, B Spargo, FG Toback. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol. 1992; 148:1517-9. PMID: 1433562
4. **Lieske JC**, FG Toback. Autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1993; 3:1442-50. PMID: 8490115
5. **Lieske JC**, FG Toback. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol 264 (. 1993; Renal Fluid Electrol: F800-7.
6. **Lieske JC**, H Swift, T Martin, B Patterson, FG Toback. Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. Proc Natl Acad Sci USA. 1994; 91:6987-91. PMID: 8041733 PMCID: PMC44323
7. **Lieske JC**, R Leonard, FG Toback. Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol 268 (. 1995; Renal Fluid Electrol: F604-12.
8. Hammes MS, **Lieske JC**, Pawar S, Spargo BH, Toback FG. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int. 1995; 48:501-9. PMID: 7564119
9. Wagener OE, **Lieske JC**, FG Toback. Molecular and cell biology of acute renal failure: new therapeutic strategies. New Horizons. 1995; 3:634-49. PMID: 8574594
10. **Lieske JC**, R Leonard, FG Toback. Adhesion of calcium oxalate monohydrate crystals to anionic sites on the surface of renal epithelial cells. Am J Physiol 270 (. 1996; Renal Fluid Electrol: F192-9.
11. **Lieske JC**, MS Hammes, FG Toback. Calcium oxalate monohydrate crystal interactions with renal epithelial cells and the pathogenesis of nephrolithiasis. Scanning Microsc. 1996; 10:519-34. PMID: 9813629
12. **Lieske JC**, FG Toback, SD Deganello. Face-selective adhesion of renal epithelial cells to calcium oxalate dihydrate crystals. Calcif Tissue Int. 1996; 58:195-200. PMID: 8852576
13. **Lieske JC**, FG Toback. Interaction of urinary crystals with renal epithelial cells in the pathogenesis of nephrolithiasis. Sem Nephrol. 1996; 16:458-73.
14. **Lieske JC**, R Norris, FG Toback. Adhesion of hydroxyapatite crystals to anionic sites on the surface of renal epithelial cells. Am J Physiol 273 (. 1997; Renal Physiology 42): F224-33.
15. **Lieske JC**, R Norris, H Swift, FG Toback. Adhesion, internalization and metabolism of calcium oxalate monohydrate crystals by renal epithelial cells. Kidney Int. 1997; 52:1291-301. PMID: 9350652

16. **Lieske JC**, MS Hammes, JR Hoyer, FG Toback. Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals. *Kidney Int.* 1997; 51:679-86. PMID: 9067899
17. **Lieske JC**, FG Toback, S Deganello. Direct nucleation of calcium oxalate dihydrate crystals onto the surface of living renal epithelial cells. *Kidney Int.* 1998; 54:796-803. PMID: 9734604
18. **Lieske JC**, S Deganello, FG Toback. Cell-crystal interactions and kidney stone formation. *Nephron.* 1999; 81(Suppl 1):8-17. PMID: 9873209
19. **Lieske JC**, S Deganello. Nucleation, adhesion and internalization of calcium-containing urinary crystals by renal cells. *J Am Soc Nephrol.* 1999; 10:S422-9. PMID: 10541277
20. Asplin JR, Parks JH, Chen MS, **Lieske JC**, Toback FG, Pillay SN, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from men with nephrolithiasis. *Kidney Int.* 1999; 56:1505-16. PMID: 10504502
21. **Lieske JC**, E Huang, FG Toback. Regulation of renal epithelial cell affinity for calcium oxalate monohydrate crystals. *Am J Physiol.* 2000; 278:F130-7.
22. **Lieske JC**, FG Toback. Renal cell-urinary crystal interactions. *Curr Opin Nephrol Hyperten.* 2000; 9:349-55.
23. Koka RM, Huang E, **Lieske JC**. Adhesion of uric acid crystals to the surface of renal epithelial cells. *Am J Physiol Renal Physiol.* 2000 Jun; 278(6):F989-98. PMID: 10836987
24. **Lieske JC**, Toback FG, Deganello S. Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. *Kidney Int.* 2001 Nov; 60 (5):1784-91 PMID: 11703596 DOI: 10.1046/j.1523-1755.2001.00015.x
25. Kumar V, Farell G, Deganello S, **Lieske JC**. Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals. *J Am Soc Nephrol.* 2003 Feb; 14 (2):289-97 PMID: 12538728 DOI: 10.1097/01.asn.0000046030.24938.0a
26. Kumar V, Farell G, **Lieske JC**. Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells. *J Urol.* 2003 Jul; 170(1):221-5. PMID: 12796693 DOI: 10.1097/01.ju.0000059540.36463.9f
27. Erickson SB, **Lieske JC**. Medical management. *Clinical Reviews in Bone & Mineral Metabolism.* 2004; 2(3):237-51.
28. Erickson , Stephen B., **Lieske John C.**. Treatment Clinical Reviews in Bone and Mineral Metabolism. 2004.
29. **Lieske JC**, Farell G, Deganello S. The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions. *Urol Res.* 2004 May; 32 (2):117-23 Epub 2003 Dec 09 PMID: 14663633 DOI: 10.1007/s00240-003-0391-5
30. Shah NS, Kruse SA, Lager DJ, Farell-Baril G, **Lieske JC**, King BF, Ehman RL. Evaluation of renal parenchymal disease in a rat model with magnetic resonance elastography. *Magn Reson Med.* 2004 Jul; 52(1):56-64. PMID: 15236367 DOI: 10.1002/mrm.20101
31. Miller VM, Rodgers G, Charlesworth JA, Kirkland B, Severson SR, Rasmussen TE, Yagubyan M, Rodgers JC, Cockerill FR 3rd, Folk RL, Rzewuska-Lech E, Kumar V, Farell-Baril G, **Lieske JC**. Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. *Am J Physiol Heart Circ Physiol.* 2004 Sep; 287 (3):H1115-24 Epub 2004 May 13 PMID: 15142839 DOI: 10.1152/ajpheart.00075.2004

32. Kumar V, Yu S, Farell G, Toback FG, **Lieske JC**. Renal epithelial cells constitutively produce a protein that blocks adhesion of crystals to their surface. *Am J Physiol Renal Physiol*. 2004 Sep; 287 (3):F373-83 Epub 2004 Apr 20 PMID: 15100100 DOI: 10.1152/ajprenal.00418.2003
33. Atmani F, Farell G, **Lieske JC**. Extract from herniaria hirsuta coats calcium oxalate monohydrate crystals and blocks their adhesion to renal epithelial cells. *J Urol*. 2004 Oct; 172(4 Part 1):1510-4. PMID: 15371881
34. Pena de la Vega L, **Lieske JC**, Milliner D, Gonyea J, Kelly DG. Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. *JPEN J Parenter Enteral Nutr*. 2004 Nov-Dec; 28 (6):435-8 PMID: 15568291 DOI: 10.1177/0148607104028006435
35. Farell G, Huang E, Kim SY, Horstkorte R, **Lieske JC**. Modulation of proliferating renal epithelial cell affinity for calcium oxalate monohydrate crystals. *J Am Soc Nephrol*. 2004 Dec; 15(12):3052-62. PMID: 15579508 DOI: 10.1097/01.ASN.0000144205.49134.64
36. **Lieske JC**, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, Olson JB, Milliner DS. International registry for primary hyperoxaluria. *Am J Nephrol*. 2005 May-Jun; 25 (3):290-6 Epub 2005 June 15 PMID: 15961949 DOI: 10.1159/000086360
37. Nelson WK, Houghton SG, Milliner DS, **Lieske JC**, Sarr MG. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. *Surg Obes Relat Dis*. 2005 Sep-Oct; 1(5):481-5. Epub 2005 Aug 26. PMID: 16925274 DOI: 10.1016/j.soard.2005.07.002
38. **Lieske JC**, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. *Kidney Int*. 2005 Sep; 68(3):1244-9. PMID: 0
39. **Lieske JC**, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. *Kidney Int*. 2005 Sep; 68 (3):1244-9 PMID: 16105057 DOI: 10.1111/j.1523-1755.2005.00520.x
40. Kumar V, de la Vega LP, Farell G, **Lieske JC**. Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. *Kidney Int*. 2005 Oct; 68(4):1784-92. PMID: 16164655
41. Greene EL, Farell G, Yu S, Matthews T, Kumar V, **Lieske JC**. Renal cell adaptation to oxalate. *Urol Res*. 2005 Nov; 33 (5):340-8 Epub 2005 Nov 13 PMID: 16284879 DOI: 10.1007/s00240-005-0491-5
42. Ladwig PM, Liedtke RR, Larson TS, **Lieske JC**. Sensitive spectrophotometric assay for plasma oxalate. *Clin Chem*. 2005 Dec; 51(12):2377-80. PMID: 16306102 DOI: 10.1373/clinchem.2005.054353
43. **Lieske JC**, Pena de la Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, Gettman MT. Renal stone epidemiology in Rochester, Minnesota: an update. *Kidney Int*. 2006 Feb; 69 (4):760-4 PMID: 16518332 DOI: 10.1038/sj.ki.5000150
44. Kumar V, **Lieske JC**. Protein regulation of intrarenal crystallization. *Curr Opin Nephrol Hypertens*. 2006 Jul; 15(4):374-80. PMID: 16775451 PMCID: PMC0 DOI: 10.1097/01.mnh.0000232877.12599.f4
45. Kumar V, Farell G, Yu S, Harrington S, Fitzpatrick L, Rzewuska E, Miller VM, **Lieske JC**. Cell biology of pathologic renal calcification: contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. *J Invest Med*. 2006 Nov; 54: (7)412-24. PMID: 17169263
46. Miller VM, **Lieske JC**, Salahudeen AK. Introduction to pathologic calcification: crystallization, infection, or cellular transdifferentiation. *J Invest Med*. 2006 Nov; 54: (7)365-6. PMID: 17169257

47. Benzerara K, Miller VM, Barell G, Kumar V, Miot J, Brown GE, **Lieske JC**. Search for microbial signatures within human and microbial calcifications using soft x-ray spectromicroscopy. *J Investig Med*. 2006 Nov; 54(7):367-79. PMID: 17169258
48. **Lieske JC**, de la Vega LS, Gettman MT, Slezak JM, Bergstralh EJ, Melton LJ 3rd, Leibson CL. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. *Am J Kidney Dis*. 2006 Dec; 48 (6):897-904 PMID: 17162144 DOI: 10.1053/j.ajkd.2006.09.002
49. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, Kumar R, **Lieske JC**. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. *Kidney Int*. 2007 Jul; 72: (1)100-7. PMID: 17377509 DOI: 10.1038/sj.ki.5002194
50. Primak AN, Fletcher JG, Vrtiska TJ, Dzyubak OP, **Lieske JC**, Jackson ME, Williams JC Jr, McCollough CH. Noninvasive differentiation of uric acid versus non-uric acid kidney stones using dual-energy CT. *Acad Radiol*. 2007 Dec; 14 (12):1441-7 PMID: 18035274 PMCID: PMC2743375 DOI: 10.1016/j.acra.2007.09.016
51. Mo L, Liaw L, Evan AP, Sommer AJ, **Lieske JC**, Wu XR. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. *Am J Physiol Renal Physiol*. 2007 Dec; 293(6):F1935-43. Epub 2007 Sep 26. PMID: 17898038 DOI: 10.1152/ajprenal.00383.2007
52. Schwartz MA, **Lieske JC**, Kumar V, Farell-Baril G, Miller VM. Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: proof of principle. *Int J Nanomedicine*. 2008; 3 (2):243-8 PMID: 18686783 PMCID: PMC2527666 DOI: 10.2147/ijn.s2473
53. **Lieske JC**, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. *Semin Nephrol*. 2008 Mar; 28 (2):163-73 PMID: 18359397 PMCID: PMC2831413 DOI: 10.1016/j.semnephrol.2008.01.009
54. **Lieske JC**, Regnier C, Dillon JJ. Use of sevelamer hydrochloride as an oxalate binder. *J Urol*. 2008 Apr; 179 (4):1407-10 Epub 2008 Mar 04 PMID: 18289565 PMCID: PMC2655347 DOI: 10.1016/j.juro.2007.11.062
55. **Lieske JC**. Can biologic nanoparticles initiate nephrolithiasis? *Nat Clin Pract Nephrol*. 2008 Jun; 4(6):308-9. Epub 2008 Mar 18. PMID: 18349851 DOI: 10.1038/ncpneph0794
56. Shaikh A, Seegmiller JC, Borland TM, Burns BE, Ladwig PM, Singh RJ, Kumar R, Larson TS, **Lieske JC**. Comparison between immunoturbidimetry, size-exclusion chromatography, and LC-MS to quantify urinary albumin. *Clin Chem*. 2008 Sep; 54(9):1504-10. Epub 2008 Jul 10. PMID: 18617580 PMCID: PMC3903150 DOI: 10.1373/clinchem.2008.107508
57. Ward VL, **Lieske JC**. Dipstick on spun urine. *MLO Med Lab Obs*. 2008 Sep; 40(9):44. PMID: 0
58. Shiekh FA, Miller VM, **Lieske JC**. Do calcifying nanoparticles promote nephrolithiasis? A review of the evidence. *Clin Nephrol*. 2009 Jan; 71 (1):1-8 PMID: 19203544 DOI: 10.5414/cnp71001
59. Lee JH, Lee HJ, Lee HJ, Choi WC, Yoon SW, Ko SG, Ahn KS, Choi SH, Ahn KS, **Lieske JC**, Kim SH. Rhus verniciflua Stokes prevents cisplatin-induced cytotoxicity and reactive oxygen species production in MDCK-I renal cells and intact mice. *Phytomedicine*. 2009 Mar; 16 (2-3):188-97 Epub 2009 Jan 15 PMID: 19150236 DOI: 10.1016/j.phymed.2008.10.009
60. Lee JH, Yehl M, Ahn KS, Kim SH, **Lieske JC**. 1,2,3,4,6-penta-O-galloyl-beta-D-glucose attenuates renal cell migration, hyaluronan expression, and crystal adhesion. *Eur J Pharmacol*. 2009 Mar 15; 606 (1-3):32-7 Epub 2009 Jan 25 PMID: 19374853 DOI: 10.1016/j.ejphar.2009.01.024

61. Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, **Lieske JC**. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol. 2009 Apr; 4 (4):804-11 Epub 2009 Apr 01 PMID: 19339425 PMCID: PMC2666438 DOI: 10.2215/CJN.05811108
62. Rule AD, Bailey KR, Schwartz GL, Khosla S, **Lieske JC**, Melton LJ 3rd. For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int. 2009 May; 75 (10):1071-8 Epub 2009 Jan 28 PMID: 19177154 PMCID: PMC2681487 DOI: 10.1038/ki.2008.698
63. Schwartz MK, **Lieske JC**, Hunter LW, Miller VM. Systemic injection of planktonic forms of mammalian-derived nanoparticles alters arterial response to injury in rabbits. Am J Physiol Heart Circ Physiol. 2009 May; 296 (5):H1434-41 Epub 2009 Mar 13 PMID: 19286948 PMCID: PMC2685330 DOI: 10.1152/ajpheart.00993.2008
64. Seegmiller JC, Barnidge DR, Burns BE, Larson TS, **Lieske JC**, Kumar R. Quantification of urinary albumin by using protein cleavage and LC-MS/MS. Clin Chem. 2009 Jun; 55 (6):1100-7 Epub 2009 Mar 26 PMID: 19325011 PMCID: PMC3922069 DOI: 10.1373/clinchem.2008.115543
65. Miller VM, Hunter LW, Chu K, Kaul V, Squillace PD, **Lieske JC**, Jayachandran M. Biologic nanoparticles and platelet reactivity. Nanomedicine (Lond). 2009 Oct; 4 (7):725-33 PMID: 19839809 PMCID: PMC2785539 DOI: 10.2217/nnm.09.61
66. Seegmiller JC, Sviridov D, Larson TS, Borland TM, Hortin GL, **Lieske JC**. Comparison of urinary albumin quantification by immunoturbidimetry, competitive immunoassay, and protein-cleavage liquid chromatography-tandem mass spectrometry. Clin Chem. 2009 Nov; 55 (11):1991-4 Epub 2009 Sept 10 PMID: 19745060 DOI: 10.1373/clinchem.2009.129833
67. Schwartz MK, Hunter LW, Huebner M, **Lieske JC**, Miller VM. Characterization of biofilm formed by human-derived nanoparticles. Nanomedicine (Lond). 2009 Dec; 4 (8):931-41 PMID: 19958229 PMCID: PMC3023954 DOI: 10.2217/nnm.09.72
68. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, Itoh Y, **Lieske JC**, Secombe DW, Jones G, Bunk DM, Curhan GC, Narva AS, National Kidney Disease Education Program-IFCC Working Group on Standardization of Albumin in Urine. [Current issues in measurement and reporting of urinary albumin excretion]. Ann Biol Clin (Paris). 2010 Jan-Feb; 68(1):9-25. PMID: 20146974 DOI: 10.1684/abc.2010.0402
69. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, Itoh Y, **Lieske JC**, Secombe DW, Jones G, Bunk DM, Curhan GC, Narva AS. Current issues in measurement and report of urinary albumin excretion. Jornal Brasileiro de Patologia e Medicina Laboratorial. 2010; 46(3):187-206.
70. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, Itoh Y, **Lieske JC**, Secombe DW, Jones G, Bunk DM, Curhan GC, Narva AS. Current issues in measurement and reporting of urinary albumin excretion. Biochim clin. 2010; 34(5):337-50.
71. Kim JH, Jeong SJ, Kwon HY, Park SY, Lee HJ, Lee HJ, **Lieske JC**, Kim SH. Decursin prevents cisplatin-induced apoptosis via the enhancement of antioxidant enzymes in human renal epithelial cells. Biol Pharm Bull. 2010; 33 (8):1279-84 PMID: 20686219 DOI: 10.1248/bpb.33.1279
72. Saucier NA, Sinha MK, Liang KV, Krambeck AE, Weaver AL, Bergstralh EJ, Li X, Rule AD, **Lieske JC**. Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis. 2010 Jan; 55 (1):61-8 Epub 2009 Oct 22 PMID: 19853335 PMCID: PMC2812807 DOI: 10.1053/j.ajkd.2009.08.008

73. Schwartz MK, **Lieske JC**, Miller VM. Contribution of biologically derived nanoparticles to disease. *Surgery*. 2010 Feb; 147(2):181-4. Epub 2009 Sep 20. PMID: 19767047 PMCID: PMC2813968 DOI: 10.1016/j.surg.2009.07.009
74. Lorenz EC, Vrtiska TJ, **Lieske JC**, Dillon JJ, Stegall MD, Li X, Bergstralh EJ, Rule AD. Prevalence of renal artery and kidney abnormalities by computed tomography among healthy adults. *Clin J Am Soc Nephrol*. 2010 Mar; 5 (3):431-8 Epub 2010 Jan 14 PMID: 20089492 PMCID: PMC2827579 DOI: 10.2215/CJN.07641009
75. Seegmiller JC, Burns BE, Fauq AH, Mukhtar N, **Lieske JC**, Larson TS. Iothalamate quantification by tandem mass spectrometry to measure glomerular filtration rate. *Clin Chem*. 2010 Apr; 56 (4):568-74 Epub 2010 Feb 18 PMID: 20167698 DOI: 10.1373/clinchem.2009.133751
76. Vrtiska TJ, Krambeck AE, McCollough CH, Leng S, Qu M, Yu L, **Lieske JC**. Imaging evaluation and treatment of nephrolithiasis: an update. *Minn Med*. 2010 Aug; 93 (8):48-51 PMID: 20862880 PMCID: PMC3927414
77. Liu Y, Mo L, Goldfarb DS, Evan AP, Liang F, Khan SR, **Lieske JC**, Wu XR. Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein. *Am J Physiol Renal Physiol*. 2010 Sep; 299(3):F469-78. Epub 2010 Jun 30. PMID: 20591941 PMCID: PMC2944300 DOI: 10.1152/ajprenal.00243.2010
78. Rule AD, Roger VL, Melton LJ 3rd, Bergstralh EJ, Li X, Peyser PA, Krambeck AE, **Lieske JC**. Kidney stones associate with increased risk for myocardial infarction. *J Am Soc Nephrol*. 2010 Oct; 21 (10):1641-4 Epub 2010 July 08 PMID: 20616170 PMCID: PMC3013539 DOI: 10.1681/ASN.2010030253
79. Shiekh FA, Charlesworth JE, Kim SH, Hunter LW, Jayachandran M, Miller VM, **Lieske JC**. Proteomic evaluation of biological nanoparticles isolated from human kidney stones and calcified arteries. *Acta Biomater*. 2010 Oct; 6 (10):4065-72 Epub 2010 May 11 PMID: 20466084 PMCID: PMC2930148 DOI: 10.1016/j.actbio.2010.05.004
80. Mookadam F, Smith T, Jiamsripong P, Moustafa SE, Monico CG, **Lieske JC**, Milliner DS. Cardiac abnormalities in primary hyperoxaluria. *Circ J*. 2010 Nov; 74 (11):2403-9 Epub 2010 Sept 29 PMID: 20921818 PMCID: PMC5929473 DOI: 10.1253/circj.cj-10-0107
81. Bergstralh EJ, Monico CG, **Lieske JC**, Herges RM, Langman CB, Hoppe B, Milliner DS, IPHR Investigators. Transplantation outcomes in primary hyperoxaluria. *Am J Transplant*. 2010 Nov; 10 (11):2493-501 Epub 2010 Sept 17 PMID: 20849551 PMCID: PMC2965313 DOI: 10.1111/j.1600-6143.2010.03271.x
82. **Lieske JC**, Tremaine WJ, De Simone C, O'Connor HM, Li X, Bergstralh EJ, Goldfarb DS. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. *Kidney Int*. 2010 Dec; 78 (11):1178-85 Epub 2010 Aug 25 PMID: 20736987 PMCID: PMC3923490 DOI: 10.1038/ki.2010.310
83. Krambeck AE, **Lieske JC**. Infection-related kidney stones. *Clinical Reviews in Bone and Mineral Metabolism*. 2011; 9(3-4):218-28.
84. Linnes MP, Shiekh FA, Hunter LW, Miller VM, **Lieske JC**. Isolation, propagation, and analysis of biological nanoparticles. *Methods Mol Biol*. 2011; 790:263-75. PMID: 21948421 DOI: 10.1007/978-1-61779-319-6_20
85. Qu M, Ramirez-Giraldo JC, Leng S, Williams JC, Vrtiska TJ, **Lieske JC**, McCollough CH. Re: Dual-energy dual-source CT with additional spectral filtration can improve the differentiation of non-uric acid renal stones: An ex vivo phantom study. *J Urol*. 2011; 186(5):1916.

86. Krambeck AE, Rule AD, Li X, Bergstralh EJ, Gettman MT, **Lieske JC**. Shock wave lithotripsy is not predictive of hypertension among community stone formers at long-term followup. J Urol. 2011 Jan; 185 (1):164-9 Epub 2010 Nov 13 PMID: 21074794 PMCID: PMC3086040 DOI: 10.1016/j.juro.2010.09.033
87. Lee HJ, Jeong SJ, Lee HJ, Lee EO, Bae H, **Lieske JC**, Kim SH. 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose reduces renal crystallization and oxidative stress in a hyperoxaluric rat model. Kidney Int. 2011 Mar; 79 (5):538-45 Epub 2010 Nov 17 PMID: 21085110 PMCID: PMC4019041 DOI: 10.1038/ki.2010.458
88. Hunter LW, Shiekh FA, Pisimisis GT, Kim SH, Edeh SN, Miller VM, **Lieske JC**. Key role of alkaline phosphatase in the development of human-derived nanoparticles in vitro. Acta Biomater. 2011 Mar; 7 (3):1339-45 Epub 2010 Oct 26 PMID: 21029794 PMCID: PMC3031733 DOI: 10.1016/j.actbio.2010.10.027
89. Rule AD, Semret MH, Amer H, Cornell LD, Taler SJ, **Lieske JC**, Melton LJ 3rd, Stegall MD, Textor SC, Kremers WK, Lerman LO. Association of kidney function and metabolic risk factors with density of glomeruli on renal biopsy samples from living donors. Mayo Clin Proc. 2011 Apr; 86 (4):282-90 PMID: 21454731 PMCID: PMC3068887 DOI: 10.4065/mcp.2010.0821
90. Kumar R, **Lieske JC**, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ, Bergstralh EJ, Li X. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery. 2011 May; 149 (5):654-61 Epub 2011 Feb 05 PMID: 21295813 PMCID: PMC3078956 DOI: 10.1016/j.surg.2010.11.015
91. Erickson SB, Vrtiska TJ, Canzanella VJ, **Lieske JC**. Cystone(R) for 1 year did not change urine chemistry or decrease stone burden in cystine stone formers. Urol Res. 2011 Jun; 39 (3):197-203 Epub 2010 Dec 16 PMID: 21161651 DOI: 10.1007/s00240-010-0334-x
92. Qu M, Ramirez-Giraldo JC, Leng S, Williams JC, Vrtiska TJ, **Lieske JC**, McCollough CH. Dual-energy dual-source CT with additional spectral filtration can improve the differentiation of non-uric acid renal stones: an ex vivo phantom study. AJR Am J Roentgenol. 2011 Jun; 196 (6):1279-87 PMID: 21606290 PMCID: PMC3901037 DOI: 10.2214/AJR.10.5041
93. Erickson SB, Vrtiska TJ, **Lieske JC**. Effect of Cystone(R) on urinary composition and stone formation over a one year period. Phytomedicine. 2011 Jul 15; 18 (10):863-7 Epub 2011 Mar 17 PMID: 21419609 PMCID: PMC3925635 DOI: 10.1016/j.phymed.2011.01.018
94. Rule AD, Krambeck AE, **Lieske JC**. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol. 2011 Aug; 6 (8):2069-75 Epub 2011 July 22 PMID: 21784825 PMCID: PMC3156433 DOI: 10.2215/CJN.10651110
95. Lorenz EC, **Lieske JC**, Vrtiska TJ, Krambeck AE, Li X, Bergstralh EJ, Melton LJ 3rd, Rule AD. Clinical characteristics of potential kidney donors with asymptomatic kidney stones. Nephrol Dial Transplant. 2011 Aug; 26 (8):2695-700 Epub 2011 Feb 01 PMID: 21285126 PMCID: PMC3145914 DOI: 10.1093/ndt/gfq769
96. Murata K, Baumann NA, Saenger AK, Larson TS, Rule AD, **Lieske JC**. Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. Clin J Am Soc Nephrol. 2011 Aug; 6 (8):1963-72 Epub 2011 July 07 PMID: 21737852 PMCID: PMC3156428 DOI: 10.2215/CJN.02300311
97. White CA, Rule AD, Collier CP, Akbari A, **Lieske JC**, Lepage N, Doucette S, Knoll GA. The impact of interlaboratory differences in cystatin C assay measurement on glomerular filtration rate estimation. Clin J Am Soc Nephrol. 2011 Sep; 6(9):2150-6. Epub 2011 Jul 28. PMID: 21799146 PMCID: PMC3358990 DOI: 10.2215/CJN.00130111

98. **Lieske JC**, Bonebrake D, Thesing J, Bella G. Eosinophiluria is common among patients after ileal conduit surgery. Clin Chem Lab Med. 2011 Nov; 49: (11)1869-71. PMID: 21767218 DOI: 10.1515/CCLM.2011.665
99. Hunter LW, **Lieske JC**, Tran NV, Miller VM. The association of matrix Gla protein isomers with calcification in capsules surrounding silicone breast implants. Biomaterials. 2011 Nov; 32 (33):8364-73 Epub 2011 Aug 11 PMID: 21839505 PMCID: PMC3177005 DOI: 10.1016/j.biomaterials.2011.07.073
100. Maalouf NM, Adams Huet B, Pasch A, **Lieske JC**, Asplin JR, Siener R, Hesse A, Nuoffer JM, Frey FJ, Knight J, Holmes RP, Zerwekh JE, Bonny O. Variability in urinary oxalate measurements between six international laboratories. Nephrol Dial Transplant. 2011 Dec; 26(12):3954-9. Epub 2011 Mar 31. PMID: 21454350 PMCID: PMC3254161 DOI: 10.1093/ndt/gfr147
101. Lee HJ, Jeong SJ, Park MN, Linnes M, Han HJ, Kim JH, **Lieske JC**, Kim SH. Gallotannin suppresses calcium oxalate crystal binding and oxalate-induced oxidative stress in renal epithelial cells. Biol Pharm Bull. 2012; 35(4):539-44. PMID: 22466558 PMCID: PMC3910304
102. Beara-Lasic L, Edvardsson VO, Palsson R, **Lieske JC**, Goldfarb DS, Milliner DS. Genetic causes of kidney stones and kidney failure. Clinical Reviews in Bone and Mineral Metabolism. 2012; 10(1):2-18.
103. de Cogain M, Krambeck AE, Rule AD, Li X, Bergstralh EJ, Gettman MT, **Lieske JC**. Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. Urology. 2012 Feb; 79 (2):298-302 Epub 2011 Nov 16 PMID: 22088569 PMCID: PMC3274621 DOI: 10.1016/j.urology.2011.07.1430
104. Voskoboev NV, Larson TS, Rule AD, **Lieske JC**. Analytic and clinical validation of a standardized cystatin C particle enhanced turbidimetric assay (PETIA) to estimate glomerular filtration rate. Clin Chem Lab Med. 2012 Mar 30; 50 (9):1591-6 PMID: 22962219 DOI: 10.1515/cclm-2012-0063
105. Rule AD, Sasiwimonphan K, **Lieske JC**, Keddis MT, Torres VE, Vrtiska TJ. Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors. Am J Kidney Dis. 2012 May; 59 (5):611-8 Epub 2012 Mar 06 PMID: 22398108 PMCID: PMC3328591 DOI: 10.1053/j.ajkd.2011.12.022
106. Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, **Lieske JC**, Rule AD. Temporal trends in incidence of kidney stones among children: a 25-year population based study. J Urol. 2012 Jul; 188 (1):247-52 Epub 2012 May 15 PMID: 22595060 PMCID: PMC3482509 DOI: 10.1016/j.juro.2012.03.021
107. Pang R, Linnes MP, O'Connor HM, Li X, Bergstralh E, **Lieske JC**. Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery. Urology. 2012 Aug; 80 (2):250-4 Epub 2012 May 02 PMID: 22554593 PMCID: PMC3411876 DOI: 10.1016/j.urology.2012.02.052
108. El-Zoghby ZM, **Lieske JC**, Foley RN, Bergstralh EJ, Li X, Melton LJ 3rd, Krambeck AE, Rule AD. Urolithiasis and the risk of ESRD. Clin J Am Soc Nephrol. 2012 Sep; 7 (9):1409-15 Epub 2012 June 28 PMID: 22745275 PMCID: PMC3430957 DOI: 10.2215/CJN.03210312
109. Block DR, **Lieske JC**. Automated urinalysis in the clinical lab. MLO Med Lab Obs. 2012 Oct; 44(10):8-10, 12; quiz 14. PMID: 23091955
110. Viers BR, Williams JC, **Lieske JC**, Krambeck AE. Calcite urolithiasis in patient with acromegaly confirmed by percutaneous removal, infrared spectroscopic analysis BJUI.2012;DOI: 10.1002/BJUIW-7:

111. Wockenfus AM, Koch CD, Conlon PM, Sorensen LD, Cambern KL, Chihak AJ, Zmolek JA, Petersen AE, Burns BE, **Lieske JC**, Karon BS. Discordance between urine pH measured by dipstick and pH meter: implications for methotrexate administration protocols. Clin Biochem. 2013 Jan; 46(1-2):152-4. Epub 2012 Oct 24. PMID: 23103706 DOI: 10.1016/j.clinbiochem.2012.10.018
112. Krambeck AE, **Lieske JC**, Li X, Bergstralh EJ, Melton LJ 3rd, Rule AD. Effect of age on the clinical presentation of incident symptomatic urolithiasis in the general population. J Urol. 2013 Jan; 189(1):158-64 Epub 2012 Nov 16 PMID: 23164393 PMCID: PMC3648841 DOI: 10.1016/j.juro.2012.09.023
113. Irazabal MV, Eirin A, **Lieske J**, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant. 2013 Jan; 28(1):137-46 Epub 2012 Sept 17 PMID: 22987142 PMCID: PMC3616763 DOI: 10.1093/ndt/gfs379
114. Linnes MP, Krambeck AE, Cornell L, Williams JC Jr, Korinek M, Bergstralh EJ, Li X, Rule AD, McCollough CM, Vrtiska TJ, **Lieske JC**. Re: Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. J Urol. 2013; 190(5):1785.
115. Amer H, **Lieske JC**, Rule AD, Kremers WK, Larson TS, Franco Palacios CR, Stegall MD, Cosio FG. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant. 2013 Mar; 13(3):676-84 Epub 2013 Feb 15 PMID: 23414180 PMCID: PMC3582782 DOI: 10.1111/ajt.12044
116. Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, **Lieske JC**, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013 Apr; 83(4):749-56. Epub 2013 Jan 16. PMID: 23325076 PMCID: PMC3612359 DOI: 10.1038/ki.2012.428
117. **Lieske JC**, Bondar O, Miller WG, Bachmann LM, Narva AS, Itoh Y, Zegers I, Schimmel H, Phinney K, Bunk DM, National Kidney Disease Education Program - IFCC Working Group on Standardization of Albumin in Urine (WG-SAU). A reference system for urinary albumin: current status. Clin Chem Lab Med. 2013 May; 51(5):981-9. PMID: 23241608 DOI: 10.1515/cclm-2012-0768
118. Schinstock CA, Semret MH, Wagner SJ, Borland TM, Bryant SC, Kashani KB, Larson TS, **Lieske JC**. Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrol Dial Transplant. 2013 May; 28(5):1175-85 Epub 2012 Apr 23 PMID: 22529161 DOI: 10.1093/ndt/gfs127
119. Qu M, Jaramillo-Alvarez G, Ramirez-Giraldo JC, Liu Y, Duan X, Wang J, Vrtiska TJ, Krambeck AE, **Lieske J**, McCollough CH. Urinary stone differentiation in patients with large body size using dual-energy dual-source computed tomography. Eur Radiol. 2013 May; 23(5):1408-14 Epub 2012 Dec 21 PMID: 23263603 PMCID: PMC3780962 DOI: 10.1007/s00330-012-2727-4
120. Duan X, Qu M, Wang J, Trevathan J, Vrtiska T, Williams JC Jr, Krambeck A, **Lieske J**, McCollough C. Differentiation of calcium oxalate monohydrate and calcium oxalate dihydrate stones using quantitative morphological information from micro-computerized and clinical computerized tomography. J Urol. 2013 Jun; 189(6):2350-6 Epub 2012 Nov 07 PMID: 23142201 PMCID: PMC3966517 DOI: 10.1016/j.juro.2012.11.004

121. Rule AD, Bailey KR, **Lieske JC**, Peyser PA, Turner ST. Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. *Kidney Int.* 2013 Jun; 83 (6):1169-76 Epub 2013 Feb 20 PMID: 23423253 PMCID: PMC3661736 DOI: 10.1038/ki.2013.7
122. Giesen CD, Greeno AM, Thompson KA, Patel R, Jenkins SM, **Lieske JC**. Performance of flow cytometry to screen urine for bacteria and white blood cells prior to urine culture. *Clin Biochem.* 2013 Jun; 46(9):810-3. Epub 2013 Mar 13. PMID: 23500010 DOI: 10.1016/j.clinbiochem.2013.03.005
123. Lorenz EC, Michet CJ, Milliner DS, **Lieske JC**. Update on oxalate crystal disease. *Curr Rheumatol Rep.* 2013 Jul; 15 (7):340 PMID: 23666469 PMCID: PMC3710657 DOI: 10.1007/s11926-013-0340-4
124. Krambeck AE, **Lieske JC**, Li X, Bergstralh EJ, Rule AD, Holmes D 3rd, McCollough CM, Vrtiska TJ. Current computed tomography techniques can detect duct of Bellini plugging but not Randall's plaques. *Urology.* 2013 Aug; 82 (2):301-6 Epub 2013 June 20 PMID: 23791212 PMCID: PMC3744363 DOI: 10.1016/j.urology.2013.04.028
125. Franco Palacios CR, **Lieske JC**, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. *Transplantation.* 2013 Aug 27; 96 (4):394-9 PMID: 23736353 PMCID: PMC4119827 DOI: 10.1097/TP.0b013e3182977ab1
126. Edvardsson VO, Goldfarb DS, **Lieske JC**, Beara-Lasic L, Anglani F, Milliner DS, Palsson R. Hereditary causes of kidney stones and chronic kidney disease. *Pediatr Nephrol.* 2013 Oct; 28 (10):1923-42 Epub 2013 Jan 20 PMID: 23334384 PMCID: PMC4138059 DOI: 10.1007/s00467-012-2329-z
127. Tsapenko MV, Nwoko RE, Borland TM, Voskoboev NV, Pflueger A, Rule AD, **Lieske JC**. Measurement of urinary TGF-beta1 in patients with diabetes mellitus and normal controls. *Clin Biochem.* 2013 Oct; 46(15):1430-5. Epub 2013 May 16. PMID: 23685222 DOI: 10.1016/j.clinbiochem.2013.05.041
128. Linnes MP, Krambeck AE, Cornell L, Williams JC Jr, Korinek M, Bergstralh EJ, Li X, Rule AD, McCollough CM, Vrtiska TJ, **Lieske JC**. Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. *Kidney Int.* 2013 Oct; 84 (4):818-25 Epub 2013 May 22 PMID: 23698231 PMCID: PMC3784621 DOI: 10.1038/ki.2013.189
129. Liu Y, Qu M, Carter RE, Leng S, Ramirez-Giraldo JC, Jaramillo G, Krambeck AE, **Lieske JC**, Vrtiska TJ, McCollough CH. Differentiating calcium oxalate and hydroxyapatite stones in vivo using dual-energy CT and urine supersaturation and pH values. *Acad Radiol.* 2013 Dec; 20 (12):1521-5 PMID: 24200478 PMCID: PMC3963806 DOI: 10.1016/j.acra.2013.08.018
130. Hunter LW, Charlesworth JE, Yu S, **Lieske JC**, Miller VM. Calcifying nanoparticles promote mineralization in vascular smooth muscle cells: implications for atherosclerosis. *Int J Nanomedicine.* 2014; 9:2689-98 Epub 2014 May 27 PMID: 24920905 PMCID: PMC4043721 DOI: 10.2147/IJN.S63189
131. Tang X, Voskoboev NV, Wannarka SL, Olson JB, Milliner DS, **Lieske JC**. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. *Am J Nephrol.* 2014; 39 (5):376-82 Epub 2014 Apr 26 PMID: 24776840 PMCID: PMC4485608 DOI: 10.1159/000360624
132. Frazee EN, Rule AD, Herrmann SM, Kashani KB, Leung N, Virk A, Voskoboev N, **Lieske JC**. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: A cohort study. *Crit. Care.* 2014; 18(3):R110. PMID: 4887089 PMCID: PMC4075252

133. Rodgers A, Gauvin D, Edeh S, Allie-Hamdulay S, Jackson G, **Lieske JC**. Sulfate but not thiosulfate reduces calculated and measured urinary ionized calcium and supersaturation: implications for the treatment of calcium renal stones. PLoS One. 2014; 9 (7):e103602 Epub 2014 July 25 PMID: 25061988 PMCID: PMC4111609 DOI: 10.1371/journal.pone.0103602
134. **Lieske JC**, Chawla L, Kashani K, Kellum JA, Koyner JL, Mehta RL. Biomarkers for acute kidney injury: where are we today? Where should we go? Clin Chem. 2014 Feb; 60(2):294-300. Epub 2013 Aug 19 PMID: 23958848 DOI: 10.1373/clinchem.2012.201988
135. Bachmann LM, Nilsson G, Bruns DE, McQueen MJ, **Lieske JC**, Zakowski JJ, Miller WG. State of the art for measurement of urine albumin: comparison of routine measurement procedures to isotope dilution tandem mass spectrometry. Clin Chem. 2014 Mar; 60(3):471-80. PMID: 24281781
136. **Lieske JC**, Turner ST, Edeh SN, Smith JA, Kardia SL. Heritability of urinary traits that contribute to nephrolithiasis. Clin J Am Soc Nephrol. 2014 May; 9 (5):943-50 Epub 2014 Feb 27 PMID: 24578335 PMCID: PMC4011445 DOI: 10.2215/CJN.08210813
137. Shaffi K, Uhlig K, Perrone RD, Ruthazer R, Rule A, **Lieske JC**, Navis G, Poggio ED, Inker LA, Levey AS. Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney Dis. 2014 Jun; 63(6):1007-18. Epub 2014 Apr 02. PMID: 24703720 PMCID: PMC4113340 DOI: 10.1053/j.ajkd.2014.01.436
138. Lorenz EC, **Lieske JC**, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant. 2014 Jun; 14 (6):1433-8 Epub 2014 May 02 PMID: 24797341 PMCID: PMC4543374 DOI: 10.1111/ajt.12706
139. Kim H, Zhen DB, **Lieske JC**, McBane RD, Grande JP, Sandhu GS, Melduni RM. Treatment of Cholesterol Embolization Syndrome in the Setting of an Acute Indication for Anticoagulation Therapy. J Med Cases. 2014 Jun 1; 5 (6):376-379 PMID: 25197328 PMCID: PMC4156113 DOI: 10.14740/jmc1804w
140. Tang X, **Lieske JC**. Acute and chronic kidney injury in nephrolithiasis. Curr Opin Nephrol Hypertens. 2014 Jul; 23 (4):385-90 PMID: 24848936 PMCID: PMC4096690 DOI: 10.1097/01.mnh.0000447017.28852.52
141. Tosetto E, Casarin A, Salviati L, Familiari A, **Lieske JC**, Anglani F. Complexity of the 5' utr region of the clcn5 gene: eleven 5' utr ends are differentially expressed in the human kidney. BMC Medical Genomics. 2014 Jul 7; 7:41. PMID: 25001568 PMCID: PMC4105828
142. Meeusen JW, **Lieske JC**. Looking for a better creatinine. Clin Chem. 2014 Aug; 60 (8):1036-9 Epub 2014 Feb 26 PMID: 24573605 DOI: 10.1373/clinchem.2013.220764
143. Wang X, Krambeck AE, Williams JC Jr, Tang X, Rule AD, Zhao F, Bergstralh E, Haskic Z, Edeh S, Holmes DR 3rd, Herrera Hernandez LP, **Lieske JC**. Distinguishing characteristics of idiopathic calcium oxalate kidney stone formers with low amounts of Randall's plaque. Clin J Am Soc Nephrol. 2014 Oct 7; 9 (10):1757-63 Epub 2014 Aug 04 PMID: 25092598 PMCID: PMC4186508 DOI: 10.2215/CJN.01490214
144. Elsherbiny HE, Alexander MP, Kremers WK, Park WD, Poggio ED, Prieto M, **Lieske JC**, Rule AD. Nephron hypertrophy and glomerulosclerosis and their association with kidney function and risk factors among living kidney donors. Clin J Am Soc Nephrol. 2014 Nov 7; 9 (11):1892-902 Epub 2014 Oct 15 PMID: 25318758 PMCID: PMC4220756 DOI: 10.2215/CJN.02560314

145. de Cogain MR, **Lieske JC**, Vrtiska TJ, Tosh PK, Krambeck AE. Secondly infected nonstruvite urolithiasis: a prospective evaluation. *Urology*. 2014 Dec; 84 (6):1295-300 Epub 2014 Oct 11 PMID: 25306481 PMCID: PMC4257060 DOI: 10.1016/j.urology.2014.08.007
146. Rule AD, **Lieske JC**, Li X, Melton LJ 3rd, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. *J Am Soc Nephrol*. 2014 Dec; 25 (12):2878-86 Epub 2014 Aug 07 PMID: 25104803 PMCID: PMC4243346 DOI: 10.1681/ASN.2013091011
147. Singh P, Knoedler JJ, Krambeck AE, **Lieske JC**, Bergstralh EJ, Rule AD. Thiazide diuretic prophylaxis for kidney stones and the risk of diabetes mellitus. *J Urol*. 2014 Dec; 192 (6):1700-4 Epub 2014 June 30 PMID: 24992333 PMCID: PMC4252655 DOI: 10.1016/j.juro.2014.06.078
148. **Lieske JC**, Rule AD, Krambeck AE, Williams JC, Bergstralh EJ, Mehta RA, Moyer TP. Stone composition as a function of age and sex. *Clin J Am Soc Nephrol*. 2014 Dec 5; 9 (12):2141-6 Epub 2014 Oct 02 PMID: 25278549 PMCID: PMC4255407 DOI: 10.2215/CJN.05660614
149. Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, **Lieske JC**, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC, Mentor Consortium group. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). *Nephron*. 2015; 130 (3):159-68 Epub 2015 June 12 PMID: 26087670 DOI: 10.1159/000430849
150. Ketha H, Singh RJ, Grebe SK, Bergstralh EJ, Rule AD, **Lieske JC**, Kumar R. Altered Calcium and Vitamin D Homeostasis in First-Time Calcium Kidney Stone-Formers. *PLoS One*. 2015; 10 (9):e0137350 Epub 2015 Sept 02 PMID: 26332888 PMCID: PMC4558059 DOI: 10.1371/journal.pone.0137350
151. Jayachandran M, Lugo G, Heiling H, Miller VM, Rule AD, **Lieske JC**. Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. *Biol Sex Differ*. 2015; 6:2 Epub 2015 Feb 24 PMID: 25729563 PMCID: PMC4345020 DOI: 10.1186/s13293-015-0021-2
152. Leng S, Shiung M, Ai S, Qu M, Vrtiska TJ, Grant KL, Krauss B, Schmidt B, **Lieske JC**, McCollough CH. Feasibility of discriminating uric acid from non-uric acid renal stones using consecutive spatially registered low- and high-energy scans obtained on a conventional CT scanner. *AJR Am J Roentgenol*. 2015 Jan; 204 (1):92-7 PMID: 25539242 PMCID: PMC4280671 DOI: 10.2214/AJR.13.11911
153. Akhoundi A, Singh B, Vela M, Chaudhary S, Monaghan M, Wilson GA, Dillon JJ, Cartin-Ceba R, **Lieske JC**, Gajic O, Kashani K. Incidence of Adverse Events during Continuous Renal Replacement Therapy. *Blood Purif*. 2015; 39 (4):333-9 Epub 2015 May 22 PMID: 26022612 DOI: 10.1159/000380903
154. Selby MG, Vrtiska TJ, Krambeck AE, McCollough CH, Elsherbiny HE, Bergstralh EJ, **Lieske JC**, Rule AD. Quantification of asymptomatic kidney stone burden by computed tomography for predicting future symptomatic stone events. *Urology*. 2015 Jan; 85 (1):45-50 Epub 2014 Oct 22 PMID: 25440821 PMCID: PMC4275381 DOI: 10.1016/j.urology.2014.08.031
155. Ware EB, Riehle E, Smith JA, Zhao W, Turner ST, Kardia SL, **Lieske JC**. SLC2A9 Genotype Is Associated with SLC2A9 Gene Expression and Urinary Uric Acid Concentration. *PLoS One*. 2015; 10 (7):e0128593 Epub 2015 July 13 PMID: 26167684 PMCID: PMC4500555 DOI: 10.1371/journal.pone.0128593

156. Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, **Lieske JC**. Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. *Kidney Int.* 2015 Mar; 87 (3):623-31 Epub 2014 Sept 17 PMID: 25229337 PMCID: PMC4344931 DOI: 10.1038/ki.2014.298
157. de Cogain MR, Linnes MP, Lee HJ, Krambeck AE, de Mendonca Uchoa JC, Kim SH, **Lieske JC**. Aqueous extract of *Costus arabicus* inhibits calcium oxalate crystal growth and adhesion to renal epithelial cells. *Urolithiasis.* 2015 Apr; 43 (2):119-24 Epub 2015 Feb 05 PMID: 25652357 DOI: 10.1007/s00240-015-0749-5
158. Viers BR, **Lieske JC**, Vrtiska TJ, Herrera Hernandez LP, Vaughan LE, Mehta RA, Bergstralh EJ, Rule AD, Holmes DR 3rd, Krambeck AE. Endoscopic and histologic findings in a cohort of uric acid and calcium oxalate stone formers. *Urology.* 2015 Apr; 85 (4):771-6 Epub 2015 Feb 11 PMID: 25681832 PMCID: PMC4380657 DOI: 10.1016/j.urology.2014.12.036
159. **Lieske JC**, Mehta RA, Milliner DS, Rule AD, Bergstralh EJ, Sarr MG. Kidney stones are common after bariatric surgery. *Kidney Int.* 2015 Apr; 87 (4):839-45 Epub 2014 Oct 29 PMID: 25354237 PMCID: PMC4382441 DOI: 10.1038/ki.2014.352
160. Hogan MC, Bakeberg JL, Gainullin VG, Irazabal MV, Harmon AJ, **Lieske JC**, Charlesworth MC, Johnson KL, Madden BJ, Zenka RM, McCormick DJ, Sundsbak JL, Heyer CM, Torres VE, Harris PC, Ward CJ. Identification of Biomarkers for PKD1 Using Urinary Exosomes. *J Am Soc Nephrol.* 2015 Jul; 26 (7):1661-70 Epub 2014 Dec 04 PMID: 25475747 PMCID: PMC4483583 DOI: 10.1681/ASN.2014040354
161. McDonald JS, McDonald RJ, **Lieske JC**, Carter RE, Katzberg RW, Williamson EE, Kallmes DF. Risk of Acute Kidney Injury, Dialysis, and Mortality in Patients With Chronic Kidney Disease After Intravenous Contrast Material Exposure. *Mayo Clin Proc.* 2015 Aug; 90 (8):1046-53 PMID: 26250726 PMCID: PMC4550308 DOI: 10.1016/j.mayocp.2015.05.016
162. Perinpam M, Ware EB, Smith JA, Turner ST, Kardia SL, **Lieske JC**. Effect of Demographics on Excretion of Key Urinary Factors Related to Kidney Stone Risk. *Urology.* 2015 Oct; 86 (4):690-6 Epub 2015 July 20 PMID: 26206452 PMCID: PMC4592816 DOI: 10.1016/j.urology.2015.07.012
163. Meeusen JW, Rule AD, Voskoboev N, Baumann NA, **Lieske JC**. Performance of cystatin C- and creatinine-based estimated glomerular filtration rate equations depends on patient characteristics. *Clin Chem.* 2015 Oct; 61 (10):1265-72 Epub 2015 Aug 03 PMID: 26240296 PMCID: PMC4726452 DOI: 10.1373/clinchem.2015.243030
164. Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, **Lieske JC**, Milliner DS, Harris PC, Rare Kidney Stone Consortium. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. *J Am Soc Nephrol.* 2015 Oct; 26 (10):2559-70 Epub 2015 Feb 02 PMID: 25644115 PMCID: PMC4587693 DOI: 10.1681/ASN.2014070698
165. Singh P, Enders FT, Vaughan LE, Bergstralh EJ, Knoedler JJ, Krambeck AE, **Lieske JC**, Rule AD. Stone Composition Among First-Time Symptomatic Kidney Stone Formers in the Community. *Mayo Clin Proc.* 2015 Oct; 90 (10):1356-65 Epub 2015 Sept 06 PMID: 26349951 PMCID: PMC4593754 DOI: 10.1016/j.mayocp.2015.07.016
166. Voskoboev NV, Cambern SJ, Hanley MM, Giesen CD, Schilling JJ, Jannetto PJ, **Lieske JC**, Block DR. Fecal electrolyte testing for evaluation of unexplained diarrhea: Validation of body fluid test accuracy in the absence of a reference method. *Clin Biochem.* 2015 Nov; 48: (16-17)1126-30. PMID: 26093046 DOI: 10.1016/j.clinbiochem.2015.06.011
167. Hogan MC, **Lieske JC**, Lienczewski CC, Nesbitt LL, Wickman LT, Heyer CM, Harris PC, Ward CJ, Sundsbak JL, Manganelli L, Ju W, Kopp JB, Nelson PJ, Adler SG, Reich HN, Holzmann LB, Kretzler M,

- Bitzer M. Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrol. 2015 Nov 17; 16:190 PMID: 26577187 PMCID: PMC4650313 DOI: 10.1186/s12882-015-0185-3
168. Kremers WK, Denic A, **Lieske JC**, Alexander MP, Kaushik V, Elsherbiny HE, Chakkera HA, Poggio ED, Rule AD. Distinguishing age-related from disease-related glomerulosclerosis on kidney biopsy: the Aging Kidney Anatomy study. Nephrol Dial Transplant. 2015 Dec; 30 (12):2034-9 Epub 2015 Apr 16 PMID: 25888387 PMCID: PMC4783459 DOI: 10.1093/ndt/gfv072
 169. Knoedler JJ, Krambeck AE, Astorne W, Bergstralh E, **Lieske J**. Sex Steroid Hormone Levels May Not Explain Gender Differences in Development of Nephrolithiasis. J Endourol. 2015 Dec; 29 (12):1341-5 Epub 2015 Nov 05 PMID: 26422682 PMCID: PMC4677516 DOI: 10.1089/end.2015.0255
 170. Duran D, Jin SC, DeSpenza T Jr, Nelson-Williams C, Cogal AG, Abrash EW, Harris PC, **Lieske JC**, Shimshak SJ, Mane S, Bilguvar K, DiLuna ML, Gunel M, Lifton RP, Kahle KT. Digenic mutations of human OCRL paralogs in Dent's disease type 2 associated with Chiari I malformation. Hum Genome Var. 2016; 3:16042 Epub 2016 Dec 08 PMID: 28018608 PMCID: PMC5143364 DOI: 10.1038/hgv.2016.42
 171. Seegmiller JC, Burns BE, Schinstock CA, **Lieske JC**, Larson TS. Discordance Between Iothalamate and Iohexol Urinary Clearances. Am J Kidney Dis. 2016 Jan; 67 (1):49-55 Epub 2015 Oct 09 PMID: 26454686 DOI: 10.1053/j.ajkd.2015.08.020
 172. Perinpan M, Ware EB, Smith JA, Turner ST, Kardia SL, **Lieske JC**. Key influence of sex on urine volume and osmolality. Biol Sex Differ. 2016; 7:12 Epub 2016 Feb 09 PMID: 26865949 PMCID: PMC4748596 DOI: 10.1186/s13293-016-0063-0
 173. Turco AE, Lam W, Rule AD, Denic A, **Lieske JC**, Miller VM, Larson JJ, Kremers WK, Jayachandran M. Specific renal parenchymal-derived urinary extracellular vesicles identify age-associated structural changes in living donor kidneys. J Extracell Vesicles. 2016; 5:29642 Epub 2016 Feb 01 PMID: 26837814 PMCID: PMC4737715 DOI: 10.3402/jev.v5.29642
 174. Wang X, **Lieske JC**, Alexander MP, Jayachandran M, Denic A, Mathew J, Lerman LO, Kremers WK, Larson JJ, Rule AD. Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1. Am J Nephrol. 2016; 43 (6):454-9 Epub 2016 June 10 PMID: 27288357 PMCID: PMC4936940 DOI: 10.1159/000446851
 175. Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, **Lieske JC**, Milliner DS, Investigators of Rare Kidney Stone Consortium. Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Clin J Am Soc Nephrol. 2016 Jan 7; 11 (1):119-26 Epub 2015 Dec 10 PMID: 26656319 PMCID: PMC4702224 DOI: 10.2215/CJN.02810315
 176. **Lieske JC**, Turner ST, Edeh SN, Ware EB, Kardia SL, Smith JA. Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. J Nephrol. 2016 Feb; 29 (1):45-51 Epub 2015 May 12 PMID: 25963767 PMCID: PMC4643420 DOI: 10.1007/s40620-015-0204-2
 177. **Lieske JC**. Commentary. Clin Chem 2016 Mar; 62 (3):440 PMID: 26921351 DOI: 10.1373/clinchem.2015.248690
 178. Jaeger CD, Rule AD, Mehta RA, Vaughan LE, Vrtiska TJ, Holmes DR 3rd, McCollough CM, Ziegelmann MJ, Herrera Hernandez LP, **Lieske JC**, Krambeck AE. Endoscopic and Pathologic Characterization of Papillary Architecture in Struvite Stone Formers. Urology. 2016 Apr; 90:39-44 Epub 2016 Jan 06 PMID: 26772639 PMCID: PMC4818656 DOI: 10.1016/j.urology.2015.12.037

179. Tang X, Brown MR, Cogal AG, Gauvin D, Harris PC, **Lieske JC**, Romero MF, Chang MH. Functional and transport analyses of CLCN5 genetic changes identified in Dent disease patients. *Physiol Rep*. 2016 Apr; 4 (8) PMID: 27117801 PMCID: PMC4848727 DOI: 10.14814/phy2.12776
180. Frazee EN, Personett HA, Wood-Wentz CM, Herasevich V, **Lieske JC**, Kashani KB. Overestimation of Glomerular Filtration Rate Among Critically Ill Adults With Hospital-Acquired Oligoanuric Acute Kidney Injury. *J Pharm Pract*. 2016 Apr; 29(2):125-31. Epub 2014 Oct 16. PMID: 25326198 DOI: 10.1177/0897190014549841
181. Cheungpasitporn W, Rossetti S, Friend K, Erickson SB, **Lieske JC**. Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis. *J Nephrol*. 2016 Apr; 29 (2):211-219 Epub 2015 May 29 PMID: 26022722 PMCID: PMC4831051 DOI: 10.1007/s40620-015-0210-4
182. Cheungpasitporn W, Erickson SB, Rule AD, Enders F, **Lieske JC**. Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations. *J Urol*. 2016 May; 195 (5):1476-1481 Epub 2015 Nov 17 PMID: 26598423 PMCID: PMC4870116 DOI: 10.1016/j.juro.2015.11.027
183. Knoedler JJ, **Lieske JC**. Non-steroidal anti-inflammatory drugs for renal colic. *Lancet* 2016 May 14; 387 (10032):1971-2 Epub 2016 Mar 16 PMID: 26993882 DOI: 10.1016/S0140-6736(16)00745-5
184. Denic A#, Alexander MP#, Kaushik V, Lerman LO, **Lieske JC**, Stegall MD, Larson JJ, Kremers WK, Vrtiska TJ, Chakkera HA, Poggio ED, Rule AD. Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. *Am J Kidney Dis*. 2016 Jul; 68 (1):58-67 Epub 2016 Feb 06 PMID: 26857648 PMCID: PMC4921258 DOI: 10.1053/j.ajkd.2015.12.029
185. Rivera M, Cockerill PA, Enders F, Mehta RA, Vaughan L, Vrtiska TJ, Herrera Hernandez LP, Holmes DR 3rd, Rule AD, **Lieske JC**, Krambeck AE. Characterization of Inner Medullary Collecting Duct Plug Formation Among Idiopathic Calcium Oxalate Stone Formers. *Urology*. 2016 Aug; 94:47-52 Epub 2016 May 19 PMID: 27210573 PMCID: PMC5492383 DOI: 10.1016/j.urology.2016.05.026
186. Keddiss MT, Amer H, Voskoboev N, Kremers WK, Rule AD, **Lieske JC**. Creatinine-Based and Cystatin C-Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients. *Clin J Am Soc Nephrol*. 2016 Sep 7; 11 (9):1640-1649 Epub 2016 June 23 PMID: 27340283 PMCID: PMC5012488 DOI: 10.2215/CJN.11741115
187. **Lieske JC**. Editorial Comment. *J Urol* 2016 Oct; 196 (4):1147-8 Epub 2016 Aug 21 PMID: 27430388 DOI: 10.1016/j.juro.2016.04.115
188. Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, **Lieske JC**. The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. *Kidney Int*. 2016 Nov; 90 (5):1080-1089 Epub 2016 Aug 12 PMID: 27528553 PMCID: PMC5065749 DOI: 10.1016/j.kint.2016.06.020
189. Haley WE, Enders FT, Vaughan LE, Mehta RA, Thoman ME, Vrtiska TJ, Krambeck AE, **Lieske JC**, Rule AD. Kidney Function After the First Kidney Stone Event. *Mayo Clin Proc*. 2016 Dec; 91 (12):1744-1752 Epub 2016 Oct 21 PMID: 27776839 PMCID: PMC5140038 DOI: 10.1016/j.mayocp.2016.08.014
190. Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, **Lieske J**, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC, Consensus Conference Group. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its

- systemic manifestations: a consensus statement. *J Nephrol*. 2016 Dec; 29 (6):715-734 Epub 2016 July 25 PMID: 27456839 PMCID: PMC5080344 DOI: 10.1007/s40620-016-0329-y
191. Wang X, Anglani F, Beara-Lasic L, Mehta AJ, Vaughan LE, Herrera Hernandez L, Cogal A, Scheinman SJ, Ariceta G, Isom R, Copelovitch L, Enders FT, Del Prete D, Vezzoli G, Paglialonga F, Harris PC, **Lieske JC**, Investigators of the Rare Kidney Stone Consortium. Glomerular Pathology in Dent Disease and Its Association with Kidney Function. *Clin J Am Soc Nephrol*. 2016 Dec 7; 11 (12):2168-2176 Epub 2016 Oct 03 PMID: 27697782 PMCID: PMC5142066 DOI: 10.2215/CJN.03710416
 192. Kashani KB, Frazee EN, Kukralova L, Sarvottam K, Herasevich V, Young PM, Kashyap R, **Lieske JC**. Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index. *Crit Care Med*. 2017 Jan; 45: (1)e23-e29. PMID: 27611976 DOI: 10.1097/CCM.0000000000002013
 193. Ma L, Liu Y, Landry NK, El-Achkar TM, **Lieske JC**, Wu XR. Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. *PLoS One*. 2017; 12 (11):e0186769 Epub 2017 Nov 16 PMID: 29145399 PMCID: PMC5690637 DOI: 10.1371/journal.pone.0186769
 194. **Lieske JC**. Probiotics for prevention of urinary stones. *Ann Transl Med*. 2017 Jan; 5 (2):29 PMID: 28217694 PMCID: PMC5300857 DOI: 10.21037/atm.2016.11.86
 195. Denic A, **Lieske JC**, Chakker A, Poggio ED, Alexander MP, Singh P, Kremers WK, Lerman LO, Rule AD. The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging. *J Am Soc Nephrol*. 2017 Jan; 28 (1):313-320 Epub 2016 July 08 PMID: 27401688 PMCID: PMC5198286 DOI: 10.1681/ASN.2016020154
 196. **Lieske JC**. Editorial Comment. *J Urol* 2017 Feb; 197 (2):409-410 Epub 2016 Oct 27 PMID: 28346988 DOI: 10.1016/j.juro.2016.08.133
 197. Kittanamongkolchai W, Mara KC, Mehta RA, Vaughan LE, Denic A, Knoedler JJ, Enders FT, **Lieske JC**, Rule AD. Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers. *Clin J Am Soc Nephrol*. 2017 Mar 7; 12 (3):476-482 Epub 2017 Feb 01 PMID: 28148559 PMCID: PMC5338710 DOI: 10.2215/CJN.06600616
 198. Frazee E, Rule AD, **Lieske JC**, Kashani KB, Barreto JN, Virk A, Kuper PJ, Dierkhising RA, Leung N. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project. *Am J Kidney Dis*. 2017 May; 69: (5)658-666. PMID: 28131530 DOI: 10.1053/j.ajkd.2016.11.016
 199. Cods E, Garovic VD, Gonzalez-Suarez ML, Milic N, Borowski KS, Rose CH, Davies NP, Kashani KB, **Lieske JC**, White WM. Longitudinal characterization of renal proximal tubular markers in normotensive and preeclamptic pregnancies. *Am J Physiol Regul Integr Comp Physiol*. 2017 May 1; 312 (5):R773-R778 Epub 2017 Apr 24 PMID: 28438765 DOI: 10.1152/ajpregu.00509.2016
 200. Denic A, Mathew J, Lerman LO, **Lieske JC**, Larson JJ, Alexander MP, Poggio E, Glassock RJ, Rule AD. Single-Nephron Glomerular Filtration Rate in Healthy Adults. *N Engl J Med*. 2017 Jun 15; 376 (24):2349-2357 PMID: 28614683 PMCID: PMC5664219 DOI: 10.1056/NEJMoa1614329
 201. Brady CT, Giesen CD, Voskoboev N, Chirackal RS, Gavrilov DK, Flanagan RM, **Lieske JC**. Cyanide-Nitroprusside Colorimetric Assay: A Rapid Colorimetric Screen for Urinary Cystine. *J Appl Lab Med*. 2017 Jul 1; 2 (1):55-64 PMID: 33636959 DOI: 10.1373/jalm.2016.022582
 202. Kashani K, Shao M, Li G, Williams AW, Rule AD, Kremers WK, Malinchoc M, Gajic O, **Lieske JC**. No increase in the incidence of acute kidney injury in a population-based annual temporal trends epidemiology study. *Kidney Int*. 2017 Sep; 92 (3):721-728 Epub 2017 May 18 PMID: 28528131 PMCID: PMC5761670 DOI: 10.1016/j.kint.2017.03.020

203. Perinpam M, Ware EB, Smith JA, Turner ST, Kardia SLR, **Lieske JC**. Association of urinary citrate excretion, pH, and net gastrointestinal alkali absorption with diet, diuretic use, and blood glucose concentration. *Physiol Rep*. 2017 Oct; 5 (19) Epub 2017 Oct 16 PMID: 29038354 PMCID: PMC5641929 DOI: 10.14814/phy2.13411
204. Kashani KB, Mao SA, Safadi S, Amiot BP, Glorioso JM, **Lieske JC**, Nyberg SL, Zhang X. Association between kidney intracapsular pressure and ultrasound elastography. *Crit Care*. 2017 Oct 19; 21 (1):251 PMID: 29047410 PMCID: PMC5648471 DOI: 10.1186/s13054-017-1847-2
205. Ranawaka R, Sirisena ND, Dayasiri KC, Cogal AG, **Lieske JC**, Gamage MP, Dissanayake VHW. The first Sri Lankan family with Dent disease-1 due to a pathogenic variant in the CLCN5 gene: a case report. *BMC Res Notes*. 2017 Oct 30; 10 (1):539 PMID: 29084614 PMCID: PMC5663100 DOI: 10.1186/s13104-017-2881-5
206. Canales BK, Smith JA, Weiner ID, Ware EB, Zhao W, Kardia SLR, Curhan GC, Turner ST, Perinpam M, **Lieske JC**. Polymorphisms in Renal Ammonia Metabolism Genes Correlate With 24-Hour Urine pH. *Kidney Int Rep*. 2017 Nov; 2 (6):1111-1121 Epub 2017 June 21 PMID: 29270519 PMCID: PMC5733879 DOI: 10.1016/j.ekir.2017.06.009
207. Miller WG, Seegmiller JC, **Lieske JC**, Narva AS, Bachmann LM. Standardization of Urine Albumin Measurements: Status and Performance Goals. *J Appl Lab Med*. 2017 Nov 1; 2 (3):423-429 PMID: 33636850 DOI: 10.1373/jalm.2017.023614
208. Gilani SI, Anderson UD, Jayachandran M, Weissgerber TL, Zand L, White WM, Milic N, Suarez Gonzalez ML, Vallapureddy RR, Naav A, Erlandsson L, **Lieske JC**, Grande JP, Nath KA, Hansson SR, Garovic VD. Urinary Extracellular Vesicles of Podocyte Origin and Renal Injury in Preeclampsia. *J Am Soc Nephrol*. 2017 Nov; 28 (11):3363-3372 Epub 2017 July 20 PMID: 28729288 PMCID: PMC5661277 DOI: 10.1681/ASN.2016111202
209. Perinpam M, Enders FT, Mara KC, Vaughan LE, Mehta RA, Voskoboev N, Milliner DS, **Lieske JC**. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. *Clin Biochem*. 2017 Dec; 50 (18):1014-1019 Epub 2017 July 29 PMID: 28764885 PMCID: PMC5705406 DOI: 10.1016/j.clinbiochem.2017.07.017
210. Seegmiller JC, Eckfeldt JH, **Lieske JC**. Challenges in Measuring Glomerular Filtration Rate: A Clinical Laboratory Perspective. *Adv Chronic Kidney Dis*. 2018 Jan; 25 (1):84-92 PMID: 29499892 DOI: 10.1053/j.ackd.2017.10.006
211. Dhondup T, Lorenz EC, Milliner DS, **Lieske JC**. Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report. *Am J Transplant*. 2018 Jan; 18 (1):253-257 Epub 2017 Aug 14 PMID: 28681512 PMCID: PMC5739996 DOI: 10.1111/ajt.14418
212. Nasr SH, Vrana JA, Dasari S, Bridoux F, Fidler ME, Kaaki S, Quellard N, Rinsant A, Goujon JM, Sethi S, Fervenza FC, Cornell LD, Said SM, McPhail ED, Herrera Hernandez LP, Grande JP, Hogan MC, **Lieske JC**, Leung N, Kurtin PJ, Alexander MP. DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. *Kidney Int Rep*. 2018 Jan; 3 (1):56-64 Epub 2017 Aug 08 PMID: 29340314 PMCID: PMC5762944 DOI: 10.1016/j.ekir.2017.07.017
213. Abd El-Salam M, Bastos JK, Han JJ, Previdi D, Coelho EB, Donate PM, Romero MF, **Lieske J**. The Synthesized Plant Metabolite 3,4,5-Tri-O-Galloylquinic Acid Methyl Ester Inhibits Calcium Oxalate Crystal Growth in a Drosophila Model, Downregulates Renal Cell Surface Annexin A1 Expression, and Decreases Crystal Adhesion to Cells. *J Med Chem*. 2018 Feb 22; 61 (4):1609-1621 Epub 2018 Feb 13 PMID: 29406740 PMCID: PMC9190264 DOI: 10.1021/acs.jmedchem.7b01566

214. Gharaibeh KA, Hamadah AM, El-Zoghby ZM, **Lieske JC**, Larson TS, Leung N. Cystatin C Predicts Renal Recovery Earlier Than Creatinine Among Patients With Acute Kidney Injury. *Kidney Int Rep.* 2018 Mar; 3 (2):337-342 Epub 2017 Nov 03 PMID: 29725637 PMCID: PMC5932123 DOI: 10.1016/j.ekir.2017.10.012
215. Schwartz GJ, Wang H, Erway B, Nordin G, Seegmiller J, **Lieske JC**, Back SE, Miller WG, Eckfeldt JH. Multicenter Laboratory Comparison of Iohexol Measurement. *J Appl Lab Med.* 2018 Mar; 2 (5):711-724 PMID: 31276084 PMCID: PMC6608591 DOI: 10.1373/jalm.2017.024240
216. Kittanamongkolchai W, Vaughan LE, Enders FT, Dhondup T, Mehta RA, Krambeck AE, McCollough CH, Vrtiska TJ, **Lieske JC**, Rule AD. The Changing Incidence and Presentation of Urinary Stones Over 3 Decades. *Mayo Clin Proc.* 2018 Mar; 93 (3):291-299 Epub 2018 Feb 14 PMID: 29452705 PMCID: PMC5849397 DOI: 10.1016/j.mayocp.2017.11.018
217. **Lieske JC**. Bariatric Surgery and Kidney Health. *J Am Soc Nephrol* 2018 Apr; 29 (4):1085-1086 Epub 2018 Mar 12 PMID: 29531098 PMCID: PMC5875969 DOI: 10.1681/ASN.2018020176
218. Liu Y, Goldfarb DS, El-Achkar TM, **Lieske JC**, Wu XR. Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia. *Am J Physiol Renal Physiol.* 2018 Jun 1; 314 (6):F1062-F1076 Epub 2018 Jan 10 PMID: 29357410 PMCID: PMC6032075 DOI: 10.1152/ajprenal.00233.2017
219. Denic A, Mathew J, Nagineni VV, Thompson RH, Leibovich BC, Lerman LO, **Lieske JC**, Alexander MP, Augustine JJ, Kremers WK, Rule AD. Clinical and Pathology Findings Associate Consistently with Larger Glomerular Volume. *J Am Soc Nephrol.* 2018 Jul; 29 (7):1960-1969 Epub 2018 May 22 PMID: 29789431 PMCID: PMC6050922 DOI: 10.1681/ASN.2017121305
220. Donato LJ, Meeusen JW, **Lieske JC**, Bergmann D, Sparwasser A, Jaffe AS. Analytical performance of an immunoassay to measure proenkephalin. *Clin Biochem.* 2018 Aug; 58:72-77 Epub 2018 May 18 PMID: 29782819 DOI: 10.1016/j.clinbiochem.2018.05.010
221. Hamadah AM, Gharaibeh K, Mara KC, Thompson KA, **Lieske JC**, Said S, Nasr SH, Leung N. Urinalysis for the diagnosis of glomerulonephritis: role of dysmorphic red blood cells. *Nephrol Dial Transplant.* 2018 Aug 1; 33 (8):1397-1403 PMID: 29156008 DOI: 10.1093/ndt/gfx274
222. Sivaguru M, Saw JJ, Williams JC Jr, Williams JC Jr, **Lieske JC**, Krambeck AE, Romero MF, Chia N, Schwaderer AL, Alcalde RE, Bruce WJ, Wildman DE, Fried GA, Werth CJ, Reeder RJ, Yau PM, Sanford RA, Fouke BW. Geobiology reveals how human kidney stones dissolve in vivo. *Sci Rep.* 2018 Sep 13; 8 (1):13731 Epub 2018 Sept 13 PMID: 30213974 PMCID: PMC6137216 DOI: 10.1038/s41598-018-31890-9
223. Peters BJ, Rule AD, Kashani KB, **Lieske JC**, Mara KC, Dierkhising RA, Barreto EF. Impact of Serum Cystatin C-Based Glomerular Filtration Rate Estimates on Drug Dose Selection in Hospitalized Patients. *Pharmacotherapy.* 2018 Oct; 38 (10):1068-1073 Epub 2018 Sept 12 PMID: 30120844 DOI: 10.1002/phar.2175
224. Dhondup T, Kittanamongkolchai W, Vaughan LE, Mehta RA, Chhina JK, Enders FT, Hickson LJ, **Lieske JC**, Rule AD. Risk of ESRD and Mortality in Kidney and Bladder Stone Formers. *Am J Kidney Dis.* 2018 Dec; 72 (6):790-797 Epub 2018 Aug 23 PMID: 30146423 PMCID: PMC6252145 DOI: 10.1053/j.ajkd.2018.06.012
225. Chirackal R, **Lieske JC**. Pathophysiology and Treatment of Hyperoxaluria *Urology.* 2018. DOI: 10.2310/7900.11017

226. **Lieske JC**, Wang X. Heritable traits that contribute to nephrolithiasis. Urolithiasis. 2019 Feb; 47 (1):5-10 Epub 2018 Nov 20 PMID: 30460525 PMCID: PMC6474242 DOI: 10.1007/s00240-018-1095-1
227. Bobart SA, De Vriese AS, Pawar AS, Zand L, Sethi S, Giesen C, **Lieske JC**, Fervenza FC. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019 Feb; 95 (2):429-438 PMID: 30665573 DOI: 10.1016/j.kint.2018.10.021
228. Vaughan LE, Enders FT, **Lieske JC**, Pais VM, Rivera ME, Mehta RA, Vrtiska TJ, Rule AD. Predictors of Symptomatic Kidney Stone Recurrence After the First and Subsequent Episodes. Mayo Clin Proc. 2019 Feb; 94 (2):202-210 Epub 2018 Dec 04 PMID: 30527866 PMCID: PMC6390834 DOI: 10.1016/j.mayocp.2018.09.016
229. El-Salam MA, Furtado N, Haskic Z, **Lieske J**, Bastos J. Antiuro lithic activity and biotransformation of galloylquinic acids by Aspergillus alliaceus ATCC10060, Aspergillus brasiliensis ATCC 16404, and Cunninghamella elegans ATCC 10028b. Biocatal Agric Biotechnol. 2019 Mar; 18 Epub 2019 Jan 29 PMID: 31890054 PMCID: PMC6936763 DOI: 10.1016/j.bcab.2019.01.050
230. Barreto EF, Rule AD, Murad MH, Kashani KB, **Lieske JC**, Erwin PJ, Steckelberg JM, Gajic O, Reid JM, Kane-Gill SL. Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review. Mayo Clin Proc. 2019 Mar; 94 (3):500-514 Epub 2019 Jan 31 PMID: 30713050 DOI: 10.1016/j.mayocp.2018.08.002
231. Waikar SS, Srivastava A, Palsson R, Shafi T, Hsu CY, Sharma K, Lash JP, Chen J, He J, **Lieske J**, Xie D, Zhang X, Feldman HI, Curhan GC, Chronic Renal Insufficiency Cohort study investigators. Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression. JAMA Intern Med. 2019 Apr 1; 179 (4):542-551 PMID: 30830167 PMCID: PMC6450310 DOI: 10.1001/jamainternmed.2018.7980
232. Kleinguetl C, Williams JC Jr, **Lieske JC**, Daudon M, Rivera ME, Jannetto PJ, Bornhorst J, Rokke D, Bird ET, Lingeman JE, El Tayeb MM. Uncovering a Novel Stone in 27 Patients: Calcium Tartrate Tetrahydrate. Urology. 2019 Apr; 126:49-53 Epub 2019 Jan 14 PMID: 30654140 DOI: 10.1016/j.urology.2019.01.005
233. Ferrero A, Takahashi N, Vrtiska TJ, Krambeck AE, **Lieske JC**, McCollough CH. Understanding, justifying, and optimizing radiation exposure for CT imaging in nephrourology. Nat Rev Urol. 2019 Apr; 16 (4):231-244 PMID: 30728476 PMCID: PMC6447446 DOI: 10.1038/s41585-019-0148-8
234. Nasr SH, Dasari S, **Lieske JC**, Benson LM, Vanderboom PM, Holtz-Heppelmann CJ, Giesen CD, Snyder MR, Erickson SB, Fervenza FC, Leung N, Kurtin PJ, Alexander MP. Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients. Kidney Int. 2019 May; 95 (5):1269-1272 Epub 2019 Mar 01 PMID: 31010480 DOI: 10.1016/j.kint.2019.01.024
235. D'Costa MR, Haley WE, Mara KC, Enders FT, Vrtiska TJ, Pais VM, Jacobsen SJ, McCollough CH, **Lieske JC**, Rule AD. Symptomatic and Radiographic Manifestations of Kidney Stone Recurrence and Their Prediction by Risk Factors: A Prospective Cohort Study. J Am Soc Nephrol. 2019 Jul; 30 (7):1251-1260 Epub 2019 June 07 PMID: 31175141 PMCID: PMC6622409 DOI: 10.1681/ASN.2018121241
236. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, **Lieske JC**, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Juni P, Cattran DC, MENTOR Investigators. Rituximab or

- Cyclosporine in the Treatment of Membranous Nephropathy. *N Engl J Med*. 2019 Jul 4; 381 (1):36-46 PMID: 31269364 DOI: 10.1056/NEJMoa1814427
237. Denic A, Ricaurte L, Lopez CL, Narasimhan R, Lerman LO, **Lieske JC**, Thompson RH, Kremers WK, Rule AD. Glomerular Volume and Glomerulosclerosis at Different Depths within the Human Kidney. *J Am Soc Nephrol*. 2019 Aug; 30 (8):1471-1480 Epub 2019 July 05 PMID: 31278193 PMCID: PMC6683701 DOI: 10.1681/ASN.2019020183
 238. D'Costa MR, Winkler NS, Milliner DS, Norby SM, Hickson LJ, **Lieske JC**. Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient. *Am J Kidney Dis*. 2019 Sep; 74 (3):417-420 Epub 2019 Mar 22 PMID: 30910370 PMCID: PMC6708738 DOI: 10.1053/j.ajkd.2019.01.022
 239. Anglani F, Giancesello L, Beara-Lasic L, **Lieske J**. Dent disease: A window into calcium and phosphate transport. *J Cell Mol Med*. 2019 Nov; 23 (11):7132-7142 Epub 2019 Aug 31 PMID: 31472005 PMCID: PMC6815805 DOI: 10.1111/jcmm.14590
 240. Fernandez K, Korinek M, Camp J, **Lieske J**, Holmes D. Automatic detection of calcium phosphate deposit plugs at the terminal ends of kidney tubules. *Healthc Technol Lett*. 2019 Dec; 6 (6):271-274 Epub 2019 Dec 06 PMID: 32038870 PMCID: PMC6952263 DOI: 10.1049/htl.2019.0086
 241. Ware EB, Smith JA, Zhao W, Ganesvoort RT, Curhan GC, Pollak M, Mount DB, Turner ST, Chen G, Shah RJ, Kardia SLR, **Lieske JC**. Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid. *Mayo Clin Proc Innov Qual Outcomes*. 2019 Dec; 3 (4):448-460 Epub 2019 Nov 22 PMID: 31993563 PMCID: PMC6978610 DOI: 10.1016/j.mayocpiqo.2019.08.007
 242. Merino J#, Dashti HS#, Li SX, Sarnowski C, Justice AE, Graff M, Papoutsakis C, Smith CE, Dedoussis GV, Lemaitre RN, Wojczynski MK, Mannisto S, Ngwa JS, Kho M, Ahluwalia TS, Pervjakova N, Houston DK, Bouchard C, Huang T, Orho-Melander M, Frazier-Wood AC, Mook-Kanamori DO, Perusse L, Pennell CE, de Vries PS, Voortman T, Li O, Kanoni S, Rose LM, Lehtimäki T, Zhao JH, Feitosa MF, Luan J, McKeown NM, Smith JA, Hansen T, Eklund N, Nalls MA, Rankinen T, Huang J, Hernandez DG, Schulz CA, Manichaikul A, Li-Gao R, Vohl MC, Wang CA, van Rooij FJA, Shin J, Kalafati IP, Day F, Ridker PM, Kahonen M, Siscovick DS, Langenberg C, Zhao W, Astrup A, Knekt P, Garcia M, Rao DC, Qi Q, Ferrucci L, Ericson U, Blangero J, Hofman A, Pausova Z, Mikkilä V, Wareham NJ, Kardia SLR, Pedersen O, Jula A, Curran JE, Zillikens MC, Viikari JS, Forouhi NG, Ordovas JM, **Lieske JC**, Rissanen H, Uitterlinden AG, Raitakari OT, Kieft-de Jong JC, Dupuis J, Rotter JI, North KE, Scott RA, Province MA, Perola M, Cupples LA, Turner ST, Sorensen TIA, Salomaa V, Liu Y, Sung YJ, Qi L, Bandinelli S, Rich SS, de Mutsert R, Tremblay A, Oddy WH, Franco OH, Paus T, Florez JC, Deloukas P, Lyytikäinen LP, Chasman DI#, Chu AY#, Tanaka T#. Genome-wide meta-analysis of macronutrient intake of 91,114 European ancestry participants from the cohorts for heart and aging research in genomic epidemiology consortium. *Mol Psychiatry*. 2019 Dec; 24 (12):1920-1932 Epub 2018 July 09 PMID: 29988085 PMCID: PMC6326896 DOI: 10.1038/s41380-018-0079-4
 243. Chirackal RS, Jayachandran M, Wang X, Edeh S, Haskic Z, Perinpam M, Halling TM, Mehta R, Rivera ME, **Lieske JC**. Urinary extracellular vesicle-associated MCP-1 and NGAL derived from specific nephron segments differ between calcium oxalate stone formers and controls. *Am J Physiol Renal Physiol*. 2019 Dec 1; 317 (6):F1475-F1482 Epub 2019 Aug 28 PMID: 31461349 PMCID: PMC6962507 DOI: 10.1152/ajprenal.00515.2018
 244. Markos JR, Schaepe KS, Teaforde HR, Rule AD, Kashani KB, **Lieske JC**, Barreto EF. Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic. *PLoS One*. 2020; 15 (12):e0243618 Epub 2020 Dec 11 PMID: 33306741 PMCID: PMC7732069 DOI: 10.1371/journal.pone.0243618

245. Sivaguru M, **Lieske JC**, Krambeck AE, Fouke BW. GeoBioMed sheds new light on human kidney stone crystallization and dissolution. *Nat Rev Urol*. 2020 Jan; 17 (1):1-2 PMID: 31676884 PMCID: PMC7201202 DOI: 10.1038/s41585-019-0256-5
246. Castiglione V, Pottel H, **Lieske JC**, Lukas P, Cavalier E, Delanaye P, Rule AD. Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones. *J Nephrol*. 2020 Feb; 33 (1):101-107 Epub 2019 June 20 PMID: 31222647 DOI: 10.1007/s40620-019-00623-0
247. **Lieske JC**, Kashani K, Kellum J, Koyner J, Mehta R, Parikh CR. Use of Biomarkers to Detect and Manage Acute Kidney Injury: Has Progress Stalled? *Clin Chem* 2020 Feb 1; 66 (2):271-276 PMID: 32040587 DOI: 10.1093/clinchem/hvz026
248. Chang MH, Brown MR, Liu Y, Gainullin VG, Harris PC, Romero MF, **Lieske JC**. Cl(-) and H(+) coupling properties and subcellular localizations of wildtype and disease-associated variants of the voltage-gated Cl(-)/H(+) exchanger ClC-5. *J Biol Chem*. 2020 Feb 7; 295 (6):1464-1473 Epub 2019 Dec 18 PMID: 31852738 PMCID: PMC7008381 DOI: 10.1074/jbc.RA119.011366
249. Safadi S, Hommos MS, Enders FT, **Lieske JC**, Kashani KB. Risk Factors for Acute Kidney Injury in Hospitalized Non-Critically Ill Patients: A Population-Based Study. *Mayo Clin Proc*. 2020 Mar; 95 (3):459-467 Epub 2020 Jan 31 PMID: 32008812 PMCID: PMC7060836 DOI: 10.1016/j.mayocp.2019.06.011
250. McGregor TL, Hunt KA, Yee E, Mason D, Nioi P, Ticau S, Pelosi M, Loken PR, Finer S, Lawlor DA, Fauman EB, Huang QQ, Griffiths CJ, MacArthur DG, Trembath RC, Oglesbee D, **Lieske JC**, Erbe DV, Wright J, van Heel DA. Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria. *Elife*. 2020 Mar 24; 9 PMID: 32207686 PMCID: PMC7108859 DOI: 10.7554/eLife.54363
251. Zhang X, Rule AD, McCulloch CE, **Lieske JC**, Ku E, Hsu CY. Tubular secretion of creatinine and kidney function: an observational study. *BMC Nephrol*. 2020 Mar 30; 21 (1):108 PMID: 32228497 PMCID: PMC7104490 DOI: 10.1186/s12882-020-01736-6
252. Sas DJ, Enders FT, Mehta RA, Tang X, Zhao F, Seide BM, Milliner DS, **Lieske JC**. Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. *Kidney Int*. 2020 Apr; 97 (4):786-792 Epub 2019 Dec 13 PMID: 32093915 PMCID: PMC7175669 DOI: 10.1016/j.kint.2019.11.023
253. Beara-Lasic L, Cogal A, Mara K, Enders F, Mehta RA, Haskic Z, Furth SL, Trachtman H, Scheinman SJ, Milliner DS, Goldfarb DS, Harris PC, **Lieske JC**, investigators of the Rare Kidney Stone Consortium. Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts. *Pediatr Nephrol*. 2020 Apr; 35 (4):633-640 Epub 2019 Mar 10 PMID: 30852663 PMCID: PMC6736764 DOI: 10.1007/s00467-019-04210-0
254. Wang X, Bhutani G, Vaughan LE, Enders FT, Haskic Z, Milliner D, **Lieske JC**, investigators of the Rare Kidney Stone Consortium. Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria. *BMC Nephrol*. 2020 Apr 15; 21 (1):133 PMID: 32293313 PMCID: PMC7161151 DOI: 10.1186/s12882-020-01783-z
255. Rule AD, **Lieske JC**, Pais VM Jr. Management of Kidney Stones in 2020. *JAMA*. 2020 May 19; 323 (19):1961-1962 PMID: 32191284 DOI: 10.1001/jama.2020.0662
256. Shah RJ, Vaughan LE, Enders FT, Milliner DS, **Lieske JC**. Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort. *Int J Mol Sci*. 2020 May 20; 21 (10) PMID: 32443777 PMCID: PMC7279271 DOI: 10.3390/ijms21103608

257. Chakkera HA, Denic A, Kremers WK, Stegall MD, Larson JJ, Ravipati H, Taler SJ, **Lieske JC**, Lerman LO, Augustine JJ, Rule AD. Comparison of high glomerular filtration rate thresholds for identifying hyperfiltration. *Nephrol Dial Transplant*. 2020 Jun 1; 35 (6):1017-1026 PMID: 30403810 PMCID: PMC7282825 DOI: 10.1093/ndt/gfy332
258. Singh P, Chebib FT, Cogal AG, Gavrilov DK, Harris PC, **Lieske JC**. Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) AGXT Gene Mutation. *Kidney Int Rep*. 2020 Jun; 5 (6):955-958 Epub 2020 Apr 13 PMID: 32518881 PMCID: PMC7270974 DOI: 10.1016/j.ekir.2020.04.004
259. Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, **Lieske JC**. End Points for Clinical Trials in Primary Hyperoxaluria. *Clin J Am Soc Nephrol*. 2020 Jul 1; 15 (7):1056-1065 Epub 2020 Mar 12 PMID: 32165440 PMCID: PMC7341772 DOI: 10.2215/CJN.13821119
260. Teaford HR, Rule AD, Mara KC, Kashani KB, **Lieske JC**, Schreier DJ, Wieruszewski PM, Barreto EF. Patterns of Cystatin C Uptake and Use Across and Within Hospitals. *Mayo Clin Proc*. 2020 Aug; 95 (8):1649-1659 PMID: 32753139 PMCID: PMC7412578 DOI: 10.1016/j.mayocp.2020.03.030
261. Troost JP, Waldo A, Carlozzi NE, Murphy S, Modersitzki F, Trachtman H, Nachman PH, Reidy KJ, Selewski DT, Herreshoff EG, Srivastava T, Gibson KL, Derebail VK, Lin JJ, Hingorani S, Fornoni A, Fervenza FC, Sambandam K, Athavale AM, Kopp JB, Reich HN, Adler SG, Greenbaum LA, Dell KM, Appel G, Wang CS, Sedor J, Kaskel FJ, Lafayette RA, Atkinson MA, **Lieske JC**, Sethna CB, Kretzler M, Hladunewich MA, Lemley KV, Brown E, Meyers KE, Gadegbeku CA, Holzman LB, Jefferson JA, Tuttle KR, Singer P, Hogan MC, Cattran DC, Barisoni L, Gipson DS, Nephrotic Syndrome Study Network. The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. *Clin Kidney J*. 2020 Aug; 13 (4):597-606 Epub 2019 Aug 05 PMID: 32905199 PMCID: PMC7467600 DOI: 10.1093/ckj/sfz092
262. Kho M, Smith JA, Verweij N, Shang L, Ryan KA, Zhao W, Ware EB, Gansevoort RT, Irvin MR, Lee JE, Turner ST, Sung J, van der Harst P, Arnett DK, Baylin A, Park SK, Seo YA, Kelly KM, Chang YPC, Zhou X, **Lieske JC**, Kardia SLR. Genome-Wide Association Meta-Analysis of Individuals of European Ancestry Identifies Suggestive Loci for Sodium Intake, Potassium Intake, and Their Ratio Measured from 24-Hour or Half-Day Urine Samples. *J Nutr*. 2020 Oct 12; 150 (10):2635-2645 PMID: 32840624 PMCID: PMC7549298 DOI: 10.1093/jn/nxaa241
263. Rule AD, **Lieske JC**, Pais VM Jr. Diagnostic Imaging for Kidney Stones-Reply. *JAMA* 2020 Oct 13; 324 (14):1465 PMID: 33048149 DOI: 10.1001/jama.2020.14877
264. Eisner BH, Goldfarb DS, Baum MA, Langman CB, Curhan GC, Preminger GM, **Lieske JC**, Pareek G, Thomas K, Zisman AL, Papagiannopoulos D, Sur RL. Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus Statement. *J Endourol*. 2020 Nov; 34 (11):1103-1110 Epub 2020 Apr 06 PMID: 32066273 PMCID: PMC7869875 DOI: 10.1089/end.2019.0703
265. Denic A, Elsherbiny H, Mullan AF, Leibovich BC, Thompson RH, Ricaurte Archila L, Narasimhan R, Kremers WK, Alexander MP, **Lieske JC**, Lerman LO, Rule AD. Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. *J Am Soc Nephrol*. 2020 Nov; 31 (11):2642-2652 Epub 2020 Sept 16 PMID: 32938650 PMCID: PMC7608955 DOI: 10.1681/ASN.2020040449
266. Gonzalez Guerrico AM, **Lieske J**, Klee G, Kumar S, Lopez-Baez V, Wright AM, Bobart S, Shevell D, Maldonado M, Troost JP, Hogan MC, Nephrotic Syndrome Study Network Consortium (NEPTUNE). Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease

- Activity. *Kidney Int Rep.* 2020 Nov; 5 (11):2021-2031 Epub 2020 Aug 14 PMID: 33163723 PMCID: PMC7609973 DOI: 10.1016/j.ekir.2020.08.001
267. Jayachandran M, Yuzhakov SV, Kumar S, Larson NB, Enders FT, Milliner DS, Rule AD, **Lieske JC**. Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones. *Orphanet J Rare Dis.* 2020 Nov 11; 15 (1):319 PMID: 33176829 PMCID: PMC7659070 DOI: 10.1186/s13023-020-01607-1
 268. Stokes F, Acquaviva-Bourdain C, Hoppe B, **Lieske JC**, Lindner E, Toulson G, Vaz FM, Rumsby G. Plasma oxalate: comparison of methodologies. *Urolithiasis.* 2020 Dec; 48 (6):473-480 Epub 2020 May 29 PMID: 32472220 PMCID: PMC7666277 DOI: 10.1007/s00240-020-01197-4
 269. Visram A, Al Saleh AS, Parmar H, McDonald JS, **Lieske JC**, Vaxman I, Muchtar E, Hobbs M, Fonder A, Hwa YL, Buadi FK, Dingli D, Lacy MQ, Dispenzieri A, Kapoor P, Hayman SR, Warsame R, Kourelis TV, Siddiqui M, Gonsalves WI, Lust JA, Kyle RA, Vincent Rajkumar S, Gertz MA, Kumar SK, Leung N. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. *Blood Cancer J.* 2020 Dec 11; 10 (12):124 PMID: 33311451 PMCID: PMC7733489 DOI: 10.1038/s41408-020-00391-2
 270. Teaford HR, Stevens RW, Rule AD, Mara KC, Kashani KB, **Lieske JC**, O'Horo J, Barreto EF. Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients. *Antimicrob Agents Chemother.* 2020 Dec 16; 65 (1) PMID: 33106257 PMCID: PMC7927827 DOI: 10.1128/AAC.01487-20
 271. Reddy S, Bolen E, Abdelmalek M, **Lieske JC**, Ryan M, Keddis MT. Clinical Outcomes and Histological Patterns in Oxalate Nephropathy due to Enteric and Nonenteric Risk Factors. *Am J Nephrol.* 2021; 52 (12):961-968 Epub 2021 Nov 29 PMID: 34844241 DOI: 10.1159/000520286
 272. Pinto E Vairo F, Prochnow C, Kemppainen JL, Lisi EC, Steyermark JM, Kruisselbrink TM, Pichurin PN, Dhamija R, Hager MM, Albadri S, Cornell LD, Lazaridis KN, Klee EW, Senum SR, El Ters M, Amer H, Baudhuin LM, Moyer AM, Keddis MT, Zand L, Sas DJ, Erickson SB, Fervenza FC, **Lieske JC**, Harris PC, Hogan MC. Genomics Integration Into Nephrology Practice. *Kidney Med.* 2021 Sep-Oct; 3(5):785-798. Epub 2021 Jun 29. PMID: 34746741 PMCID: PMC8551494 DOI: 10.1016/j.xkme.2021.04.014
 273. Sas DJ, Enders FT, Gunderson TM, Mehta RA, Olson JB, Seide BM, Banks CJ, Dehmel B, Pellikka PA, **Lieske JC**, Milliner DS. Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis. *Front Med (Lausanne).* 2021; 8:592357 Epub 2021 Apr 09 PMID: 33898474 PMCID: PMC8062902 DOI: 10.3389/fmed.2021.592357
 274. Klomjit N, Shah K, Herrmann SM, **Lieske JC**. The Case | An unusual cause of tender skin lesion in an end-stage kidney disease patient. *Kidney Int.* 2021 Jan; 99 (1):275-276 PMID: 33390236 DOI: 10.1016/j.kint.2020.06.011
 275. Saw JJ, Sivaguru M, Wilson EM, Dong Y, Sanford RA, Fields CJ, Cregger MA, Merkel AC, Bruce WJ, Weber JR, **Lieske JC**, Krambeck AE, Rivera ME, Large T, Lange D, Bhattacharjee AS, Romero MF, Chia N, Fouke BW. In Vivo Entombment of Bacteria and Fungi during Calcium Oxalate, Brushite, and Struvite Urolithiasis. *Kidney360.* 2021 Feb 25; 2 (2):298-311 Epub 2020 Dec 23 PMID: 35373025 PMCID: PMC8740987 DOI: 10.34067/KID.0006942020
 276. Bobart SA, Tehranian S, Sethi S, Alexander MP, Nasr SH, Moura Marta C, Vrana JA, Said S, Giesen CD, **Lieske JC**, Fervenza FC, De Vriese AS. A Target Antigen-Based Approach to the Classification of Membranous Nephropathy. *Mayo Clin Proc.* 2021 Mar; 96 (3):577-591 PMID: 33673911 DOI: 10.1016/j.mayocp.2020.11.028

277. Witting C, Langman CB, Assimios D, Baum MA, Kausz A, Milliner D, Tasian G, Worcester E, Allain M, West M, Knauf F, **Lieske JC**. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2021 Mar 08; 16(3):487-495. Epub 2020 Sep 08. PMID: 32900691 PMCID: PMC8011014 DOI: 10.2215/CJN.08000520
278. El-Khoury JM, Ovalle AA, Cervinski MA, Levey AS, Jones G, Eneanya ND, **Lieske JC**, Jha V, Moderators://Experts:. Is It Time to Move On? Reexamining Race in Glomerular Filtration Rate Equations. Clin Chem 2021 Mar 31; 67 (4):585-591 PMID: 33686430 DOI: 10.1093/clinchem/hvaa333
279. Isik B, Alexander MP, Manohar S, Vaughan L, Kottschade L, Markovic S, **Lieske J**, Kukla A, Leung N, Herrmann SM. Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. Kidney Int Rep. 2021 Apr; 6 (4):1022-1031 Epub 2021 Feb 02 PMID: 33912752 PMCID: PMC8071627 DOI: 10.1016/j.ekir.2021.01.013
280. Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschenes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, **Lieske JC**, ILLUMINATE-A Collaborators. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr 1; 384 (13):1216-1226 PMID: 33789010 DOI: 10.1056/NEJMoa2021712
281. Pfau A, Grujic D, Keddis MT, Kausz AT, **Lieske JC**, Knauf F. Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia. Nephrol Dial Transplant 2021 Apr 26; 36 (5):945-948 PMID: 33416876 PMCID: PMC8075375 DOI: 10.1093/ndt/gfaa379
282. Lorenz EC, **Lieske JC**, Seide BM, Olson JB, Mehta R, Milliner DS. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases. Am J Kidney Dis. 2021 May; 77 (5):816-819 Epub 2020 Sept 04 PMID: 32891627 PMCID: PMC7930154 DOI: 10.1053/j.ajkd.2020.07.017
283. Zhang J, Kumar S, Jayachandran M, Herrera Hernandez LP, Wang S, Wilson EM, **Lieske JC**. Excretion of urine extracellular vesicles bearing markers of activated immune cells and calcium/phosphorus physiology differ between calcium kidney stone formers and non-stone formers. BMC Nephrol. 2021 Jun 1; 22 (1):204 Epub 2021 June 01 PMID: 34074247 PMCID: PMC8170929 DOI: 10.1186/s12882-021-02417-8
284. Hanna C, Potretzke TA, Cogal AG, Mkhaimer YG, Tebben PJ, Torres VE, **Lieske JC**, Harris PC, Sas DJ, Milliner DS, Chebib FT. High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency. Kidney Int Rep. 2021 Jul; 6 (7):1895-1903 Epub 2021 May 12 PMID: 34307984 PMCID: PMC8258502 DOI: 10.1016/j.ekir.2021.04.030
285. Sivaguru M, Saw JJ, Wilson EM, **Lieske JC**, Krambeck AE, Williams JC, Romero MF, Fouke KW, Curtis MW, Kear-Scott JL, Chia N, Fouke BW. Human kidney stones: a natural record of universal biomineralization. Nat Rev Urol. 2021 Jul; 18 (7):404-432 Epub 2021 May 24 PMID: 34031587 DOI: 10.1038/s41585-021-00469-x
286. Frishberg Y, Deschenes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, **Lieske JC**, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P, study collaborators. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clin J Am Soc Nephrol. 2021 Jul; 16 (7):1025-1036 Epub 2021 May 13 PMID: 33985991 PMCID: PMC8425611 DOI: 10.2215/CJN.14730920

287. Zhang JQ, Zhu HD, Xia JJ, Zhang JH, **Lieske JC**. Surgical interventions for symptomatic urinary stones during pregnancy. *Chin Med J (Engl)* 2021 Jul 29; 134 (16):1994-1996 Epub 2021 July 29 PMID: 34334629 PMCID: PMC8382336 DOI: 10.1097/CM9.0000000000001648
288. Mohammadinejad P, Ferrero A, Bartlett DJ, Khandelwal A, Marcus R, **Lieske JC**, Moen TR, Mara KC, Enders FT, McCollough CH, Fletcher JG. Automated radiomic analysis of CT images to predict likelihood of spontaneous passage of symptomatic renal stones. *Emerg Radiol.* 2021 Aug; 28 (4):781-788 Epub 2021 Mar 01 PMID: 33644833 PMCID: PMC8477419 DOI: 10.1007/s10140-021-01915-4
289. Meeusen JW, Amer H, **Lieske JC**. Has Noninvasive Kidney Transplant Surveillance Finally Arrived? *Clin Chem.* 2021 Aug 5; 67 (8):1047-1049 PMID: 34352081 DOI: 10.1093/clinchem/hvab015
290. Zee J, McNulty MT, Hodgins JB, Zhdanova O, Hingorani S, Jefferson JA, Gibson KL, Trachtman H, Fornoni A, Dell KM, Reich HN, Bagnasco S, Greenbaum LA, Lafayette RA, Gipson DS, Brown E, Kretzler M, Appel G, Sambandam KK, Tuttle KR, Chen D, Atkinson MA, Hogan MC, Kaskel FJ, Meyers KE, O'Toole J, Srivastava T, Sethna CB, Hladunewich MA, Lin JJ, Nast CC, Derebail VK, Patel J, Vento S, Holzman LB, Athavale AM, Adler SG, Lemley KV, **Lieske JC**, Hogan JJ, Gadegbeku CA, Fervenza FC, Wang CS, Matar RB, Singer P, Kopp JB, Barisoni L, Sampson MG. APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. *Pediatr Nephrol.* 2021 Sep; 36 (9):2747-2757 Epub 2021 Mar 01 PMID: 33646395 PMCID: PMC8524347 DOI: 10.1007/s00467-021-04990-4
291. Thongprayoon C, Vaughan LE, Chewcharat A, Kattah AG, Enders FT, Kumar R, **Lieske JC**, Pais VM, Garovic VD, Rule AD. Risk of Symptomatic Kidney Stones During and After Pregnancy. *Am J Kidney Dis.* 2021 Sep; 78 (3):409-417 Epub 2021 Apr 15 PMID: 33867205 PMCID: PMC8384636 DOI: 10.1053/j.ajkd.2021.01.008
292. Vuckovic I, Denic A, Charlesworth MC, Suvakov M, Bobart S, **Lieske JC**, Fervenza FC, Macura S. (1)H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine. *Anal Chem.* 2021 Oct 5; 93 (39):13177-13186 Epub 2021 Sept 21 PMID: 34546699 DOI: 10.1021/acs.analchem.1c01618
293. Giansello L, Arroyo J, Del Prete D, Priante G, Ceol M, Harris PC, **Lieske JC**, Anglani F. Genotype Phenotype Correlation in Dent Disease 2 and Review of the Literature: OCRL Gene Pleiotropism or Extreme Phenotypic Variability of Lowe Syndrome? *Genes (Basel).* 2021 Oct 11; 12 (10) PMID: 34680992 PMCID: PMC8535715 DOI: 10.3390/genes12101597
294. Cogal AG, Arroyo J, Shah RJ, Reese KJ, Walton BN, Reynolds LM, Kennedy GN, Seide BM, Senum SR, Baum M, Erickson SB, Jagadeesh S, Soliman NA, Goldfarb DS, Beara-Lasic L, Edvardsson VO, Palsson R, Milliner DS, Sas DJ, **Lieske JC**, Harris PC, Investigators of the Rare Kidney Stone Consortium. Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. *Kidney Int Rep.* 2021 Nov; 6 (11):2862-2884 Epub 2021 Sept 08 PMID: 34805638 PMCID: PMC8589729 DOI: 10.1016/j.ekir.2021.08.033
295. Milliner DS, **Lieske JC**. Back to the Future: The Role of Metabolic Studies in Therapeutic Advances. *J Am Soc Nephrol* 2021 Dec 1; 32 (12):2980-2982 Epub 2021 Dec 01 PMID: 36734820 PMCID: PMC8638383 DOI: 10.1681/ASN.2021101325
296. D'Costa MR, Kausz AT, Carroll KJ, Ingimarsson JP, Enders FT, Mara KC, Mehta RA, **Lieske JC**. Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria. *Nephrol Dial Transplant.* 2021 Dec 2; 36 (12):2208-2215 PMID: 33367720 PMCID: PMC8826697 DOI: 10.1093/ndt/gfaa281

297. Stammeler F, Grassi M, Meeusen JW, **Lieske JC**, Dasari S, Dubourg L, Lemoine S, Ehrich J, Schiffer E. Estimating Glomerular Filtration Rate from Serum Myo-Inositol, Valine, Creatinine and Cystatin C. *Diagnostics (Basel)*. 2021 Dec 7; 11 (12) Epub 2021 Dec 07 PMID: 34943527 PMCID: PMC8700166 DOI: 10.3390/diagnostics11122291
298. Tiulentino Sy-Go JP, Wegehaupt AK, Sethi S, **Lieske JC**, D'Costa MR. Microsporidium Infection-Associated Acute Kidney Injury in a Patient With HIV. *Kidney Med*. 2022 Jan; 4 (1):100390 Epub 2021 Nov 21 PMID: 35072050 PMCID: PMC8767129 DOI: 10.1016/j.xkme.2021.10.004
299. Schreier DJ, Rule AD, Kashani KB, Mara KC, Kane-Gill SL, **Lieske JC**, Chamberlain AM, Barreto EF, ACT Study Team. Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors. *Am J Nephrol*. 2022; 53 (4):273-281 Epub 2022 Mar 16 PMID: 35294951 PMCID: PMC9090945 DOI: 10.1159/000522139
300. Cornell LD, Amer H, Viehman JK, Mehta RA, **Lieske JC**, Lorenz EC, Heimbach JK, Stegall MD, Milliner DS, Rare Kidney Stone Consortium Primary Hyperoxaluria (RKSC PH) investigators. Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function. *Am J Transplant*. 2022 Jan; 22 (1):85-95 Epub 2021 July 26 PMID: 34174139 PMCID: PMC8710184 DOI: 10.1111/ajt.16732
301. Singh P, Granberg CF, Harris PC, **Lieske JC**, Licht JH, Weiss A, Milliner DS. Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report. *Am J Kidney Dis*. 2022 Jan; 79 (1):125-128 Epub 2021 July 07 PMID: 34245816 PMCID: PMC8692335 DOI: 10.1053/j.ajkd.2021.05.016
302. Meeusen JW, Stammeler F, Dasari S, Schiffer E, **Lieske JC**. Serum myo-inositol and valine improve metabolomic-based estimated glomerular filtration rate among kidney transplant recipients. *Front Med (Lausanne)*. 2022; 9:988989 Epub 2022 Nov 17 PMID: 36465899 PMCID: PMC9712186 DOI: 10.3389/fmed.2022.988989
303. Dejban P, Wilson EM, Jayachandran M, Herrera Hernandez LP, Haskic Z, Wellik LE, Sinha S, Rule AD, Denic A, Koo K, Potretzke AM, **Lieske JC**. Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease. *Clin J Am Soc Nephrol*. 2022 Mar; 17 (3):414-422 Epub 2022 Jan 25 PMID: 35078782 PMCID: PMC8975022 DOI: 10.2215/CJN.11730921
304. Hanna C, Potretzke TA, Chedid M, Rangel LJ, Arroyo J, Zubidat D, Tebben PJ, Cogal AG, Torres VE, Harris PC, Sas DJ, **Lieske JC**, Milliner DS, Chebib FT. Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series. *Kidney Med*. 2022 Mar; 4 (3):100419 Epub 2022 Jan 24 PMID: 35386604 PMCID: PMC8978140 DOI: 10.1016/j.xkme.2022.100419
305. Hulton SA, Groothoff JW, Frishberg Y, Koren MJ, Overcash JS, Sellier-Leclerc AL, Shasha-Lavsky H, Saland JM, Hayes W, Magen D, Mochhala SH, Coenen M, Simkova E, Garrelfs SF, Sas DJ, Meliambro KA, Ngo T, Sweetser MT, Habtemariam BA, Gansner JM, McGregor TL, **Lieske JC**. Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1. *Kidney Int Rep*. 2022 Mar; 7 (3):494-506 Epub 2021 Dec 11 PMID: 35257062 PMCID: PMC8897294 DOI: 10.1016/j.ekir.2021.12.001
306. Meeusen JW, Kasozi RN, Larson TS, **Lieske JC**. Clinical Impact of the Refit CKD-EPI 2021 Creatinine-Based eGFR Equation. *Clin Chem*. 2022 Mar 31; 68 (4):534-539 PMID: 35038721 DOI: 10.1093/clinchem/hvab282
307. Miller WG, Kaufman HW, Levey AS, Straseski JA, Wilhelms KW, Yu HE, Klutts JS, Hilborne LH, Horowitz GL, **Lieske J**, Ennis JL, Bowling JL, Lewis MJ, Montgomery E, Vassalotti JA, Inker LA. National Kidney Foundation Laboratory Engagement Working Group Recommendations for

- Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories. Clin Chem. 2022 Mar 31; 68 (4):511-520 PMID: 34918062 DOI: 10.1093/clinchem/hvab278
308. Singh P, Harris PC, Sas DJ, **Lieske JC**. The genetics of kidney stone disease and nephrocalcinosis. Nat Rev Nephrol. 2022 Apr; 18 (4):224-240 Epub 2021 Dec 14 PMID: 34907378 DOI: 10.1038/s41581-021-00513-4
 309. Singh P, Viehman JK, Mehta RA, Cogal AG, Hasadsri L, Oglesbee D, Olson JB, Seide BM, Sas DJ, Harris PC, **Lieske JC**, Milliner DS. Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2. Nephrol Dial Transplant. 2022 Apr 25; 37 (5):869-875 PMID: 33543760 PMCID: PMC9214566 DOI: 10.1093/ndt/gfab027
 310. Bacchetta J, **Lieske JC**. Primary hyperoxaluria type 1: novel therapies at a glance. Clin Kidney J. 2022 May; 15 (Suppl 1):i17-i22 Epub 2022 May 17 PMID: 35592618 PMCID: PMC9113449 DOI: 10.1093/ckj/sfab245
 311. Barreto JN, Kashani KB, Mara KC, Rule AD, **Lieske JC**, Giesen CD, Thompson CA, Leung N, Witzig TE, Barreto EF. A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate. Kidney Int Rep. 2022 Jul; 7 (7):1690-1693 Epub 2022 Mar 26 PMID: 35812294 PMCID: PMC9263243 DOI: 10.1016/j.ekir.2022.03.013
 312. Miao J, Mehta RA, Norby S, Seide B, Milliner DS, **Lieske J**, Kattah A. Comparison of clinical features of pregnant and non-pregnant females with primary hyperoxaluria. J Nephrol 2022 Jul; 35 (6):1771-1774 Epub 2022 Jan 18 PMID: 35041195 PMCID: PMC9694097 DOI: 10.1007/s40620-022-01253-9
 313. Dejban P, **Lieske JC**. New therapeutics for primary hyperoxaluria type 1. Curr Opin Nephrol Hypertens. 2022 Jul 1; 31 (4):344-350 Epub 2022 Mar 09 PMID: 35266883 PMCID: PMC9232952 DOI: 10.1097/MNH.0000000000000790
 314. **Lieske JC**, Lingeman JE, Ferraro PM, Wyatt CM, Tosone C, Kausz AT, Knauf F. Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria. NEJM Evid. 2022 Jul; 1 (7):EVIDoa2100053 Epub 2022 May 06 PMID: 38319254 DOI: 10.1056/EVIDoa2100053
 315. Thongprayoon C, Vuckovic I, Vaughan L, Macura S, Larson N, D'Costa M, **Lieske J**, Rule A, Denic A. NMR Metabolomic Profiling and Urine Chemistries in Incident Kidney Stone Formers Compared to Controls. J Am Soc Nephrol. 2022 Jul 19 Epub 2022 July 19 PMID: 35853716 DOI: 10.1681/ASN.2022040416
 316. Chewcharat A, Thongprayoon C, Vaughan LE, Mehta RA, Schulte PJ, O'Connor HM, **Lieske JC**, Taylor EN, Rule AD. Dietary Risk Factors for Incident and Recurrent Symptomatic Kidney Stones. Mayo Clin Proc. 2022 Aug; 97 (8):1437-1448 Epub 2022 Aug 01 PMID: 35933132 DOI: 10.1016/j.mayocp.2022.04.016
 317. Singh P, Vaughan LE, Schulte PJ, Sas DJ, Milliner DS, **Lieske JC**. Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1. Am J Kidney Dis. 2022 Sep; 80 (3):373-382 Epub 2022 Mar 16 PMID: 35306035 PMCID: PMC9398980 DOI: 10.1053/j.ajkd.2022.01.428
 318. Lin Z, Jayachandran M, Haskic Z, Kumar S, **Lieske JC**. Differences of Uric Acid Transporters Carrying Extracellular Vesicles in the Urine from Uric Acid and Calcium Stone Formers and Non-Stone Formers. Int J Mol Sci. 2022 Sep 2; 23 (17) Epub 2022 Sept 02 PMID: 36077407 PMCID: PMC9456222 DOI: 10.3390/ijms231710010
 319. Takis PG, Vuckovic I, Tan T, Denic A, **Lieske JC**, Lewis MR, Macura S. NMRpQuant: an automated software for large scale urinary total protein quantification by one-dimensional 1H NMR profiles.

- Bioinformatics. 2022 Sep 15; 38 (18):4437-4439 PMID: 35861573 PMCID: PMC9477529 DOI: 10.1093/bioinformatics/btac502
320. Todorov LG#, Sivaguru M#, Krambeck AE, Lee MS, **Lieske JC**, Fouke BW#. GeoBioMed perspectives on kidney stone recurrence from the reactive surface area of SWL-derived particles. Sci Rep. 2022 Nov 1; 12 (1):18371 Epub 2022 Nov 01 PMID: 36319741 PMCID: PMC9626463 DOI: 10.1038/s41598-022-23331-5
 321. Thongprayoon C, Vuckovic I, Vaughan LE, Macura S, Larson NB, D'Costa MR, **Lieske JC**, Rule AD, Denic A. Nuclear Magnetic Resonance Metabolomic Profiling and Urine Chemistries in Incident Kidney Stone Formers Compared with Controls. J Am Soc Nephrol. 2022 Nov; 33 (11):2071-2086 Epub 2022 July 19 PMID: 36316097 PMCID: PMC9678037 DOI: 10.1681/ASN.2022040416
 322. Britton CJ, Sharma V, Lohse CM, **Lieske JC**, Nichols PE, Khanna A, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH, Potretzke AM. Progression of Chronic Kidney Disease Following Radical and Partial Nephrectomy. Urology. 2022 Nov; 169:125-133 Epub 2022 July 22 PMID: 35878813 DOI: 10.1016/j.urology.2022.07.009
 323. Vaughan LE, **Lieske JC**, Milliner DS, Schulte PJ. Application of multivariate joint modeling of longitudinal biomarkers and time-to-event data to a rare kidney stone cohort. J Clin Transl Sci. 2023; 7 (1):e8 Epub 2022 Sept 26 PMID: 36755528 PMCID: PMC9879888 DOI: 10.1017/cts.2022.465
 324. Liaw CW, Potretzke AM, Winoker JS, Matlaga BR, **Lieske JC**, Koo K. Dietary Assessment of Lithogenic Factors in Plant-Based Meat Products. J Endourol. 2023 Jan; 37 (1):119-122 Epub 2022 Oct 10 PMID: 36103379 DOI: 10.1089/end.2022.0189
 325. Baum MA, Langman C, Cochat P, **Lieske JC**, Mochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tonshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B, PHYOX2 study investigators. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 2023 Jan; 103 (1):207-217 Epub 2022 Aug 22 PMID: 36007597 DOI: 10.1016/j.kint.2022.07.025
 326. Potretzke A, Britton CJ, Sharma V, Lohse CM, Thompson R, **Lieske JC**, Rule AD. Non-race-based Glomerular Filtration Rates to Estimate Renal Functional Outcomes Following Nephrectomy AUA Journal. 2023.
 327. Michael M, Groothoff JW, Shasha-Lavsky H, **Lieske JC**, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. Am J Kidney Dis. 2023 Feb; 81 (2):145-155.e1 Epub 2022 July 14 PMID: 35843439 DOI: 10.1053/j.ajkd.2022.05.012
 328. Lobo R, **Lieske JC**, Donato LJ, Hickson LJ, Hodge DO, Chapman A, Schwartz GL, Jaffe AS. Measuring copeptin, a surrogate for vasopressin in patients with hypertension - Can it identify those who are volume Responsive? Clin Biochem. 2023 Feb; 112:48-52. Epub 2022 Dec 05. PMID: 36470342 DOI: 10.1016/j.clinbiochem.2022.11.011
 329. Mariani LH, Eddy S, AlAkwa FM, McCown PJ, Harder JL, Nair V, Eichinger F, Martini S, Ademola AD, Boima V, Reich HN, El Saghir J, Godfrey B, Ju W, Tanner EC, Vega-Warner V, Wys NL, Adler SG, Appel GB, Athavale A, Atkinson MA, Bagnasco SM, Barisoni L, Brown E, Cattran DC, Coppock GM, Dell KM, Derebail VK, Fervenza FC, Fornoni A, Gadegbeku CA, Gibson KL, Greenbaum LA, Hingorani SR, Hladunewich MA, Hodgin JB, Hogan MC, Holzman LB, Jefferson JA, Kaskel FJ, Kopp JB, Lafayette RA,

- Lemley KV, **Lieske JC**, Lin JJ, Menon R, Meyers KE, Nachman PH, Nast CC, O'Shaughnessy MM, Otto EA, Reidy KJ, Sambandam KK, Sedor JR, Sethna CB, Singer P, Srivastava T, Tran CL, Tuttle KR, Vento SM, Wang CS, Ojo AO, Adu D, Gipson DS, Trachtman H, Kretzler M. Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis. *Kidney Int.* 2023 Mar; 103 (3):565-579 Epub 2022 Nov 25 PMID: 36442540 PMCID: PMC10347421 DOI: 10.1016/j.kint.2022.10.023
330. Stammer F#, Derain-Dubourg L#, Lemoine S, Meeusen JW, Dasari S, **Lieske JC**, Robertson A, Schiffer E. Impact of race-independent equations on estimating glomerular filtration rate for the assessment of kidney dysfunction in liver disease. *BMC Nephrol.* 2023 Mar 31; 24 (1):83 PMID: 37003973 PMCID: PMC10064726 DOI: 10.1186/s12882-023-03136-y
 331. Goldfarb DS, **Lieske JC**, Groothoff J, Schalk G, Russell K, Yu S, Vrhnjak B. Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). *Urolithiasis.* 2023 Apr 28; 51 (1):80 PMID: 37118061 PMCID: PMC10147791 DOI: 10.1007/s00240-023-01453-3
 332. Britton CJ, Sharma V, Lohse CM, Thompson RH, **Lieske JC**, Rule AD, Potretzke AM. Non-race-based Glomerular Filtration Rates to Estimate Renal Functional Outcomes Following Radical and Partial Nephrectomy. *Urol Pract* 2023 May; 10 (3):213-216 Epub 2023 Jan 24 PMID: 37103500 DOI: 10.1097/UPJ.0000000000000389
 333. Britton CJ, Sharma V, Lohse CM, Thompson RH, **Lieske JC**, Rule AD, Potretzke AM. Reply by Authors. *Urol Pract.* 2023 May; 10 (3):216 Epub 2023 Mar 09 PMID: 37103512 DOI: 10.1097/UPJ.0000000000000389.02
 334. Barreto JN, Barreto EF, Mara KC, Rule AD, **Lieske JC**, Giesen CD, Thompson CA, Leung N, Witzig TE, Kashani KB. Tissue Inhibitor Metalloproteinase-2 and Insulin-Like Growth Factor Binding Protein-7 Kinetics Following Exposure to High-Dose Methotrexate. *Kidney360.* 2023 May 1; 4 (5):673-679 Epub 2023 Mar 08 PMID: 36888987 PMCID: PMC10278852 DOI: 10.34067/KID.0000000000000099
 335. Thongprayoon C, **Lieske JC**, Rule AD, Denic A. Authors' Reply: Urine Metabolomic Versus Standard Chemistry Analysis: What can Metabolomic Analysis Bring to the Treatment and Prevention of Urolithiasis? *J Am Soc Nephrol* 2023 Jun 1; 34 (6):1124-1125 Epub 2023 Apr 24 PMID: 37259199 PMCID: PMC10278795 DOI: 10.1681/ASN.0000000000000138
 336. Arnous MG, Vaughan L, Mehta RA, Schulte PJ, **Lieske JC**, Milliner DS. Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria. *J Urol.* 2023 Jun; 209 (6):1141-1150 Epub 2023 Mar 08 PMID: 36888927 PMCID: PMC11034812 DOI: 10.1097/JU.00000000000003400
 337. Arnous MG, Arroyo J, Cogal AG, Anglani F, Kang HG, Sas D, Harris PC, **Lieske JC**. The Site and Type of CLCN5 Genetic Variation Impact the Resulting Dent Disease-1 Phenotype. *Kidney Int Rep.* 2023 Jun; 8 (6):1220-1230 Epub 2023 Mar 23 PMID: 37284679 PMCID: PMC10239918 DOI: 10.1016/j.ekir.2023.03.012
 338. Goldfarb DS, **Lieske JC**, Groothoff J, Schalk G, Russell K, Yu S, Vrhnjak B. Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). *Urolithiasis.* 2023 Jun 5; 51 (1):85 Epub 2023 June 05 PMID: 37273015 PMCID: PMC10241720 DOI: 10.1007/s00240-023-01455-1
 339. Schwäble Santamaria A, Grassi M, Meeusen JW, **Lieske JC**, Scott R, Robertson A, Schiffer E. Performance of Nuclear Magnetic Resonance-Based Estimated Glomerular Filtration Rate in a Real-World Setting. *Bioengineering (Basel).* 2023 Jun 13; 10(6). PMID: 37370648 PMCID: PMC10295228 DOI: 10.3390/bioengineering10060717

340. Genena KM, Sas DJ, Milliner DS, **Lieske JC**. Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant. *Kidney Int Rep*. 2023 Jul; 8 (7):1469-1472 Epub 2023 Mar 23 PMID: 37441487 PMCID: PMC10334313 DOI: 10.1016/j.ekir.2023.03.013
341. Thongprayoon C, Vaughan LE, Barreto EF, Mehta RA, Koo K, Schulte PJ, **Lieske JC**, Rule AD. Outpatient Antibiotic Use is Not Associated with an Increased Risk of First-Time Symptomatic Kidney Stones. *J Am Soc Nephrol*. 2023 Aug 1; 34 (8):1399-1408 Epub 2023 May 15 PMID: 37184480 PMCID: PMC10400106 DOI: 10.1681/ASN.0000000000000155
342. Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, Reich HN, Lafayette R, Aslam N, Appel GB, Zand L, Kiryluk K, Liu L, Cattran DC, **MENTOR Trial Investigators**. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy. *Clin J Am Soc Nephrol*. 2023 Oct 1; 18 (10):1283-1293 Epub 2023 July 20 PMID: 37471101 PMCID: PMC10578640 DOI: 10.2215/CJN.0000000000000237
343. Beunders R, Donato LJ, van Groenendael R, Arlt B, Carvalho-Wodarz C, Schulte J, Coolen AC, **Lieske JC**, Meeusen JW, Jaffe AS, Pickkers P. Assessing GFR With Proenkephalin. *Kidney Int Rep*. 2023 Nov; 8(11):2345-2355. Epub 2023 Aug 19. PMID: 38025210 PMCID: PMC10658254 DOI: 10.1016/j.ekir.2023.08.006
344. Kasozi RN, Meeusen JW, **Lieske JC**. Estimating glomerular filtration rate with new equations: can one size ever fit all? *Crit Rev Clin Lab Sci*. 2023 Nov; 60 (7):549-559 Epub 2023 June 01 PMID: 37259709 PMCID: PMC10592396 DOI: 10.1080/10408363.2023.2214812
345. Sethi S, Beck LH Jr, Glassock RJ, Haas M, De Vriese AS, Caza TN, Hoxha E, Lambeau G, Tomas NM, Madden B, Debiec H, D'Agati VD, Alexander MP, Amer H, Appel GB, Barbour SJ, Caravaca-Fontan F, Cattran DC, Casal Moura M, D'Avila DO, Eick RG, Garovic VD, Greene EL, Herrera Hernandez LP, Jennette JC, **Lieske JC**, Markowitz GS, Nath KA, Nasr SH, Nast CC, Pani A, Praga M, Remuzzi G, Rennke HG, Ruggenenti P, Roccattello D, Soler MJ, Specks U, Stahl RAK, Singh RD, Theis JD, Velosa JA, Wetzels JFM, Winearls CG, Yandian F, Zand L, Ronco P, Fervenza FC. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification. *Mayo Clin Proc*. 2023 Nov; 98(11):1671-1684. Epub 2023 Oct 05. PMID: 37804268 DOI: 10.1016/j.mayocp.2023.08.006
346. Langman CB, Assimos D, Blank M, Calle J, Grauer A, Kausz A, Milliner D, Nazzal L, Smith K, Tasian G, Thompson A, Wood KD, Worcester E, Yang S, Malley MA, Knauf F, **Lieske JC**, Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup). End Point Considerations for Clinical Trials in Enteric Hyperoxaluria. *Clin J Am Soc Nephrol*. 2023 Dec 1; 18 (12):1637-1644 Epub 2023 June 21 PMID: 37342976 PMCID: PMC10723917 DOI: 10.2215/CJN.0000000000000234
347. Sethi S, Beck LH Jr, Glassock RJ, Haas M, De Vriese AS, Caza TN, Hoxha E, Lambeau G, Tomas NM, Madden B, Debiec H, D'Agati VD, Alexander MP, Amer H, Appel GB, Barbour SJ, Caravaca-Fontan F, Cattran DC, Casal Moura M, D'Avila DO, Eick RG, Garovic VD, Greene EL, Herrera Hernandez LP, Jennette JC, **Lieske JC**, Markowitz GS, Nath KA, Nasr SH, Nast CC, Pani A, Praga M, Remuzzi G, Rennke HG, Ruggenenti P, Roccattello D, Soler MJ, Specks U, Stahl RAK, Singh RD, Theis JD, Velosa JA, Wetzels JFM, Winearls CG, Yandian F, Zand L, Ronco P, Fervenza FC. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. *Kidney Int*. 2023 Dec; 104(6):1092-1102. Epub 2023 Oct 05. PMID: 37795587 DOI: 10.1016/j.kint.2023.06.032
348. Sas DJ, Mara K, Mehta RA, Seide BM, Banks CJ, Danese DS, McGregor TL, **Lieske JC**, Milliner DS. Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1. *Pediatr Nephrol*. 2024 Jan; 39 (1):141-148 Epub 2023 July 17 PMID: 37458799 PMCID: PMC11044200 DOI: 10.1007/s00467-023-06074-x

349. Nasr SH, Valeri AM, Said SM, Sethi S, Nath KA, **Lieske JC**, Bu L. Clinicopathologic Characteristics, Etiologies, and Outcome of Secondary Oxalate Nephropathy. Mayo Clin Proc. 2024 Apr; 99 (4):593-606 Epub 2024 Feb 01 PMID: 38310502 PMCID: PMC11017309 DOI: 10.1016/j.mayocp.2023.08.014
350. Breeggemann MC, Harris PC, **Lieske JC**, Tasian GE, Wood KD. How We Treat Primary Hyperoxaluria Type 1. Clin J Am Soc Nephrol. 2024 Jun 1; 19 (6):800-802 Epub 2024 Mar 18 PMID: 38494457 PMCID: PMC11168812 DOI: 10.2215/CJN.0000000000000460
351. Zaidan N, Wang C, Chen Z, **Lieske JC**, Milliner D, Seide B, Ho M, Li H, Ruggles KV, Modersitzki F, Goldfarb DS, Blaser M, Nazzal L. Multiomics Assessment of the Gut Microbiome in Rare Hyperoxaluric Conditions. Kidney Int Rep. 2024 Jun; 9 (6):1836-1848 Epub 2024 Mar 11 PMID: 38899198 PMCID: PMC11184406 DOI: 10.1016/j.ekir.2024.03.004
352. Safadi S, Hommos MS, Thongprayoon C, Giesen CD, Bernaba M, Kashani KB, **Lieske JC**. The role of biomarkers in early identification of acute kidney injury among non-critically ill patients. J Nephrol. 2024 Jun; 37 (5):1327-1338 Epub 2024 June 05 PMID: 38837000 DOI: 10.1007/s40620-024-01950-7
353. Miao J, Mehta RA, Kattah A, Norby SM, **Lieske JC**, Milliner DS. Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases. Kidney Med. 2024 Jun; 6 (6):100824 Epub 2024 Apr 16 PMID: 38826567 PMCID: PMC11141431 DOI: 10.1016/j.xkme.2024.100824
354. Saland JM, **Lieske JC**, Groothoff JW, Frishberg Y, Shasha-Lavsky H, Magen D, Moochhala SH, Simkova E, Coenen M, Hayes W, Hogan J, Sellier-Leclerc AL, Willey R, Gansner JM, Hulton SA. Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial. Kidney Int Rep. 2024 Jul; 9 (7):2037-2046 Epub 2024 Apr 26 PMID: 39081738 PMCID: PMC11284403 DOI: 10.1016/j.ekir.2024.04.048
355. Stammler F, Grassi M, Meeusen JW, **Lieske JC**, Dasari S, Dubourg L, Lemoine S, Ehrich J, Schiffer E. Correction: Stammler et al. Estimating Glomerular Filtration Rate from Serum Myo-Inositol, Valine, Creatinine and Cystatin C. Diagnostics 2021, 11, 2291. Diagnostics (Basel). 2024 Sep 3; 14 (17) Epub 2024 Sept 03 PMID: 39272782 PMCID: PMC11394443 DOI: 10.3390/diagnostics14171949
356. Rodriguez RA, Sparks MA, Conway PT, Gavhane A, Reddy S, Awdishu L, Waheed S, Davidson S, Adey DB, Lea JP, **Lieske JC**, McDonald FS. American Board of Internal Medicine Nephrology Procedure Requirements for Initial Certification: Time for a Change and Pursuing Consensus in the Nephrology Community. Am J Kidney Dis. 2024 Oct; 84 (4):507-515 Epub 2024 Apr 17 PMID: 38640993 DOI: 10.1053/j.ajkd.2024.03.014
357. Cellini B, Baum MA, Frishberg Y, Groothoff JW, Harris PC, Hulton SA, Knauf F, Knight J, **Lieske JC**, Lowther WT, Moochhala S, Nazzal L, Tasian GE, Whittamore JM, Sas DJ. Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory. Kidney Int Rep. 2024 Nov; 9 (11):3083-3096 Epub 2024 Sept 01 PMID: 39534212 PMCID: PMC11551133 DOI: 10.1016/j.ekir.2024.08.031
358. Breeggemann MC, Harris PC, **Lieske JC**, Tasian GE, Wood KD. The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria. J Urol. 2024 Nov; 212 (5):649-659 Epub 2024 Aug 02 PMID: 39093847 DOI: 10.1097/JU.00000000000004147
359. Craici I, Kadatz M, Klarenbach S, So H, Fervenza FC, Cattran DC, Barbour SJ, **MENTOR Study Investigators**. Rituximab or cyclosporine A for the treatment of membranous nephropathy:

- economic evaluation of the MENTOR trial. *Nephrol Dial Transplant*. 2024 Nov 27; 39 (12):2058-2066 PMID: 38621719 PMCID: PMC11596091 DOI: 10.1093/ndt/gfae084
360. Wessells H, **Lieske JC**, Lai HH, Al-Khalidi HR, Desai AC, Harper JD, Kirkali Z, Maalouf NM, McCune R, Reese PP, Scales CD, Tasian GE, NIDDK Urinary Stone Disease Research Network. Adjudication of Self-reported Symptomatic Stone Recurrence in the Prevention of Urinary Stones With Hydration Trial. *Urology*. 2024 Dec; 194:27-35 Epub 2024 Sept 04 PMID: 39242045 PMCID: PMC11625008 DOI: 10.1016/j.urology.2024.08.026
 361. Zhou LT, Ali AE, Jayachandran M, Haskic Z, Harris PC, Rule AD, Koo K, McDonnell SK, Larson NB, **Lieske JC**. Association between Kidney Stones and CKD: A Bidirectional Mendelian Randomization Study. *J Am Soc Nephrol*. 2024 Dec 1; 35 (12):1746-1757 Epub 2024 Aug 05 PMID: 39102294 PMCID: PMC11617471 DOI: 10.1681/ASN.0000000000000453
 362. fichadiya harshil#, **lieske john#**. A RARE CASE OF OXALATE NEPHROPATHY ASSOCIATED WITH CARCINOID SYNDROME *Kidney International Reports* Volume 10, Issue 2, Supplement, February 2025, Page S755. 2025.
 363. Barbir EB, Mohan A, Koirala P, Gutierrez LE, Giesen CD, **Lieske JC**, Herrmann SM. Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis. *Nephrol Dial Transplant*. 2025 Feb 28; 40 (3):602-604 PMID: 39516049 DOI: 10.1093/ndt/gfae257
 364. Titan SM, **Lieske JC**, Meeusen JW, Thorson S, Lin Y, Nowakowski GS, Barreto JN, Barreto EF, Ruddy KJ, Leung N, Rule AD, Herrmann SM. Performance of Creatinine and Cystatin-Based Equations on Estimating Measured GFR in People with Hematological and Solid Cancers. *Clin J Am Soc Nephrol*. 2025 Mar 1; 20 (3):358-366 Epub 2025 Feb 10 PMID: 39874103 PMCID: PMC11905996 DOI: 10.2215/CJN.00000000616
 365. Lehner K, Day P, Bornhorst J, Jannetto P, **Lieske J**, Koo K. Contemporary kidney stone analysis composition among U.S. adults and children in a large reference laboratory setting. *Int Urol Nephrol*. 2025 Mar 13 [Epub ahead of print] PMID: 40080334 DOI: 10.1007/s11255-025-04453-x
 366. fichadiya harshil, **lieske john**, garovic vesna. AN UNUSUAL CAUSE OF HYPERCALCEMIA AND NEPHROCALCINOSIS DURING PREGNANCY-CYP24A1 DEFICIENCY *AMERICAN JOURNAL OF KIDNEY DISEASES* (Vol. 85, No. 4). 2025.
 367. Barbour SJ, Ronco P, Praga M, Fervenza FC, Induruwage D, Zhu B, Debiec H, Fernandez-Juarez G, Caravaca-Fontan F, Cattran DC, **GEMRITUX, MENTOR and STARMEN investigators**. Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials. *Clin J Am Soc Nephrol*. 2025 Apr 14; 20 (6):854-865 PMID: 40228233 PMCID: PMC12160951 DOI: 10.2215/CJN.00000000694
 368. **Lieske JC**, Ariceta G, Groothoff JW, Lipkin G, Moochhala SH, Schalk G, Sellier-Leclerc AL, Torres SE, Rawson V, Zhou J, Hoppe B. Phyox3: nedosiran long-term safety and efficacy in patients with primary hyperoxaluria type 1. *Kidney International Reports*. 2025 Jun; 10 (6):1993-2002
 369. Zhou LT, Stark IW, Jayachandran M, Harris PC, Rule AD, Koo K, McDonnell SK, Larson NB, **Lieske JC**. A Multiomics Study of Circulating Proteins and Kidney Stone Risk. *J Am Soc Nephrol*. 2025 Jun 27. [Epub ahead of print] PMID: 40577066 DOI: 10.1681/ASN.00000000768
 370. Ruta L, Cogal AG, Pampalone G, Sas DJ, **Lieske JC**, Rumsby G, Cellini B, Harris PC. A Minor Haplotype Variant Determines the Pathogenicity of the p.Ile279Thr Substitution in the Primary Hyperoxaluria Type 1 Gene, AGXT. *J Inherit Metab Dis*. 2025 Jul; 48 (4):e70052 PMID: 40495747 PMCID: PMC12152710 DOI: 10.1002/jimd.70052

Non-Peer-reviewed Articles

1. Atmani F, Farell G, **Lieske JC**. Extract from Herniaria Hirsuta coats calcium oxalate monohydrate crystals and blocks their adhesion to renal epithelial cells. *Kidney Stones: Inside out, Proceedings of the 10th International Symposium on Urolithiasis*, Hong Kong, Gohel MDI, Au, DWT eds. 2004:135-136.
2. Milliner DS, Olson JB, Monico CG, Scheinman SJ, **Lieske JC**. International registry of Primary Hyperoxaluria. *Kidney Stones: Inside out, Proceedings of the 10th International Symposium on Urolithiasis*, Hong Kong, Gohel MDI, Au, DWT eds. 2004:226-228.
3. Pena de la Vega L, Kumar V, Farell G, **Lieske JC**. Modulation of crystal adhesion to renal epithelial cells by urinary macromolecules. *Kidney Stones: Inside out, Proceedings of the 10th International Symposium on Urolithiasis*, Hong Kong, Gohel MDI, Au, DWT eds. 2004:107.
4. **Lieske JC**. Renal cell-urinary crystal interactions in the pathogenesis of renal lithiasis. *Kidney Stones: Inside out, Proceedings of the 10th International Symposium on Urolithiasis*, Hong Kong, Gohel MDI, Au, DWT eds. 2004:101-106.
5. **Lieske JC**, Regnier C, Goldfarb DS, De Simone C. Use of a probiotic to decrease urinary oxalate excretion in enteric hyperoxaluria. *Kidney Stones: Inside out, Proceedings of the 10th International Symposium on Urolithiasis*, Hong Kong, Gohel MDI, Au, DWT eds. 2004; 277-278.
6. * **Lieske JC**, Vanderboom P. Renal Pathology and Clinical Chemistry Case Mayo Clinic Proceedings. 2022.

Book Chapters

1. **Lieske JC**, FG Toback. Renal epithelial repair after acute tubular necrosis. 90-121. In: *Acute renal failure in the critically ill*. R Bellomo and C Ronco, Editors. New York: Springer-Verlag, 1995.
2. Scheid CR, Koul H, Hill WA, **Lieske JC**, Toback FG, Menon M. Oxalate ion and calcium oxalate crystal interactions with renal epithelial cells. 129-144. In: *Kidney stones: Medical and surgical management*. F Coe, Et. Al., Editors. Philadelphia: Lippincott-Raven Publishers, 1996.
3. **Lieske JC**, FL Coe. Urinary inhibitors and renal stone formation. 65-114. In: *Kidney stones: Medical and surgical management*. F Coe, Et. Al., Editors. Philadelphia: Lippincott-Raven Publishers, 1996.
4. **Lieske JC**, Segura JW. Evaluation and medical management of kidney stones. In: Potts JM, editor. *Essential urology: a guide to clinical practice*. Totowa: Humana Press; 2004. (Current Clinical Urology.). p. 117-52.
5. Vrtiska TJ, **Lieske JC**. Radiographic Evaluation of Nephrolithiasis. In: *Clinical Reviews in Bone and Mineral Metabolism Vol. 2*. 2004. p. 217-236.
6. Erickson SB, **Lieske JC**. Treatment of Nephrolithiasis. In: *Clinical Reviews in Bone and Mineral Metabolism Vol. 2*. 2004. p. 237-252.
7. **Lieske JC**. Pathophysiology and evaluation of obstructive uropathy. In: Smith AD, et al, editors. *Smith's textbook of endourology*. 2nd Edition. Hamilton: BC Decker Inc.; 2007. p. 101-6.
8. Schwartz MK, **Lieske JC**, Miller VM. Biologic nanoparticles and vascular disease. In: *Atherosclerosis disease management*. 2011. p. 749-63.
9. **Lieske JC**, Milliner DS, Beara-Lasic L, Rossetti S. Dent Disease. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP editors. *GeneReviews [Internet]*. Seattle (WA): University of Washington, Seattle; 2012 Aug 9.

10. **Lieske JC.** Calcium stones. In: Urinary stones: medical and surgical management. 2014. p. 36-47.
11. Ingimarsson JP, **Lieske JC.** Nephrolithiasis in primary hyperparathyroidism. In: Kearns AE; Wermers RA, Hyperparathyroidism: a clinical casebook. 2016. p. 19-26.
12. **Lieske JC.** Nutritional aspects of kidney stones. In: Mitch WE; Ikizler TA editors., Handbook of nutrition and the kidney. Seventh Edition. Philadelphia: Wolters Kluwer; 2018. p. 184-93.
13. Rule Andrew, **Lieske John.** Chronic Kidney Disease and Stone Disease. In: Coe, Worcester, Evan, and Lingeman, editor(s). Kidney Stones Medical and Surgical Management. 2nd ed. Chapter 25. Jaypee Brothers Medical Publishers; 2020. p. 544-555.

Editorials

1. Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, **Lieske JC.** Re: nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. J Urol. 2015 Mar; 193(3):900-1.
2. **Lieske JC.** Preeclampsia: an old disease with new tools for better diagnosis and risk management commentary. Clin Chem. 2015 May; 61(5):702-3.
3. **Lieske JC.** How much information is lost when you only collect one 24-hour urine sample during the initial metabolic evaluation? editorial comment Journal Of Urology 2016 Oct; 196 (4):1147-8
4. Giesen C, **Lieske JC.** The Influence of Processing and Storage Conditions on Renal Protein Biomarkers. Clin J Am Soc Nephrol 2016 Oct 7; 11 (10):1726-1728 Epub 2016 Sept 21
5. **Lieske JC.** Is the intestinal microbiome a modifiable cofactor in the development of hyperoxaluria after Roux-en-Y gastric bypass? Surg Obes Relat Dis 2017 Jul; 13 (7):1157-1158 Epub 2017 May 04
6. Shah RJ, **Lieske JC.** Inching toward a Greater Understanding of Genetic Hypercalciuria: The Role of Claudins. Clin J Am Soc Nephrol 2018 Oct 8; 13 (10):1460-1462 Epub 2018 Sept 19
7. Pinto E Vairo F, Kemppainen JL, **Lieske JC,** Harris PC, Hogan MC. Establishing a nephrology genetic clinic. Kidney Int. 2021 Aug; 100(2):254-259.
8. Sas DJ, **Lieske JC.** New Insights Regarding Organ Transplantation in Primary Hyperoxaluria Type 1. Kidney Int Rep 2022 Feb; 7 (2):146-148 Epub 2021 Dec 31
9. **Lieske JC,** Malley MA, West M, Hollander K, Milliner DS. End Points for Clinical Trials in Hyperoxaluria: Case Study of Patient-Focused Drug Development in a Rare Disease. Am J Kidney Dis 2022 May; 79 (5):754-756 Epub 2021 Oct 08
10. **Lieske JC.** Mendelian Randomization: A Powerful Tool to Illuminate Pathophysiologic Mechanisms. Mayo Clin Proc 2023 Apr; 98 (4):500-501
11. Fichadiya HA, **Lieske JC.** Do Topiramate and Zonisamide Cause Kidney Stones? Am J Kidney Dis. 2025 Jun; 85(6):674-675. Epub 2025 Apr 25.

Commentaries

1. **Lieske JC.** Gastric bypass procedures and renal calculi--how should we counsel patients and bariatric surgeons? J Urol. 2009 Nov; 182(5):2105-6. Epub 2009 Sep 16. PMID:19758648 DOI:10.1016/j.juro.2009.08.079
2. Rule AD, **Lieske JC.** The estimated glomerular filtration rate as a test for chronic kidney disease: problems and solutions. Cleve Clin J Med. 2011 Mar; 78(3):186-8. PMID:21364163 DOI:10.3949/ccjm.78a.11004

3. Rule AD, **Lieske JC**. Cystatin C is more than GFR, and this may be a good thing. J Am Soc Nephrol. 2011 May; 22(5):795-7. Epub 2011 Apr 14. PMID:21493768 DOI:10.1681/ASN.2011030288
4. **Lieske JC**. Severe hyponatremia in a schizophrenic patient: Commentary. Clin Chem. 2013; 59(6):890.
5. **Lieske JC**. Commentary. Clin Chem 2013 Jun; 59 (6):890 PMID:23719824 DOI:10.1373/clinchem.2012.199307
6. **Lieske JC**. New insights regarding the interrelationship of obesity, diet, physical activity, and kidney stones. J Am Soc Nephrol 2014 Feb; 25 (2):211-2 Epub 2013 Dec 12 PMID:24335974 DOI:10.1681/ASN.2013111189

Letters

1. Toback FG, **Lieske JC**. Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells. U.S. Letters Patent No. 5,618,917, issued 1997 Apr 8.
2. Kelly DG, de la Vega LP, **Lieske JC**, Milliner D. Untitled - Response. JPEN J Parenter Enteral Nutr. 2005 Nov-Dec; 29(6):454.
3. Singh R, Crow FW, Babic N, Lutz WH, **Lieske JC**, Larson TS, Kumar R. A liquid chromatography-mass spectrometry method for the quantification of urinary albumin using a novel ¹⁵N-isotopically labeled albumin internal standard. Clin Chem. 2007 Mar; 53(3):540-2. PMID:17327509 DOI:
4. Voskoboev NV, Larson TS, Rule AD, **Lieske JC**. Importance of cystatin C assay standardization. Clin Chem. 2011 Aug; 57(8):1209-11. Epub 2011 Jun 10. PMID:21666068 DOI:10.1373/clinchem.2011.164798
5. **Lieske JC**, Collazo-Clavell ML, Sarr MG, Rule AD, Bergstralh EJ, Kumar R. Gastric bypass surgery and measured and estimated GFR in women. Am J Kidney Dis 2014 Oct; 64 (4):663-5 Epub 2014 July 29 PMID:25085645 DOI:10.1053/j.ajkd.2014.06.016
6. Krambeck AE, **Lieske JC**. Prevention of recurrent nephrolithiasis in adults. Ann Intern Med 2015 Apr 07; 162 (7):528-9 PMID:25845008 DOI:10.7326/L15-5074-2
7. Dhondup T, Lorenz EC, Milliner DS, **Lieske JC**. Invited response to recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2. Am J Transplant 2018 Feb; 18 (2):527 Epub 2017 Dec 15 PMID:29160959 DOI:10.1111/ajt.14596
8. Sy-Go JPT, Zand L, Harris PC, **Lieske JC**. CYP24A1 deficiency causing persistent hypercalciuria in a stone former. J Nephrol. 2021 Jun; 34(3):949-951. Epub 2021 Jan 02. PMID:33387340 DOI:10.1007/s40620-020-00927-6
9. Garrelfs SF, Gansner JM, **Lieske JC**. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. Reply. N Engl J Med 2021 Nov 11; 385 (20):e69 PMID:34758265 DOI:10.1056/NEJMc2107661
10. Britton CJ, Sharma V, Lohse CM, **Lieske JC**, Nichols PE, Khanna A, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH, Potretzke AM. AUTHOR REPLY. Urology 2022 Nov; 169:132-133 PMID:36371093 DOI:10.1016/j.urology.2022.07.016
11. Britton CJ, Sharma V, Lohse CM, Thompson RH, **Lieske JC**, Rule AD, Potretzke AM. Reply by authors. Urology Practice 2023; 10 (3):216

12. Sellier-Leclerc AL, Magen D, Shasha-Lavsky H, Simkova E, Devresse A, Guebre-Egziabher F, Michael M, **Lieske JC**, Frishberg Y, Bakaloglu SA, Mourani C, Saqan R, Singer R, Guzzo I, Makarova N, Willey R, Kaspar C, Gansner JM, Groothoff JW. Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial. Am J Kidney Dis 2025 Mar 13 [Epub ahead of print] PMID:40086686 DOI:10.1053/j.ajkd.2025.01.016
13. Zhou LT, Jayachandran M, Larson NB, **Lieske JC**. Authors' Reply: Association between CKD and Kidney Stones: A Reliable Relationship? J Am Soc Nephrol. 2025 Jun 1; 36 (6):1229 Epub 2025 Mar 26 PMID:40137859 DOI:10.1681/ASN.0000000679

Thesis

1. Kashani Kianoush, Shao Min, Li Guangxi, Williams Amy W., Rule Andrew D., Kremers Walter K., Malinchoc Michael, Gajic Ognjen, **Lieske John C.**. Use of and electronic surveillance sniffer for a early detection and intervention for acute kidney injury (AKI) Kidney International.2017;92:(3):721-728.

Miscellaneous

1. Jayachandran M, Yuzhakov SV, Kumar S, Larson NB, Enders FT, Milliner DS, Rule AD, **Lieske JC**. Correction to: Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones. Orphanet J Rare Dis. 2021 Feb 18; 16 (1):91